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N OTI CE
The knowledge and the body of evidence within the field of medi-
cine grow constantly. As new investigations and experience broaden 
our understanding of the human (mal)functioning, changes in the 
research methodology, concepts, and clinical practice may follow. 
Therefore, healthcare providers and researchers should always rely 
on their own knowledge and experience in evaluating and using any 
information, method, or experiment discussed in this thesis.  
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CHAPTER 1
INTRODUCTION
“Disease is very old and nothing about it has changed. It is we who change as we learn to recognize what was formerly imperceptible.”
     Jean-Martin Charcot 
The heart–kidney interactions described in this thesis are based on our experience 
derived from clinical studies conducted among patients with heart failure (HF) and 
those with ischemic heart disease (IHD). The thesis describes heart–kidney inter-
actions not only as the organs’ interplay assessed at a single moment in time as is 
commonly done, but also their temporal relationships over time preceding adverse 
clinical events. This is important to note because these temporal patterns have so 
far received insufficient attention, mainly due to the methodological limitations 
of previous studies. However, these patterns are inherently linked to the progres-
sion of the conditions that affect both the heart and the kidneys such as HF and 
atherosclerosis. 
HF and IHD are global health problems that pose a great burden on patients, 
healthcare systems, and society in general.1,2 Besides their high prevalence, HF and 
IHD are the leading causes of death worldwide, with HF being also the leading 
cause of re-hospitalization.1-4 One of the common denominators in both condi-
tions is kidney dysfunction, where approximately half of patients with HF and one 
fourth of those with IHD suffer from chronic kidney disease (CKD).5,6 Importantly, 
the kidney disease not only co-exists, but also interacts with cardiac diseases there-
by further reducing patients’ survival.1,5 Interestingly, CKD patients are six times 
more likely to die of cardiovascular diseases than to reach end-stage renal disease.7 
Taken together, it is clear that heart–kidney interactions are bidirectional and that 
their identification, assessment and proper management still remain challenging.  
“A scientist does not (only) aim at the immediate results. He does not expect that his advanced ideas will be readily taken up. His work is like that of a planter – for the future. His duty is to lay the foundation for those who are to come, and point the way.”  
      Nikola Tesla
This book is divided into four main parts: “Methodological concepts”, “The role 
of the kidneys in heart failure and beyond”, “Implications of renal function for isch-
emic heart disease”, and “Lessons learned from clinical practice”. Each part contains 
chapters that explain specific aspects of heart–kidney interactions, but also build 
on the preceding chapter. In chapter 2, the concepts of the “temporal patterns” and 
the “personalized risk assessment” are described, which have not been extensively 
explored in medicine. These concepts were subsequently applied in clinical stud-
ies reported in chapters 4 to 9. Briefly, in these chapters we examined individual 
temporal trajectories of multiple blood and urine markers to derive estimates of 
patient-specific (i.e., personalized) prognosis. For this purpose, we assessed the 
marker’s levels, but also the slope (i.e., rate of change) of the marker’s trajectory, 
and the cumulative effect of all values that the marker has taken until the time of 
the assessment. These aspects are valuable as they provide us with a comprehensive 
picture of disease dynamics and the patient’s prognosis.
“I did not care to get a diploma, but to get qualified as an independent scientist. That was my goal! I have realized that the true science 
makes only what is of general scientific significance.” 
  Milutin Milankovic
This thesis was guided by four main objectives. The first objective was to per-
form a critical appraisal of dynamic prediction modeling (chapter 2) and interac-
tion testing (chapter 3) in clinical studies.  
The second objective was to investigate how trajectories of glomerular and tu-
bular renal compartments relate to each other over time preceding adverse clinical 
events, and how their individual and joint assessments relate to the prognosis of 
patients with chronic HF (chapters 4 and 5). Thereafter, we determined the predic-
tive utility of temporal patterns of new HF biomarkers that are expected to emerge 
in the near future (chapters 6 to 8). 
The third objective was to determine the implications of renal function for IHD. 
Specific aims included assessment of the evolution of renal function from its ini-
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Chapter 1
tial change during acute coronary syndrome (ACS) until stabilization, and investi-
gating the predictive value of serial renal assessments in these patients (chapter 9). 
Moreover, we examined the relation of a potent glomerular marker, cystatin C– and 
a tubular marker, NGAL– with coronary atherosclerosis assessed in-vivo by intra-
vascular ultrasound (IVUS) virtual histology and with patients’ adverse outcomes 
(chapter 10). 
The fourth objective was to evaluate different perspectives of clinical practice in HF 
patients with special attention to the kidneys. Specific aims included evaluation of the 
temporal relationships between guideline-recommended HF medication adjustments 
and multiple cardio-renal biomarkers, patients’ functional status, and clinical outcomes 
in patients with chronic HF (chapter 11). In patients with end-stage HF, we investigated 
the relation of right heart and pulmonary hemodynamic parameters measured before 
heart transplantation with severity of postoperative acute kidney injury (chapter 12). Fi-
nally, we assessed the relation of renal dysfunction and anemia with short- and long-term 
survival in patients with acute HF using our registry data from 1985 to 2008 (chapter 13). 
To meet the objectives, this thesis has combined several disciplines including 
methodologies of dynamic prediction modeling and interaction testing, utilization of 
modern assays based on –omics technologies for assessment of new biomarkers, so-
phisticated cardiovascular imaging techniques, and unique repeated-measures study 
designs. In the longer term, the results carry potential to contribute to reducing mortal-
ity- and hospitalization-rates in patients with acquired heart disease, improving their 
quality of life, and reducing healthcare costs.
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ABSTRACT
In medicine, repeated measures are frequently available (glomerular filtration rate 
or proteinuria) and linked to adverse outcomes. However, several features of these 
longitudinal data should be considered before making such inferences. These con-
siderations are discussed and we describe how joint modeling of repeatedly mea-
sured and time-to-event data may help to assess disease dynamics and to derive 
personalized prognosis. Joint modeling combines linear mixed-effects models and 
Cox regression model to relate patient-specific trajectory to their prognosis. We 
describe several aspects of the relationship between time-varying markers and the 
endpoint of interest that are assessed with real examples to illustrate the aforemen-
tioned aspects of the longitudinal data provided. Thus, joint models are valuable 
statistical tools for study purposes, but also may help healthcare providers in mak-
ing well-informed dynamic medical decisions. 
Personalized Dynamic Risk Assessment Chapter 2
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INTRODUCTION
Application of longitudinal study designs to assess dynamics of medical conditions 
is currently gaining interest in general medical community and particularly in the 
fields of cardiology and nephrology.1-5 Such study designs entail repeated measure-
ments of biological markers (e.g., proteins in the blood or urine) over the time-
course of the disease to infer patient prognosis. 
As an illustrative example we will consider a study by Brankovic et al. who in-
vestigated how longitudinal trajectories of several glomerular and tubular mark-
ers in patients with chronic heart failure (HF) relate to their prognosis.6 Samples 
were measured at fixed 3-month intervals during 2-year follow-up. Compared to 
studies that measured these markers at baseline only and related them to patient 
prognosis, the repeated-measures design utilized by Brankovic et al. carries several 
advantages.7 Most importantly, it reflects disease dynamics better than the single-
baseline assessment. However, when analyzing repeatedly measured biomarkers, 
the question arises how to properly relate them to prognosis.7 To do this, several 
approaches can be utilized including time-dependent Cox model (TDCM).8 Alter-
natively, joint models (JMs) of repeatedly measured and time-to-event data can be 
performed. 
Reasons for choosing JMs over TDCM for estimating prognosis using time-
varying markers are discussed below including data-collection, data-analysis, as 
well as the methodological concept behind JMs.
Data-collection
First, if repeated measurements are not collected at equally spaced time-points 
or not all patients have the same number of measurements, the longitudinal data 
are unbalanced.9 This is often seen when treating physicians determine how often 
study-visits should take place for data to be taken. For example, Breidthardt4 et al. 
studied whether worsening renal function (WRF) predicts mortality in patients 
admitted for acute HF. They defined WRF as in-hospital increase in serum creati-
nine ≥0.3mg/dl, and treating physicians determined the timing of serum creatinine 
sampling. Here, the sicker patients were likely to be monitored more closely (i.e., 
have more measurements taken) than the less sick patients. Consequently, the like-
lihood of finding WRF would increase in sicker patients. This unbalanced data-
collection would falsely strengthen the association between WRF and mortality if 
this relation is modeled improperly.
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Second, even when patient-visits occur at fixed time-points by a pre-specified 
study protocol, longitudinal data may become unbalanced. This occurs in three 
situations: when patients’ measurements are not performed in the beginning but 
start later during follow-up (“late entry”), when patients skip some of the sched-
uled visits (“intermittent missing”), or when patients withdraw before the study 
ends (“early dropout”).7 In all situations, the longitudinal data become unbalanced 
because of missing values. Importantly, if the reason for the missing values is re-
lated to patients’ survival (e.g., patient misses visits because of deteriorating condi-
tion), TDCM becomes inadequate because it assumes that missing values are in-
dependent of survival.7 For example, Li et al. studied longitudinal creatinine-based 
glomerular filtration rate (GFRCr) trajectory in the African American Study of Kid-
ney Disease in Hypertension (AASK) trial.10 Here, 23% of patients were excluded 
because they withdrew before collecting a sufficient number of measurements. In 
the majority, the reasons for withdrawal were related to their time-to-event as they 
died or were started on renal replacement therapy (RRT) before obtaining suffi-
cient serum creatinine measurements. 
Data-analysis
Covariates measured (or collected) on patients are internal (i.e., endogenous) predictors. 
This is important to note because for any internal predictor (i.e., biomarker) future mea-
surements potentially depend on the patient’s survival which should be considered when 
analyzing such covariates.11,12 This is due to two reasons: patients have to be alive and 
present at study-visits for markers to be measured, and markers’ values might be affected 
by his/her condition up to that visit.7 Additionally, internal predictors are biologically 
subjected to variability and can be measured with error.7 Examples of such predictors 
are serum creatinine, body mass index, echocardiography measurements, or proteinuria.
TDCM cannot properly handle internal predictors12 since it assumes that their 
future values are independent of patient’s survival and measured without error.7 
Importantly, it also assumes that the predictor has the same constant value between 
study-visits, until it suddenly changes when the next measurement is obtained (Fig-
ure 1A).12 This assumption is unrealistic as we expect that biomarkers continuously 
change, and not only when measured. Consequently, TDCM would produce biased 
estimates of biomarkers’ effect masking their true predictive ability. For example, 
Asar et al. studied whether repeatedly measured GFRCr predict initiation of RRT in 
1611 patients from Chronic Renal Insufficiency Standards Implementation Study 
(CRISIS). They showed that the hazard ratios (HRs) for RRT were considerably 
underestimated by TDCM as compared to JMs (HRs per log-unit GFRCr decrease: 
12.3 versus 38.7).5 This advantage of JMs over TDCM has been demonstrated by 
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theoretical work and other simulation studies.7,11-13
Methodological concept
The JMs combine two models: linear mixed-effects (LME) models and basic Cox 
model.9 The LME models estimate a marker’s trajectory using repeated measure-
ments; Cox model estimates patients’ time-to-event. 
The LME models use the 2-component equation. The first “fixed-effect” 
component estimates a marker’s average trajectory over all patients. The second 
“random-effect” component estimates by how much an individual patient devi-
ates from this average trajectory (Figure 1B). By using these two components of 
information the patient-specific trajectory is constructed. Through the “random-
effects” component they allow repeated measurements taken on the same patient 
to be correlated, and work well with unbalanced data.12 Notably, the functional 
form of time is an important aspect of LME models. That is, in case the patient-
specific trajectories are nonlinear, care should be given in the specification of the 
fixed- and random-effects components; polynomials or splines could be used to 
model such nonlinear profiles. Altogether, this allows a longitudinal trajectory 
estimated by LME models to correspond more naturally to the marker’s biologi-
cal evolution than the “jerkily” trajectory assumed by TDCM (Figure 1A). 
Subsequently, JMs combine LME and Cox models to relate patient-specific tra-
jectory to his/her prognosis (Figure S1). By doing this, JMs handles marker’s miss-
ing data and measurement error that can occur during follow-up.14 JMs are also 
advantageous when extreme values are observed because they postulate that the 
underlying rather than the observed value of the longitudinal biomarker is associ-
ated with the risk of an adverse endpoint (Figure 1A). 
The basic assumptions behind LME and Cox models are the same as when they 
are separately analyzed. For continuous longitudinal data, we assume normally 
distributed error terms. The LME models also assume that discontinuation of 
the data-collection process for reasons other than the occurrence of the adverse 
endpoint are missing at random, i.e., these reasons can depend on covariates and 
past observed longitudinal values. For the endpoint a relative risk model is used 
with the proportional hazards assumption. Further reading on methodology9, 
sample size and power determination15 is provided elsewhere. Finally, JMs have 
been successfully applied for several medical conditions including HF, aortic an-
eurisms, aortic stenosis, heart, lung and kidney transplantation.6,16-20
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FIGU R E 1  Graphical depiction of the difference between the marker’s 
trajectory estimated by the time -dependent Cox model and the joint models 
and of the different aspects of time -varying markers. The X-axis displays follow-
up time, the left Y-axis displays the value of a (bio)marker, and the right Y-axis displays a 
patient’s risk prognosis. Panel A illustrates the marker’s trajectories estimated by the time-
dependent Cox model (green dashed line) and by the joint models (smooth red solid line) 
in the same patient. The panel shows that in the JMs the underlying profile represented 
by the red solid line is include in the relative risk model, and not the directly observed 
C
B
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value represented by the red circles which is what the Cox model does. In this way, JMs 
are advantageous because they account for the biological variation that the biomarker 
exhibits, but also in the settings when extreme values are observed but are not particularly 
helpful clinically (e.g., extremely low blood pressure). Interpretation of HRs from the JMs 
is the same as from the Cox model. Panel B illustrates how the patient-specific marker 
trajectory is constructed using linear mixed-effects models. The solid green line depicts the 
marker’s value averaged over all patients at each of the study visits during follow-up (fixed-
effect part), and the black arrows depict the deviation of the patient-specific values from 
the average values at the same study visits. Patient-specific trajectories are depicted for a 
patient who experienced the event (solid red line) and the one who did not (solid blue line). 
Panel C illustrates different aspects of time-varying markers that can be assessed by joint 
models: 1) marker’s level, 2) slope of the marker’s trajectory (rate of change), 3) area under 
the marker’s trajectory (the cumulative effect of the marker’s values). The time-dependent 
slope mathematically corresponds to the first derivative of the trajectory and the cumulative 
effect to the integral of the trajectory. 
Components of time-varying markers
JMs tailor a patient’s prognosis based on his/her own marker’s values (Figure 1C). 
However, other components of the longitudinal marker can also be investigated.7 
For example, the rate at which a marker changes can be determined by estimating 
the instantaneous slope of its trajectory. The slope indicates by how much marker’s 
values have been increasing or decreasing at the certain timepoint.7 Consequently, 
disease’s progression can be adequately quantified and related to prognosis. JMs can 
also assess entire history of marker values by estimating the area under its trajectory. 
The area indicates the cumulative effect of all values that the marker has taken up to 
the certain timepoint.12 Altogether, JMs analyse comprehensively disease’s dynamics 
to accurately profile patient’s prognosis, wherein the application of TDCM is limited. 
Personalized dynamic risk assessment
Patients are often seen in different disease’s stages, react differently to treatment, 
or have other characteristics relevant for their phenotype. Thus, it is clear that a 
disease can differ both between patients and within the same patient over time. 
Consequently, a true marker’s potential in ascertaining disease’s severity in an indi-
vidual, and its accurate relation to prognosis can only be revealed if individual (i.e., 
patient-specific) values are considered. For physicians, it is also medically relevant 
to utilize all available information (baseline and follow-up) to accurately detect 
disease’s progression and profile better individual prognosis. JMs can easily update 
the patient’s prognosis whenever additional information is collected, thereby as-
sessing the risk in real-time.14
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CONCLUSION
Although attention should be taken when analyzing repeatedly measured data, 
repeated-measures designs are valuable when assessing the dynamics of medical 
conditions. The use of JMs may improve patients monitoring by providing person-
alized dynamic risk predictions.
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SUPPLEMETARY INFORMATION 
R code to fit joint model 
Joint model will be fit using primary biliary cirrhosis (PBC) data collected at the 
Mayo Clinic from 1974 to 19841 available with the package JMBayes.2 For the anal-
ysis we will consider 312 patients who have been randomized to D-penicillamine 
treatment and 154 patient randomized to placebo. During follow-up,  serum biliru-
bin was collected on average 6 times per patient with a total of 1945 measurements. 
To assess how longitudinal trajectory of serum bilirubin relates to a patient-specific 
prognosis we have to use two datasets. 
The first dataset is denoted by “pbc2” and contains repeatedly measured data 
organized in the long format (i.e., contains several rows per each patient; number of 
rows depends on how many samples the patient had provided). This dataset will be 
used to estimate longitudinal trajectory of serum bilirubin using linear mixed-effects 
(LME) models. 
The second dataset is denoted by “pbc2.id” and contains patients’ survival 
times organized in the wide format (i.e., contains a single row per patient). This 
dataset will be used to fit basic Cox model. 
Full description of R codes provided below is discussed in the paper under ref-
erence 2.  
# R code:
# first load package “JMbayes” and define the indicator “status2” as the   
# composite event 
# of transplantation or death
library(“JMbayes”)
pbc2$status2 <- as.numeric(pbc2$status != “alive”) 
pbc2.id$status2 <- as.numeric(pbc2.id$status != “alive”)
# now fit the LME model 
# variable “log(serBilir)” denotes logarithmically transformed marker: serum bilirubin 
# variable “year” denotes the time from baseline when the marker was collected 
# in this example, we used natural splines with two knots to better estimate marker’s 
# trajectory 
lmeFit <- lme(log(serBilir) ~ ns(year, 2), data = pbc2, 
random = ~ ns(year, 2) | id)
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# now fit basic Cox model
# variable “years” denotes the time to event or censoring (note: this is different than variable 
# “years” used for LME model)
# variable “status2” is event indicator
# variable “drug” denotes if a patient was randomized to D-penicillamine or placebo
# variable “age” denotes a patient’s age at baseline
coxFit <- coxph(Surv(years, status2) ~ drug + age, data = 
pbc2.id, x = TRUE)
# now fit joint model for the marker’s value
jointFit.value <- jointModelBayes(lmeFit, coxFit, timeVar = 
“year”, n.iter = 30000)
summary(jointFit.value)
# calculate hazard ratio with corresponding 95% confidence interval 
exp(confint(jointFit.value, parm = “Event”))
# in the output “Assoct” denotes HR for the value of log(serBilir)
# now fit joint model for marker’s value and slope 
dForm <- list(fixed = ~ 0 + dns(year, 2), random = ~ 0 + 
dns(year, 2), indFixed = 2:3, indRandom = 2:3)
jointFit.value.slope <- update(jointFit.value, param = “td-
both”, extraForm = dForm)
summary(jointFit.value.slope)
# calculate hazard ratio with corresponding 95% confidence interval 
exp(confint(jointFit.value.slope, parm = “Event”))
# in the output “Assoct” denotes HR for the value of log(serBilir)
# in the output “AssoctE” denotes HR for the slope i.e., delta-log(serBilir)/year)
# the time-dependent slope mathematically corresponds to the first derivative of the 
# trajectory
# now fit joint model for marker’s cumulative effect 
iForm <- list(fixed = ~ 0 + year + ins(year, 2), random = ~ 
0 + year + ins(year, 2), indFixed = 1:3, indRandom = 1:3)
jointFit.area <- update(jointFit.value, param = “td-extra”, 
extraForm = iForm)
summary(jointFit.area)
# calculate hazard ratio with corresponding 95% confidence interval 
exp(confint(jointFit.area, parm = “Event”))
# in the output “AssoctE” denotes HR for the area under log(serBilir) trajectory
# the area mathematically corresponds to the integral of the trajectory
# Plotting marker’s trajectory with corresponding survival probability in an 
# individual patient 
# in the following example we plotted serum bilirubin for patient number 4 from 
# PBC data with survival 
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# probability for serum bilirubin value
ND <- pbc2[pbc2$id == 4, ]
sfit <- survfitJM(jointFit.value, newdata = ND)
plot(sfit, estimator = “mean”, include.y = TRUE,conf.int = 
TRUE, fill.area = TRUE, col.area = “lightgrey”)
FIGU R E S1 Personalized dynamic risk assessment using patient-specific 
trajectory of serum bilirubin. Serum bilirubin levels (on a log scale) are displayed on 
the primary (left) Y-axis and survival probability on the secondary (right) Y-axis. Follow-up 
time (years) is displayed on the X-axis. Patient-specific marker’s trajectory (solid red line) 
with scatter points (asterisks) is displayed left of the vertical dotted black line. To the right of 
this line, the corresponding conditional survival probability curve (solid red line) is displayed 
with 95% confidence intervals (grey area).
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ABSTRACT
Background 
Renal dysfunction is an important component of chronic heart failure (CHF), but 
its single assessment does not sufficiently reflect clinically silent progression of 
CHF prior to adverse clinical outcome. Therefore, we aimed to investigate tempo-
ral evolutions of glomerular and tubular markers in 263 stable CHF patients, and 
to determine if their patient-specific evolutions can dynamically predict clinical 
outcome. 
Methods
We determined the risk of clinical outcome (composite endpoint of HF-hospital-
ization, cardiac death, LVAD-placement and heart transplantation) in relation to 
marker levels, slopes of their trajectories (increasing/decreasing patterns), and areas 
under their trajectories (AUCm). In each patient, the trajectories were estimated us-
ing repeatedly measured glomerular markers: creatinine/estimated glomerular filtra-
tion rate (eGFR), cystatin C (CysC); and tubular markers: urinary N-acetyl-beta-D-
glucosaminidase (NAG) and kidney-injury-molecule (KIM)-1, plasma and urinary 
neutrophil-gelatinase-associated-lipocalin (NGAL). 
Results
During 2.2 years of follow-up, we collected 8 (5–10) urine and 9 (5–10) plasma 
samples per patient. All glomerular markers predicted the endpoint (univariable 
hazard ratio [95% confidence interval] per 20% increase: creatinine: 1.18 [1.07–
1.31], CysC: 2.41 [1.81–3.41], and per 20% eGFR decrease: 1.13 [1.05–1.23]). Tubu-
lar markers, NAG and KIM-1 also predicted the endpoint (NAG: 1.06 [1.01–1.11], 
and KIM-1: 1.08 [1.04–1.11]). Larger slopes were the strongest predictors (creati-
nine: 1.57 [1.39–1.84],  eGFR: 1.59 [1.37–1.90],  CysC: 1.76 [1.52–2.09]; NAG: 1.26 
[1.11–1.44], and KIM-1: 1.64 [1.38–2.05]). Associations persisted after multivari-
able adjustment for clinical characteristics. 
Conclusions
Our findings suggest that glomerular and tubular function deteriorate, but not si-
multaneously, during clinically silent progression of CHF. Patient-specific evolu-
tions of these renal markers dynamically predict clinical outcome in CHF patients.
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INTRODUCTION 
Heart Failure (HF) is the leading cause of hospitalization worldwide.1 Despite de-
clines in HF-related mortality as a result of current therapies, re-hospitalization rates 
for decompensation of chronic heart failure (CHF) remain high.1,2 Several blood bio-
markers that predict re-hospitalization and mortality have been identified in patients 
with CHF.3 Still their predictive capabilities in practice are limited, and adequate risk 
assessment remains a challenge.3 Estimation of renal dysfunction, which coexists and 
interact with HF3 may improve risk stratification. Baseline glomerular dysfunction, 
as assessed by estimated glomerular filtration rate (eGFR), entails an unfavourable 
prognosis in CHF.4-6 Besides glomerular impairment, such patients often have tu-
bular damage due to tubulo-interstitial injury by renal tissue hypoperfusion or due 
to damaged glomerular barrier.7,8 Notably, a single assessment of damaged tubules 
predicts adverse outcome in CHF independently of eGFR.9-11 
It is clear that both glomerular and tubular function are important in patients with 
CHF, but their single assessment does not sufficiently reflect deterioration along the 
cardio-renal axis that occurs over time preceding adverse events. Yet the temporal evo-
lution of renal function preceding the event may dynamically ascertain the clinically 
silent progression of the disease. Specifically, it would enable accurate investigation of 
whether, and to which degree, increasing (or decreasing) levels of renal biomarkers 
contribute to the patient’s risk, regardless of whether these levels exceed established 
cut-points at ‘study baseline’ (i.e., a random point in time prior to event). 
In the context of cardio-renal interplay, patients with CHF also display large 
biological heterogeneity. Renal function not only changes dynamically within a 
patient over time, but also differs from patient to patient. Hence, the true potential 
of renal markers in ascertaining individual disease progression, and their accurate 
relation with clinical outcome, can only be revealed if their patient-specific evolu-
tions are considered. However, detailed individual temporal evolutions of renal 
function in CHF have never been described.
To overcome these issues, our aim was two-fold: (1) to investigate the average 
(population) temporal evolutions of glomerular function (measured with plasma 
creatinine (Cr), eGFR and cystatin C (CysC)) and tubular status (measured with 
urinary kidney injury molecule (KIM)-1, N-acetyl-beta-D-glucosaminidase (NAG), 
and urinary and plasma neutrophil gelatinase-associated lipocalin (NGAL)) in stable 
patients with CHF, and (2) to determine if patient-specific (individual) evolutions of 
these renal biomarkers during a clinically silent period can dynamically predict clini-
cal outcome. For this purpose we examined several aspects of the temporal evolution 
of each renal biomarker that may be relevant for clinical prediction. 
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MATERIALS AND METHODS 
The Serial Biomarker Measurements and New Echocardiographic Techniques in Chron-
ic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-SHiFT) is a 
prospective, observational cohort of stable patients with CHF, conducted in Erasmus 
MC, Rotterdam, and Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. Pa-
tients were recruited during their regular visits to the Cardiology outpatient clinics 
of these hospitals. For this purpose, consecutive patients were screened according 
to the inclusion and exclusion criteria specified in Figure S1, and eligible patients 
were asked for informed consent. The main  inclusion criteria were age ≥18 years, 
capability of understanding and signing informed consent, and diagnosis of CHF 
≥3 months ago according to European Society of Cardiology guidelines.12,13 Patients 
were ambulatory and stable, i.e., they had not been hospitalized for HF in the past 
three months. The study was approved by the medical ethics committees, conducted 
in accordance with the Declaration of Helsinki, and registered in ClinicalTrials.gov 
(NCT01851538). Written informed consent was obtained from all patients that par-
ticipated in the study. This investigation comprised 263 stable patients with CHF 
enrolled during the first inclusion period (October 2011 until June 2013). 
Baseline assessment
All patients were evaluated by research physicians, who collected information on 
HF-related symptoms, NYHA class, and performed a physical examination, includ-
ing blood pressure, heart rate and body mass index. Information on HF etiology, 
left ventricular ejection fraction, cardiovascular risk factors, medical history and 
medical treatment was retrieved primarily from hospital records and was checked 
if ambiguities were present. History of cardiovascular and other comorbidities was 
defined as a clinical diagnosis of these conditions. Non-fasting blood and urine 
samples were collected, as described below.
Follow-up and study endpoints
During the study, all patients were routinely followed at the outpatient clinic by 
treating physicians who were blinded for biomarkers  sampling and results. Study 
follow-up visits were predefined and scheduled every 3 months (±1 month was al-
lowed), with a maximum of 10 study follow-up visits. At each study follow-up visit, 
a short medical evaluation was performed and samples were collected. All medica-
tion changes and occurrence of adverse cardiovascular events since the previous 
visit were recorded in electronic case report forms. During follow-up, hospitaliza-
Renal function in Chronic Heart Failure
Chapter 4
63
tions for HF, MI, PCI, CABG, arrhythmias, and CVA, cardiac transplantation, left 
ventricular assist device (LVAD) implantation and mortality, were recorded in the 
electronic case report forms, and associated hospital records and discharge letters 
were collected. Subsequently, a clinical event committee, blinded to the biomarker 
sampling and results, reviewed hospital records and discharge letters and adjudi-
cated the study endpoints.
The primary endpoint comprised the composite of cardiac death, cardiac trans-
plantation, LVAD implantation, and hospitalization for the management of acute or 
worsened HF, whichever occurred first. Secondary endpoints included individual 
components of the primary endpoint, and also MI, PCI, CABG, CVA, and all-cause 
mortality. Cardiac death was defined as death from MI or other ischemic heart dis-
ease (ICD-10: I20-I25), death from other heart disease including HF (I30-I45 and 
I47-I52), sudden cardiac death (I46), sudden death undefined (R96) or unwitnessed 
or ill-described death (R98, R99). Hospitalization for acute or worsened HF was de-
fined as a hospitalization for an exacerbation of HF symptoms, in combination with 
two of the following: BNP or NT-proBNP >3x ULN, signs of worsening HF, such as 
pulmonary rales, raised jugular venous pressure or peripheral edema, increased dose 
or intravenous administration of diuretics, or administration of positive inotropic 
agents.12
Blood and urine analysis
Blood and urine samples were collected at baseline and at each study follow-up 
visit, and were processed and stored at a temperature of -80oC within two hours af-
ter collection. The biomarker measurements performed for this study did not lead 
to drug adjustments and all patients received usual care. Batch analysis of plasma 
and urine samples was performed at HaemoScan BV, Groningen, The Netherlands. 
Laboratory personnel was blinded for clinical data. 
Creatinine was determined by a colorometric test by the Jaffe’s reaction. Plasma was 
used undiluted, urine was diluted ten times in water (LLD: plasma 0,14 mg/dl,  urine: 
1.56 mg/ml). CysC was determined in plasma, diluted 2000 times in 0,1%BSA/PBS 
buffer, by ELISA (R&D systems, Minneapolis, MN) (LLD: 0.1066 µg/mL). KIM-1 was 
determined in urine, diluted 50% in 0,1%  BSA/PBS buffer, by ELISA (R&D systems, 
Minneapolis, MN, USA) (LLD: 0.146 ng/mL). NAG was determined using a substrate 
p-nitrophenyl N-acetyl-β-D-glucosaminidase at pH 4.5 (Sigma, St Louis, MO, USA) 
(LLD: 0.485 U/L). NGAL was determined in urine diluted 20 times, and plasma diluted 
100 times in 0,1% BSA-PBS buffer by ELISA (R&D systems, Minneapolis, MN) (LLD: 
urine 5.19 ng/mL, plasma 50.3 ng/mL). All urinary biomarkers were normalized to 
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urinary creatinine concentrations to correct for concentration or dilution of urine. 
Glomerular filtration rate (GFR) was determined by the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation that has been validated in HF pa-
tients.14 Patients were categorized using National Kidney Foundation–Kidney Disease 
Outcome Quality Initiative (K/DOQI) clinical practice guidelines.15
Statistical analysis
Biomarkers measured at baseline 
The association between baseline marker levels and the study endpoint was examined 
by Cox regression analysis. If skewed, 2log-tranformation of continuous variables was 
used for further analyses. Analyses were first performed univariably, then statistical ad-
justments were performed by using two models: (1) model with biomarker of interest 
plus clinical variables age, sex, diabetes, atrial fibrillation, NYHA class, diuretics, systol-
ic blood pressure, and eGFR (for tubular markers); (2) model with biomarker of inter-
est plus biomarkers of myocardial stretch and damage, NT-proBNP and hs-cTnT. Data 
on all variables were complete, except for systolic blood pressure which was missing 
in <5% of patients and for which imputations were applied using patients’ clinical and 
outcome data. The proportional hazards (PH) assumption was evaluated by plotting 
transformed Kaplan-Meier estimates, and by evaluating scaled Schoenfeld residuals.
Repeatedly measured biomarkers
We applied a joint modeling (JM) of linear mixed-effects (LME) models to assess 
the true underlying trajectory of a repeatedly measured marker, and a Cox survival 
analysis to analyze the association of this trajectory with the study endpoint. For both 
the fixed- and random-effects parts of LME, non-linear evolutions were tested using 
restricted cubic splines. If the model was not significantly improved, a linear evolu-
tion was retained. All markers were adjusted for the sampling time during follow-up. 
Additional statistical adjustments were as follows: (1) the repeatedly measured mark-
er was adjusted for its baseline level (Cox model) to examine incremental value of 
repeated over baseline measurements (2) Cox and LME models were adjusted for the 
clinical variables age, sex, diabetes, atrial fibrillation, NYHA class, diuretics, systolic 
blood pressure, and eGFR (for tubular markers) to examine incremental value of the 
renal markers over the patients’ clinical characteristics; (3) Cox and LME models 
were adjusted for biomarkers of myocardial stretch and damage (NT-proBNP and 
hs-cTnT) to examine the incremental value of the renal markers over these com-
monly used cardiac markers. Results are presented as hazard ratios (HRs) with 95% 
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confidence intervals (95%CI) per 20% change in biomarkers levels. 
To  investigate the independent predictive value of these renal markers on the 
study endpoints, all individual temporal biomarker patterns derived from the joint 
models were extracted and subsequently entered simultaneously with HF medication 
doses (repeatedly assessed during follow-up) into a time-dependent Cox analysis.
Parameterization of marker’s trajectory
The above-described analyses estimate the instantaneous risk based on repeatedly 
measured marker levels. However, in the context of repeated measurements, we also 
estimated the following aspects:16,17 (1) the time-dependent  slope (or: rate of change) 
of the marker’s trajectory, indicating whether and by how much the levels are increas-
ing or decreasing at any point in time, which corresponds to the first derivative of the 
marker’s trajectory (2) the area under the curve of the marker’s trajectory (AUCm), in-
dicating the cumulative effect of all the values the marker has taken in the past (Figure 
1). The results are presented as HRs (95%CI) per 20% change in the annual slope (delta 
of the marker’s levels/year) and the AUCm.
FIGUR E 1 Dynamic risk prediction model using repeated marker measurements. 
An illustration of the underlying trajectory of a repeatedly assessed biomarker in a patient 
who ultimately experiences the event (solid red line) and in an event-free patient (solid blue 
line). Marker’s levels are displayed on the y-axis and follow-up time on the x-axis. Figure 
shows different types of parameterization that can be examined: marker’s levels at any point 
in time (ta), slope of the marker’s trajectory at any point in time (ta), and the area under the 
curve of marker’s trajectory (AUCm) up to the same point in time (ta).  te, time when the 
event occurred; *, measured marker’s levels.
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Prospective accuracy
We determined the longitudinal marker’s predictive accuracy (i.e., the ability of a 
marker to discriminate between a patient who experiences the event within a given 
time-window after the last measurement, and the patient who does not experience 
the event within that same time-window) using the time-dependent AUC (area 
under the receiver operating curve) methodology.18 For this purpose, we chose the 
first year as the collection time period, and we assessed two risk time-windows: 6 
and 12 months after the collection time.
All analyses were performed with R Statistical Software using package JMbayes.17,19 
All tests were two-tailed and p-values <0.05 were considered statistically significant.
RESULTS
Baseline characteristics 
Table 1 displays the baseline characteristics. Patients who later experienced the 
endpoint, at baseline were older, more frequently had diabetes and atrial fibrilla-
tion, had lower systolic blood pressure, higher NYHA class, higher levels of NT-
proBNP, cardiac troponin T, CysC, urinary NAG, and plasma NGAL, and were 
more frequently on diuretics than the patients who remained endpoint-free. 
TAB LE 1 Patient characteristics in relation to the occurrence of the composite 
endpoint.
Variable Total Composite endpoint reached p-value
Yes No
n (%) 263 (100) 70 (27) 193 (73)
Demographics
Age, years (mean ± SD) 67 ± 13 69 ± 13 66 ± 12 0.05
Men, n (%) 189 (72) 53 (76) 136 (70) 0.41
Clinical characteristics
BMI, kg/m2 (mean ± SD) 27.5±4.7 27.6±4.8 27.4±4.7 0.80
Heart rate, b.p.m.  (mean  ±  SD) 67±12 69±13 67±11 0.31
SBP, mmHg (mean ± SD) 122±20 117±17 124±21 0.02
DBP, mmHg (mean ± SD) 72±11 70±10 73±11 0.06
Features of heart failure
NYHA class III or IV, n (%) 69 (26) 31 (44) 38 (20) < 0.001
HF-rEF n (%) 250 (95) 66 (94) 184 (95) 0.75
HF-pEF n (%) 13 (5) 4 (6) 9 (5)
LVEF, %  (mean ± SD) 32±11 30±11 33±10 0.18
Renal function in Chronic Heart Failure
Chapter 4
67
Variable Total Composite endpoint reached p-value
Yes No
NT pro-BNP (pmol/L) † 137.3 (51.7–272.6) 282.4 (176.4–517.4)95.3 (31.7–207.7) < 0.001
Hs-TnT (ng/L) † 18.0 (9.5–33.2) 31.9 (20.6–49.7) 13.9 (8.4–26.7) < 0.001
Etiology of heart failure, n (%)
Ischemic 117 (44) 36 (51) 81 (42) 0.17
Hypertension 34 (13) 10 (14) 24 (12) 0.70
Valvular disease 12 (5) 5 (7) 7 (4) 0.23
Cardiomyopathy 68 (26) 15 (21) 53 (28) 0.32
Unknown or Others 32 (12) 4 (6) 28 (15)
Medical history, n (%)
Prior MI 96 (36) 32 (46) 64 (33) 0.06
Prior PCI 82 (31) 27 (39) 55 (28) 0.12
Prior CABG 43 (16) 13 (19) 30 (15) 0.57
Atrial fibrillation 106 (40) 36 (51) 70 (36) 0.03
Diabetes 81 (31) 32 (46) 49 (25) 0.002
Hypercholesterolemia 96 (36) 30 (43) 66 (34) 0.20
Hypertension 120 (46) 38 (54) 82 (42) 0.09
COPD 31 (12) 12 (17) 19 (10) 0.10
Medication use, n (%)
Beta-blocker 236 (90) 61 (87) 175 (91) 0.40
ACE-I or ARB 245 (93) 63 (90) 182 (94) 0.22
Diuretics 237 (90) 68 (97) 169 (88) 0.02
Loop diuretics 236 (90) 68 (97) 168 (87) 0.02
Thiazides 7 (3) 3 (4) 4 (2) 0.28
Aldosterone antagonist 179 (68) 53 (76) 126 (65) 0.11
Glomerular function markers †
Creatinine, mg/dl 1.18 (0.99–1.49) 1.30(1.02–1.52) 1.17(0.98–1.45) 0.18
eGFR, mL/min/1.73m2 58 (43–76) 53 (40–73) 59 (44–77) 0.16
Cystatin C, mg/L 0.73 (0.57–0.97) 0.87 (0.71–1.03) 0.70 (0.53–0.90) < 0.001
KDOQI classification, n (%)
eGFR ≥90 28 (11) 7 (10) 21 (11) 0.18
eGFR 60-89 95 (36) 20 (28) 75 (39)
eGFR 30-59 119 (45) 37 (53) 82 (42)
eGFR <30 21 (8) 6 (9) 15 (8)
Tubular markers †
NAG, U/gCr [urine] 5.9 (3.8–9.3) 8.0 (6.0–11.0) 5.1 (3.3–8.0) < 0.001
KIM-1, ng/gCr [urine] 477.2 (247.0–938.6) 589.0 (255.0–957.2) 465.1 (237.6–911.5) 0.10
NGAL, µg/gCr [urine] 17.4 (9.2–32.6) 18.2 (10.0–50.5) 17.4 (9.0–31.4) 0.20
 NGAL, ng/ml [plasma] 190.1 (133.5–280.0) 260.8 (169.5–355.4)179.2 (127.9–244.5)< 0.001
BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; NYHA 
class, New York Heart Association class; HF-rEF, Heart failure with reduced ejection fraction; 
HF-pEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery 
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bypass grafting; CVA, cerebrovascular accident; TIA, transitory ischemic attack; COPD, 
chronic obstructive pulmonary disease; ACE-I, angiotensin-converting enzyme inhibitors; 
ARB, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate. Normally 
distributed continuous variables are presented as mean±standard deviation (SD), and non-
normally distributed variables as median and interquartile range (IQR). Categorical variables 
are presented as numbers and percentages.
†All biomarkers levels were presented as median (IQR).
Follow-up and study endpoints
From 263 patients with CHF, a total of 1912 urine and 1984 blood samples were 
collected with median (IQR) of 8 (5–10) urine and 9 (5–10) plasma samples per 
patient. During a median (IQR) follow-up of 2.2 (1.4–2.5) years, 70 (27%) patients 
reached the primary endpoint: 56 patients were re-hospitalized for acute or wors-
ened HF, 3 patients underwent heart transplantation, 2 patients underwent LVAD 
placement, and 9 patients died of cardiovascular causes. 
Temporal evolution of glomerular function 
Creatinine and eGFR
In patients who reached the composite endpoint, Cr levels on average showed an in-
creasing pattern over time preceding the endpoint. In endpoint-free patients Cr levels 
were lower and remained stable during follow-up (Figure 2A). eGFR displayed simi-
lar dynamics (Figure 2B). Independently of baseline levels, repeatedly measured Cr 
and eGFR predicted the endpoint (per 20% increase of Cr levels: HR [95%CI] 1.18 
[1.07–1.31], p=0.004, and per 20% eGFR decrease: 1.13 [1.05–1.23], p=0.002) (Table 
2). Similarly, their larger slopes and larger AUCm predicted the endpoint (per 20% 
increase of Cr slope: 1.57 [1.39–1.84], p<0.001, per 20% decrease of eGFR slope: 1.59 
[1.37–1.90], p<0.001) (per 20% increase of Cr’s AUCm: 1.10 [1.03–1.18], p=0.010, and 
eGFR’s AUCm: 1.07 [1.02–1.11], p<0.001). These risk estimates remained significant 
even after adjustment for clinical characteristics and dose changes of HF medications 
during follow-up. After adjustment for cardiac markers, Cr’s levels and AUCm lost 
precision, whereas eGFR remained significant (Table 2). Table S1 shows similar results 
for HF-hospitalizations (secondary endpoint).
Cystatin C
In patients who reached the composite endpoint, CysC showed on average higher 
baseline levels that increased further as the endpoint approached. In endpoint -free 
patients, CysC levels were lower and slightly decreased during follow-up (Figure 2C). 
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C
A
FIGUR E 2 Average evolution of glomerular function markers during follow-
up. Average evolution in patients who reached the study endpoint (solid red line), and in 
endpoint-free patients (solid blue line). Dashed lines represent the 95% confidence interval. 
X-axis depicts the time from baseline (left part of the x-axis), and time remaining to the event 
(patients who experienced incident events) or last sample moment (patients who remained 
event-free) (right part of the x-axis). Biomarker levels are presented on the y-axis. BL, baseline; 
pts., patients. A. creatinine (mg/dL); B. eGFR (ml/min/1.73m2); C. cystatin C (µg/ml).  
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TAB LE 2 Associations between glomerular function markers and the composite 
endpoint.
Creatinine eGFR Cystatin C
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Baseline level *
Model A 1.04 (0.99–1.09) 0.14 1.03 (0.99–1.07) 0.13 1.09 (1.05–1.14) <0.001
Model B 1.02 (0.97–1.07) 0.49 1.02 (0.97–1.06) 0.48 1.07 (1.02–1.12) 0.007
Model C 0.98 (0.93–1.03) 0.46 0.98 (0.94–1.02) 0.28 1.00 (0.95–1.06) 0.89
Temporal evolution†
Repeatedly measured levels
Model 1 1.18 (1.07–1.31) 0.004 1.13 (1.05–1.23) 0.002 2.41 (1.81–3.41) <0.001
Model 2 1.12 (1.02–1.23) 0.022 1.12 (1.06–1.20) <0.001 2.16 (1.44–3.72) <0.001
Model 3 1.05 (0.96–1.15) 0.28 1.09 (1.04–1.14) <0.001 1.63 (1.35–2.30) <0.001
Model 4 1.15 (1.08–1.24) <0.001 1.10 (1.04–1.16) <0.001 2.27 (1.99–2.59) <0.001
Annual slope 
Model 1 1.57 (1.39–1.84) <0.001 1.59 (1.37–1.90) <0.001 1.76 (1.52–2.09) <0.001
Model 2 1.65 (1.40–1.98) <0.001 1.64 (1.38–2.02) <0.001 2.00 (1.66–2.51) <0.001
Model 3 1.37 (1.22–1.57) <0.001 1.30 (1.16–1.46) 0.002 1.47 (1.32–1.66) <0.001
Model 4 1.28 (1.16–1.43) <0.001 1.18 (1.07–1.31) 0.001 1.63 (1.50–1.77) <0.001
AUCm 
Model 1 1.10 (1.03–1.18) 0.010 1.07 (1.02–1.11) <0.001 1.32 (1.17–1.54) <0.001
Model 2 1.08  (1.01–1.15) 0.020 1.07 (1.02–1.12) <0.001 1.23 (1.13–1.36) <0.001
Model 3 1.04 (0.98–1.10) 0.17 1.06 (1.02–1.10) <0.001 1.17 (1.08–1.28) <0.001
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase of 
creatinine and cystatin C, and 20% eGFR decrease. Model A: unadjusted; Model B: adjusted 
for age, sex, diabetes, atrial fibrillation, baseline NYHA class, diuretics, and systolic blood 
pressure; Model C: adjusted for baseline NT-proBNP and hs-cTnT.
† HRs and 95% CIs are given per 20% increase of the level, slope, and AUCm of creatinine 
and cystatin C, and 20% decrease of the level, slope, and AUCm of eGFR. Model 1: Cox model 
adjusted for marker’s baseline levels, LME model adjusted for sampling time; Model 2: Cox 
and LME models adjusted for the clinical variables: age, sex, diabetes, atrial fibrillation, 
Independently of baseline levels, CysC levels at any time during follow-up were asso-
ciated with the endpoint (per 20% increase of CysC levels: 2.41 [1.81–3.41], p<0.001) 
(Table 2). Similarly, larger slope and larger AUCm predicted the endpoint (1.76 
[1.52–2.09], p<0.001 and 1.32 [1.17–1.54], p<0.001). These risk estimates remained 
significant after multivariable adjustments (Table 2). Table S1 shows similar results 
for HF-hospitalizations.  
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baseline NYHA class, diuretics, systolic blood pressure, and sampling time (LME); Model 3: 
Cox and LME models adjusted for baseline NT-proBNP and hs-cTnT, and sampling time (LME); 
Model 4: Time-dependent Cox adjusted for total daily equivalent doses of carvedilol, 
enalapril, furosemide, and spironolactone during follow-up.   
Temporal evolution of tubular function
Overall, we found substantial associations between NAG, KIM-1, and NGAL, but 
only mild associations between these tubular markers and glomerular function 
markers (namely CysC), when assessed during follow-up (Table S2).
FIGU R E 3 Average evolution of tubular markers, urinary NAG and KIM-1, during 
follow-up. For description see Figure 2. Dashed black lines represent the biomarkers’ reference 
values. BL, baseline; pts., patients. A. urinary NAG (U/gCr) B. urinary KIM-1 (ng/gCr). 
A
B
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Urinary NAG
In patients who reached the composite endpoint, NAG showed on average higher base-
line levels that increased further as the endpoint approached. In endpoint -free patients, 
NAG levels were lower and decreased during follow-up (Figure 3A). Independently of 
baseline levels, higher NAG levels at any time during follow-up were associated with 
the endpoint (per 20% increase of NAG levels: 1.06 [1.01–1.11], p=0.018). Similarly, 
larger NAG slope predicted the endpoint (1.26 [1.11–1.44], p=0.004).These risk esti-
mates remained significant after multivariable adjustments, except for NAG slope that 
became insignificant after controlling for cardiac markers (Table 3). Table S3 shows 
similar results for HF-hospitalizations, except for NAG levels that lost significance after 
adjusting for cardiac markers.  
Urinary KIM-1
In patients who reached the composite endpoint, KIM-1 levels showed an average in-
creasing pattern over time preceding the endpoint. In endpoint-free patients, KIM-1 
levels were lower and slightly decreased during follow-up (Figure 3B). Independently 
of baseline levels, higher KIM-1 levels at any time during follow-up were associated 
with the endpoint (per 20% increase of KIM-1 levels: 1.08 [1.04–1.11], p<0.001). Sim-
ilarly, larger KIM-1 slope predicted the endpoint (1.64 [1.38–2.05], p<0.001). These 
risk estimates remained significant after multivariable adjustments (Table 3). Table S3 
shows similar results for HF-hospitalizations, except for KIM-1 levels that lost signifi-
cance after adjusting for cardiac markers.
Plasma and urinary NGAL
Although baseline plasma NGAL levels were higher in patients who reached the 
endpoint, this difference declined during follow-up (Figure S2A). The evolution 
of urinary NGAL levels of patients who reached the endpoint and those who did 
not substantially overlapped during follow-up (Figure S2B). No clear associations 
were found between NGAL and primary and secondary endpoints during follow-
up (Tables S4 and S5). 
Prospective accuracy 
Table S6 shows the time-dependent AUCs for the different renal markers for the 
composite endpoint. After the 1-year collection time period, markers showed rea-
sonably good discriminatory power both for the 6- and 12-month risk window 
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with slightly better accuracy for the 6-month window. The highest accuracy was 
found for clinical models using levels of CysC, NAG, and KIM-1 (6-month AUCs: 
0.80, 0.81, and 0.80 respectively). 
TAB LE 3 Associations between tubular markers, urinary NAG and KIM-1, and 
the composite endpoint.
Urinary NAG Urinary KIM-1
HR (95% CI) p-value HR (95% CI) p-value
Baseline levels*
Model A 1.07 (1.05–1.09) <0.001 1.02 (1.00–1.04) 0.06
Model B 1.06 (1.03–1.09) <0.001 1.01 (0.99–1.03) 0.26
Model C 1.03 (1.00–1.06) 0.050 0.99 (0.97–1.01) 0.44
Temporal evolution†
Repeatedly measured levels 
Model 1 1.06 (1.01–1.11) 0.018 1.08 (1.04–1.11) <0.001
Model 2 1.07 (1.03–1.12) <0.001 1.06 (1.03–1.10) <0.001
Model 3 1.05 (1.00–1.10) 0.048 1.04 (1.01–1.07) 0.016
Model 4 1.13 (1.09–1.17) <0.001 1.06 (1.03–1.09) <0.001
Annual slope
Model 1 1.26 (1.11–1.44) 0.004 1.64 (1.38–2.05) <0.001
Model 2 1.50 (1.18–2.00) 0.002 1.78 (1.41–2.39) <0.001
Model 3 0.81 (0.65–1.41) 0.16 1.52 (1.25–1.98) <0.001
Model 4 1.10 (1.02–1.20) 0.009 1.12 (1.04–1.20) 0.002
AUCm
Model 1 1.02 (0.99–1.05) 0.11 1.01(0.99–1.02) 0.23
Model 2 1.04 (1.01–1.07) 0.01 1.01 (0.99–1.03) 0.10
Model 3 1.01 (0.98–1.05) 0.33 1.01 (0.99–1.02) 0.38
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase of urinary 
NAG and KIM-1. Model A: unadjusted; Model B: adjusted for age, sex, diabetes, atrial fibrillation, 
baseline NYHA class, diuretics, systolic blood pressure, and eGFR; Model C: adjusted for baseline 
NT-proBNP and hs-cTnT. 
† HRs and 95% CIs are given per 20% increase of the level, slope, and AUCm of urinary NAG 
and KIM-1. Model 1: Cox model adjusted for marker’s baseline levels, LME model adjusted for 
sampling time; Model 2: Cox and LME models adjusted for age, sex, diabetes, atrial fibrillation, 
baseline NYHA class, diuretics, systolic blood pressure, eGFR, and sampling time (LME); Model 3: 
Cox and LME models adjusted for baseline NT-proBNP and hs-cTnT, and sampling time (LME). 
Model 4: Time-dependent Cox adjusted for total daily equivalent doses of carvedilol, enalapril, 
furosemide, and spironolactone during follow-up.   
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Patient-specific dynamic prediction
Figure S3 shows the temporal patterns of eGFR and NAG in several individual 
patients from our cohort, together with their corresponding individual survival 
probabilities as estimated by the joint model. The figure shows that each time an 
additional  measurement is performed in the patient, the individual survival prob-
ability is updated. Specifically, rising marker levels and worsening prognosis can be 
seen in the example patients who ultimately reached the composite endpoint, ver-
sus stable or decreasing marker levels and more favorable prognosis in the example 
patients who stayed event-free.
DISCUSSION
We have shown that in patients with CHF both glomerular function (as assessed 
by repeatedly measured creatinine, eGFR, and CysC), and tubular function (as as-
sessed by repeatedly measured urinary NAG and KIM-1) deteriorate over time pre-
ceding clinical outcome. Importantly, patient-specific trajectories of all glomerular 
markers dynamically predicted the event, and CysC was the strongest predictor. 
Similarly, patient-specific trajectories of urinary NAG and KIM-1 indicated pro-
gression of tubular damage in patients who later suffered adverse events. No clear 
associations were found between repeatedly measured plasma or urinary NGAL 
and the event. Therefore, the current study does not justify its use for clinical pre-
diction in patients with CHF. 
Our findings confirm that renal function is an indivisible component of HF, and 
that it is clinically relevant for the monitoring of stable patients with CHF. Importantly, 
our results show that temporal changes in renal function remain predictive for clini-
cal outcome despite controlling for NYHA class, cardiac markers and other clinical 
features, which suggests that renal dysfunction may drive adverse clinical outcomes in-
dependently of cardiac dysfunction. In addition, the results demonstrate the predictive 
value not only of GFR levels (single value or cumulative effects), but also of GFR slope. 
These findings are supported by other studies.4,10 However, unlike previous studies, our 
study underscores that GFR evolution should be assessed as a function of time. In other 
words, information on early and late GFR changes,20 as well as the time interval during 
which GFR was measured should be taken into consideration. This recommendation 
is also supported by recent results from Damman et al, who found that when eGFR is 
assessed as a function of time, any decrease in eGFR will result in increased event rates. 
In previous studies, deltas in creatinine or eGFR between any two sampling moments 
were mostly used, which may have led to bias as a consequence of differences in the 
time-periods (before the event) in which sampling was performed. In our study, the ob-
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servations were made using two glomerular markers, creatinine and CysC, which were 
assessed at fixed time intervals; using more than twice as many repeated measurements 
as previous studies did. Notably, CysC showed the strongest association with adverse 
events. Considering that generation of creatinine changes when muscle wasting occurs 
with progression of cardiac disease, this can be of particular interest when renal func-
tion is repeatedly assessed in the same individual with CHF. Nonetheless, this issue 
requires further exploration.  
In the setting of tubular injury, we found not only that patients with CHF ex-
perience tubular damage, but also that the damage progresses over time (months) 
preceding a clinical event. This extends previous findings by demonstrating that 
tubular markers, which were previously shown to capture acute kidney injury21, 
are also clinically relevant in chronic tubular damage in patients with CHF when 
followed during a prolonged time period.11 To our best knowledge, our study is the 
first to simultaneously follow glomerular and tubular markers and to show that 
glomerular dysfunction and tubular injury, in most cases, do not progress over 
time in parallel. This implies that, although the failing heart affects both renal 
compartments, the degree of damage in these compartments is usually not tempo-
rally coupled. Therefore, they should be viewed as different renal entities in CHF. 
In addition, when we examined NAG and KIM-1, we found that NAG levels will 
rise first, followed by a rise in KIM-1. This suggests that, although both markers 
are labeled as “tubular damage markers”, they reflect different biological aspects of 
tubular injury, and their values depend on the moment in time prior to the event at 
which they are assessed. These findings are in line with their behavior as previously 
found. Increased urinary excretion of NAG has been found to occur with abnormal 
increases in protein traffic across the proximal tubules as a consequence of a dam-
aged glomerular barrier.22 On the other hand,  KIM-1 gene expression has been 
found to be up-regulated in a dose-dependent manner in response to direct tubular 
injury.23 KIM-1 also correlated strongest with tubular damage as determined by 
kidney biopsies. It outperformed serum creatinine, blood urea nitrogen (BUN) and 
urinary NAG.24,25 Thus, it appears that NAG is a marker of tubular dysfunction that 
shows an early initial rise, while KIM-1 can serve as a quantitative marker of tu-
bular damage, if modeled in a time-dependent manner. Importantly, both tubular 
markers are relevant for clinical outcomes.
The unique advantages of our study include frequent repeated measurements at 
pre-specified time intervals (i.e., sampling was not left at the discretion of the treat-
ing physicians) during longer-term follow-up. This allowed us to provide an unbiased 
assessment of a patient’s risk by using the complete temporal biomarker trajectory 
as assessed over the entire follow-up period. Based on this underlying trajectory, 
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biomarker levels are used to estimate the risk of future adverse events.19 Herewith, 
a window of opportunity may be gained to modify the treatment before a future 
event occurs. Joint modeling (JM) of patient-specific marker trajectories and survival 
analysis enables us to perform individualized risk predictions based on individual 
biomarker values. Subsequently, predictions are dynamically updated to provide re-
al-time risk assessment whenever extra information is collected.18 Such dynamic risk 
profiling can enable physicians to better detect disease progression and to make well-
informed individualized treatment decisions. Applicability of JM in daily practice is 
user-friendly, and an app is already available into which a patient’s data (baseline and 
follow-up) can be uploaded (for details please see Figure S4).26
Study limitations 
Firstly, our cohort consisted mainly of HFrEF patients. The low number of patients 
with HFpEF can most likely be attributed to the fact that in the Netherlands, most 
HFpEF patients are treated by the general practitioner or in secondary referral cen-
tres, while the current study was performed in two centres which were both tertiary 
referral centres. Potential inclusion bias is not a likely reason for the low HpEF 
rate, because all consecutive patients were screened in both participating centres. 
Secondly, enrolled CHF patients were in a better health condition than previously 
reported CHF populations. Yet we were able to demonstrate, even in this ‘less sick’ 
CHF population, that evolutions of glomerular and tubular dysfunction predict 
clinical outcome. Thus, it is possible that these markers could perform even better 
in more sick CHF patients. Thirdly, although we adjusted for several confounders, 
residual confounding may be present. However, we corrected all urinary markers 
for concentration or dilution of urine caused by diuretics during follow-up. Fur-
thermore, treating physicians were blinded to biomarker data to exclude bias by 
treatment effect. Finally, although our findings underscore the importance of regu-
lar monitoring of both glomerular and tubular function in CHF, routine evaluation 
of kidneys should always be seen in the light of the patient’s clinical status. 
CONCLUSION
Altogether, our findings demonstrate that glomerular function (as assessed by cre-
atinine, eGFR, and CysC), and tubular function (as assessed by urinary NAG and 
KIM-1) deteriorate, but not simultaneously, during clinically silent progression of 
CHF over time preceding adverse events. Patient-specific temporal evolutions of 
these repeatedly measured renal markers dynamically predict clinical outcome in 
CHF patients, and are useful for individual risk profiling.
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SUPPLEMETARY INFORMATION 
FIGU R E S1 Inclusion and exclusion criteria.
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TAB LE S1 Associations between glomerular function markers and HF-
hospitalizations.
Creatinine eGFR Cystatin C
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Baseline level *
Model A 1.04 (0.98–1.10) 0.17 1.04 (0.99–1.08) 0.11 1.10 (1.05–1.15) <0.001
Model B 1.01 (0.95–1.08) 0.70 1.01 (0.96–1.07) 0.65 1.06 (1.01–1.12) 0.034
Model C 0.98 (0.92–1.04) 0.46 0.98 (0.93–1.03) 0.38 1.01 (0.95–1.07) 0.85
Temporal evolution†
Repeatedly measured levels
Model 1 1.22 (1.09–1.39) <0.001 1.17 (1.08–1.27) <0.001 2.40 (1.79–3.26) <0.001
Model 2 1.13 (1.01–1.27) 0.032 1.15 (1.07–1.24) <0.001 2.64 (1.63–4.31) <0.001
Model 3 1.07 (0.96–1.18) 0.21 1.12 (1.06–1.18) <0.001 2.04 (1.46–3.31) <0.001
Model 4 1.19 (1.10–1.28) <0.001 1.12 (1.06–1.19) <0.001 2.96 (2.46–3.56) <0.001
Annual slope
Model 1 1.61 (1.42–1.86) <0.001 1.65 (1.41–2.00) <0.001 1.75 (1.50–2.05) <0.001
Model 2 1.76 (1.45–2.17) <0.001 1.68 (1.42–2.12) <0.001 1.93 (1.61–2.3) <0.001
Model 3 1.43 (1.27–1.62) <0.001 1.36 (1.21–1.55) <0.001 1.46 (1.31–1.68) <0.001
Model 4 1.36 (1.21–1.52) <0.001 1.27 (1.14–1.41) <0.001 1.65 (1.51–1.81) <0.001
AUCm 
Model 1 1.10 (1.02–1.19) 0.014 1.07 (1.02–1.12) 0.004 1.35 (1.7–1.63) <0.001
Model 2 1.08 (1.01–1.16) 0.026 1.08 (1.03–1.12) 0.004 1.22 (1.11–1.38) <0.001
Model 3 1.05 (0.98–1.12) 0.18 1.07 (1.03–1.11) <0.01 1.20 (1.09–1.33) <0.001
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase of 
creatinine and cystatin C, and 20% eGFR decrease. Model A: unadjusted; Model B: adjusted 
for age, sex, diabetes, atrial fibrillation, baseline NYHA class, diuretics, and systolic blood 
pressure; Model C: adjusted for baseline NT-proBNP and hs-cTnT.
† HRs and 95% CIs are given per 20% increase of the level, slope, and AUCm of creatinine 
and cystatin C, and 20% decrease of the level, slope, and AUCm of eGFR. Model 1: Cox model 
adjusted for marker’s baseline levels, LME model adjusted for sampling time; Model 2: Cox and 
LME models adjusted for the clinical variables: age, sex, diabetes, atrial fibrillation, baseline 
NYHA class, diuretics, systolic blood pressure, and sampling time (LME); Model 3: Cox and 
LME models adjusted for NT-proBNP and hs-cTnT, and sampling time (LME); Model 4: Time-
dependent Cox adjusted for total daily equivalent doses of carvedilol, enalapril, furosemide, 
and spironolactone during follow-up.   
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TAB LE S3 Associations between tubular damage markers, urinary NAG and 
KIM-1, and HF-hospitalizations.
Urinary NAG Urinary KIM-1
HR (95% CI) p-value HR (95% CI) p-value
Baseline levels*
Model A 1.07 (1.05–1.10) <0.001 1.01 (0.99–1.04) 0.16
Model B 1.07 (1.04–1.10) <0.001 1.01 (0.98–1.03) 0.55
Model C 1.04 (1.01–1.07) 0.020 0.99 (0.95–1.01) 0.26
Temporal evolution†
Repeatedly measured levels 
Model 1 1.09 (1.02–1.11) 0.006 1.06 (1.02–1.10) 0.006
Model 2 1.08 (1.03–1.12) 0.002 1.04 (1.01–1.08) 0.006
Model 3 1.03 (0.98–1.07) 0.29 1.03 (0.99–1.06) 0.09
Model 4 1.13 (1.09–1.17) <0.001 1.07 (1.04–1.10) <0.001
Annual slope
Model 1 1.48 (1.21–1.99) <0.001 1.65 (1.35–2.10) <0.001
Model 2 1.80 (1.33–2.69) <0.001 1.71 (1.35–2.25) <0.001
Model 3 0.93 (0.80–1.18) 0.40 1.25 (1.13–1.39) <0.001
Model 4 1.08 (1.00–1.18) 0.06 1.16 (1.08–1.25) <0.001
AUCm
Model 1 1.03 (0.99–1.06) 0.09 1.00 (0.99–1.02) 0.59
Model 2 1.04 (1.01–1.08) 0.020 1.01 (0.99–1.03) 0.31
Model 3 1.00 (0.97 –1.03) 0.98 1.00 (0.98–1.02) 0.74
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase in 
urinary NAG and KIM-1. Model A: unadjusted; Model B: adjusted for age, sex, diabetes, 
atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure, and eGFR; Model C: 
adjusted for baseline NT-proBNP and hs-cTnT. 
† HRs and 95% CIs are given per 20% increase in the level, slope, and AUCm of urinary NAG 
and KIM-1. Model 1: Cox model adjusted for marker’s baseline levels; Model 2: Cox and 
LME models adjusted for age, sex, diabetes, atrial fibrillation, baseline NYHA class, diuretics, 
systolic blood pressure, eGFR, and sampling time (LME);  Model 3: Cox and LME models 
adjusted for baseline NT-proBNP and hs-cTnT, and sampling time (LME); Model 4: Time-
dependent Cox adjusted for total daily equivalent doses of carvedilol, enalapril, furosemide, 
and spironolactone during follow-up.   
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FIGU R E S2  Average evolution of tubular markers, urinary and plasma NGAL, 
during follow-up. Average evolution in patients who reached the study endpoint (solid 
red line), and in event-free patients (solid blue line). Dashed lines represent the 95% 
confidence interval. X-axis depicts the time from baseline (left part of the x-axis), and the 
time remaining to the event (patients who experienced incident events) or last sampling 
moment (patients who remained event-free) (right part of the x-axis). Biomarker levels are 
presented on the y-axis. Dashed black lines represent the biomarkers’ reference values (<1 
µg/gCr). A. plasma NGAL(ng/ml); B. urinary NGAL(µg/gCr). BL, baseline; pts., patients.
B
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TAB LE S4 Associations between tubular markers, urinary and plasma NGAL, 
and the composite endpoint.
urinary NGAL plasma NGAL
HR (95% CI) p-value HR (95% CI) p-value
Baseline levels*
Model A 1.01 (1.00–1.02) 0.08 1.08 (1.04–1.11) <0.001
Model B 1.01 (0.99–1.03) 0.21 1.06 (1.02–1.10) 0.004
Model C 0.99 (0.97–1.01) 0.95 1.01 (0.97–1.04) 0.74
Temporal evolution†
Repeatedly measured levels 
Model 1 0.94 (0.65–1.35) 0.78 1.01 (0.94–1.09) 0.75
Model 2 X x
Model 3 x x
Annual slope 
Model 1 x x
Model 2 x x
Model 3 x x
Model 4 x x
AUCm
Model 1 x x
Model 2 x x
Model 3 x x
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase of 
urinary and plasma NGAL. Model A: unadjusted; Model B: adjusted for age, sex, diabetes, 
atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure, and eGFR; Model C: 
adjusted for baseline NT-proBNP and hs-cTnT. 
† HRs and 95% CIs are given per 20% increase of the level, slope, and AUCm of urinary 
and plasma NGAL. Model 1: Cox model adjusted for marker’s baseline levels, LME model 
adjusted for sampling time; Model 2: Cox and LME models adjusted for age, sex, diabetes, 
atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure, eGFR, and sampling 
time (LME); Model 3: Cox and LME models adjusted for baseline NT-proBNP and hs-cTnT, 
and sampling time (LME). Model 4: Time-dependent Cox adjusted for total daily equivalent 
doses of carvedilol, enalapril, furosemide, and spironolactone during follow-up.   
x The models were not performed because repeatedly measured level was not significant.
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TAB LE S5 Associations between tubular markers, urinary and plasma NGAL, 
and HF-hospitalizations. 
urinary NGAL plasma NGAL
HR (95% CI) p-value HR (95% CI) p-value
Baseline levels*
Model A 1.02 (1.00–1.03) 0.06 1.09 (1.05–1.13) <0.001
Model B 1.01 (0.99–1.03) 0.26 1.06 (1.02–1.10) 0.007
Model C 1.00 (0.99–1.02) 0.90 1.01 (0.97–1.06) 0.49
Temporal evolution†
Repeatedly measured levels 
Model 1 0.99 (0.95–1.03) 0.68 0.99 (0.91–1.09) 0.84
Model 2 x x
Model 3 x x
Model 4 x x
Annual slope
Model 1 x x
Model 2 x x
Model 3 x x
Model 4 x x
AUCm
Model 1 x x
Model 2 x x
Model 3 X x
AUCm – area under the curve of marker’s trajectory.
* Hazard ratios (HRs) and 95% confidence intervals (CIs) are given per 20% increase of 
urinary and plasma NGAL. Model A: unadjusted; Model B: adjusted for age, sex, diabetes, 
atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure, and eGFR; Model C: 
adjusted for baseline NT-proBNP and hs-cTnT. 
† HRs and 95% CIs are given per 20% increase of the level, slope, and AUCm of urinary 
and plasma NGAL. Model 1: Cox model adjusted for marker’s baseline levels, LME model 
adjusted for sampling time; Model 2: Cox and LME models adjusted for age, sex, diabetes, 
atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure, eGFR, and sampling 
time (LME); Model 3: Cox and LME models adjusted for baseline NT-proBNP and hs-cTnT, 
and sampling time (LME). Model 4: Time-dependent Cox adjusted for total daily equivalent 
doses of carvedilol, enalapril, furosemide, and spironolactone during follow-up.   
x The models were not performed because repeatedly measured level was not significant.
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FIGU R E S3 Clinical scenarios where a patient’s risk is dynamically profiled 
using patient-specific trajectories. The solid red lines depict patients who experienced 
the study endpoint, and the solid blue lines depict patients who did not. X-axis depicts 
follow-up time in months starting from baseline (BL). Biomarker levels (on 2log scale) are 
displayed on the primary (left) Y-axis and survival probability (%) on the secondary (right) 
Y-axis. Patient-specific marker’s trajectory with scatter points is displayed left of the vertical 
dotted black line. To the right of this line, the corresponding conditional survival probability 
curve is displayed with 95% confidence intervals (grey area). To show how this conditional 
survival probability curve is dynamically updated every time an extra measurement is 
recorded, we have provided three time-points at which the risk was assessed. For each of 
the four patients, we considered: (1) information on their measurements up to these three 
time-points and (2) the fact that they had survived up to each of the time-points. This 
information was then jointly modeled to provide the conditional survival probability curve 
for the remaining time period until the study ended (i.e., the patients suffered the event or 
were censored). 
*Conditional – given that the patient survived up to the time interval during which 
measurements were collected.
A
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Scenario A. For the first patient (who did not experience the endpoint), we notice high 
baseline eGFR levels and high conditional survival probability. Conversely, the second 
patient (who ultimately experienced the endpoint) exhibits lower baseline eGFR levels, 
that continue to decline during follow-up. This eGFR decline corresponds to decline in the 
patient’s conditional survival probability. 
Scenario B. For the third patient (who did not experience the endpoint), we notice slightly 
higher NAG levels than for the fourth patient (who ultimately experienced the endpoint) at 
the moment of the first assessment. Logically, the conditional survival probability for the 
third patient is slightly lower than for the fourth patient. Yet the third patient exhibits a 
decline in NAG levels during follow-up, and the patient’s conditional survival probability 
profile improves. Conversely, in the fourth patient NAG levels increase over time preceding 
the endpoint, which reduces the patient’s survival probability. 
B
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
88
TAB LE S6 The longitudinal marker’s accuracy.
Renal Markers Risk Time Window AUC (t)Clinical model Biomarkers model
Repeatedly measured levels
Creatinine
6 months 0.77 0.75
12 months 0.72 0.76
eGFR
6 months 0.77 0.70
12 months 0.73 0.72
Cystatin C
6 months 0.80 0.77
12 months 0.74 0.72
NAG
6 months 0.81 0.77
12 months 0.76 0.79
KIM-1
6 months 0.80 0.75
12 months 0.72 0.76
Annual slope 
Creatinine
6 months 0.64 0.62
12 months 0.67 0.69
eGFR
6 months 0.64 0.62
12 months 0.68 0.69
Cystatin C
6 months 0.78 0.77
12 months 0.71 0.72
NAG
6 months 0.76 0.73
12 months 0.73 0.71
KIM-1
6 months 0.61 0.66
12 months 0.65 0.72
We determined the longitudinal marker’s predictive accuracy (i.e., an ability of a marker 
to discriminate between a patient who experiences the endpoint within a given risk time 
window after the last measurement, and the patient who does not experience the event 
within the same risk time window) using the time-dependent AUC. For this purpose, we 
chose the first year as the collection time period, and we assessed two risk time windows: 6 
and 12 months after collection time. We determined the predictive accuracy of the marker’s 
levels and slopes in two multivariable adjusted models: a) clinical model: Cox and LME 
models adjusted for age, sex, diabetes, atrial fibrillation, NYHA class, diuretics, systolic blood 
pressure, eGFR (for NAG and KIM-1), and sampling time (LME); b) biomarker model: Cox and 
LME models adjusted for NT-proBNP and hs-cTnT, and sampling time (LME).
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FIGU R E S4 An app inter face using joint modeling approach to calculate and 
communicate the risk in an individual patient.
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ABSTRACT
Background
Our aim was to explore potential use of temporal profiles of seven emerging car-
dio-renal and two pulmonary candidate biomarkers for predicting future adverse 
clinical outcome in stable patients with chronic heart failure (CHF).  
Methods
In 263 CHF patients, we determined the risk of a composite endpoint of HF-hos-
pitalization, cardiac death, LVAD-placement and heart transplantation in relation 
to repeatedly assessed (567 samples in total) blood biomarker levels, and slopes 
of their temporal trajectories (i.e., rate of biomarker change per year). In each pa-
tient, we estimated biomarker trajectories using repeatedly measured osteopontin 
(OPN), osteoprotegerin (OPG), epidermal growth factor receptor (EGFR), hepa-
rin-binding protein (HBP), trefoil factor-3 (TFF3), kallikrein-6 (KLK-6), matrix 
extracellular phosphoglycoprotein (MEPE), pulmonary surfactant-associated pro-
tein-D (PSP-D), and secretoglobulin family 3A-member-2 (SCGB3A2). 
Results
During 2.2 years of follow-up, OPN, OPG, and HBP levels predicted the composite 
endpoint (univariable hazard ratio [95% confidence interval] per 1SD increase: 
2.31 [1.76-3.15], 2.23 [1.69–3.00], and 1.36 [1.09-1.70]). Independently of the 
biomarkers’ levels, the slopes of OPG, TFF-3, PSP-D trajectories were also strong 
clinical predictors (per 0.1SD increase/year: 1.24 [1.14–1.38], 1.31 [1.17–1.49], 
and 1.32 [1.21–1.47]). All associations persisted after multivariable adjustment for 
baseline characteristics, and repeatedly assessed CHF pharmacological treatment 
and cardiac biomarkers NT-proBNP and troponin T. 
Conclusions
Repeatedly-measured levels of OPN, OPG, and HBP, and slopes of OPG, TFF-3, 
and PSP-D strongly predict clinical outcome. These candidate biomarkers may be 
clinically relevant as they could further define a patient’s risk and provide addi-
tional pathophysiological insights into CHF. 
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INTRODUCTION
Chronic heart failure (CHF) is a clinical syndrome which often requires constant 
therapeutic interventions due to recurrent episodes of cardiac decompensation.1 
The failing heart also induces structural and functional changes in distant organs 
such as the kidneys and the lungs.2,3 Eventually, a vicious circle of pathophysiologi-
cal processes is formed between these organs leading to end-stage heart failure.4,5 
In this context, circulating biomarkers that reflect the status of this multi-organ 
pathophysiology may be a valuable clinical tool, as these biological signals precede 
decompensation and may provide early organ-specific information in CHF. There-
fore, patient-specific biomarker profiles may further characterize the multi-organ 
involvement in CHF, but may also help in monitoring disease progression to allow 
timely adaptation of treatment to prevent impending decompensation. 
Although previous biomarker-based studies have increased our understand-
ing of CHF6,7, several important aspects of biological signals in CHF remain to be 
addressed. Most previous studies have examined the prognostic value of a single 
baseline assessment which is unable to capture progression of CHF that naturally 
occurs over time. These studies also used conventional statistical models that do 
not allow for individualized risk prediction using patient-specific biomarker val-
ues and their change over time. Finally, similar sets of CHF biomarkers have been 
investigated by most of the existing studies such as natriuretic peptides, troponins, 
and markers representing certain aspects of CHF like galectin-3 and ST2. 
Data on the utility of new candidate biomarkers in CHF are scarce, and their 
clinical value remains uncertain. Therefore, in this study, our aim was to explore 
the prognostic utility of temporal profiles of several emerging cardio-renal and 
pulmonary candidate biomarkers in CHF patients during their outpatient follow-
up. 
Cardio-renal candidate biomarkers included osteopontin (OPN), which is as-
sociated with accumulation of monocytes/macrophages in injured renal tissues in-
cluding both glomeruli and tubules,8 and which is mainly overexpressed in cardiac 
non-myocytes during pathological cardiac remodeling;9 osteoprotegerin (OPG), 
which is involved in bone metabolism, endocrine function, and immunity,10 and 
is secreted mainly by osteoblasts and by vascular smooth muscle and endothe-
lial cells, but also in the renal tissue;11 matrix extracellular phosphoglycoprotein 
(MEPE), which is another molecule that regulates bone metabolism, and in par-
ticular phosphates handling in the renal tubules;12 trefoil factor-3 (TFF3), which is 
a member of the trefoil factor peptide family secreted by the renal tubulocites in 
response to injury;13 heparin-binding protein (HBP), which is released from neu-
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trophils upon activation, after which it induces vascular leakage, edema formation, 
and inflammatory reactions which play a role in sepsis-induced acute kidney inju-
ry (AKI);14-16 epidermal growth factor receptor (EGFR), which is a tyrosine kinase 
receptor found to be involved in acute and chronic renal injury;17 and kallikrein 6 
(KLK-6) which is a recently identified member of the kallikrein gene family and is 
involved in degradation of extracellular matrix during tumor invasion and metas-
tasis, but also in demyelization and spinal cord injury.18,19 
Pulmonary candidate biomarkers included pulmonary surfactant-associated 
protein-D (PSP-D), which was found to reduce alveolar macrophages apoptosis 
and to promote clearance of necrotic cells after lung injury,20 and secretoglobulin 
family 3A-member-2 (SCGB3A2), which is another newly discovered biomarker 
with prominent anti-inflammatory and anti-fibrotic activity in animal models of 
pulmonary fibrosis.21 
METHODS 
CHF cohort 
The Serial Biomarker Measurements and New Echocardiographic Techniques in 
Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-
SHiFT) is a prospective cohort of stable patients with CHF, conducted in Erasmus 
MC, Rotterdam, and Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.22,23 
Patients were included if aged ≥18 years, capable of understanding and signing 
informed consent, and if CHF had been diagnosed ≥3 months ago according to Eu-
ropean Society of Cardiology guidelines.1,24,25 Patients were ambulatory and stable, 
i.e., they had not been hospitalized for HF in the past three months. The study 
was approved by the medical ethics committees, conducted in accordance with 
the Declaration of Helsinki, and registered in ClinicalTrials.gov (NCT01851538). 
Written informed consent was obtained from all patients. This investigation com-
prised 263 CHF patients enrolled during the first inclusion period (October 2011 
until June 2013). 
Baseline and follow-up assessment
All patients were evaluated by research physicians, who collected information on 
HF-related symptoms, NYHA class, and performed a physical examination. Infor-
mation on HF etiology, left ventricular ejection fraction (EF of 50% at inclusion 
used as a cut-off for HFrEF versus HFpEF)25, cardiovascular risk factors, medi-
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cal history and treatment was retrieved primarily from hospital records and was 
checked in case of ambiguities. 
During the study, all patients were routinely followed at the outpatient clinic by 
their treating physicians. Additionally, study follow-up visits were predefined and 
scheduled every 3 months (±1 month). At each study follow-up visit, a short medi-
cal evaluation was performed and blood and urine samples were collected. During 
follow-up, all medication changes and occurrence of hospitalizations for HF, MI, 
PCI, CABG, arrhythmias, and CVA, cardiac transplantation, left ventricular assist 
device (LVAD) implantation and mortality, were recorded in the electronic case 
report forms, and associated hospital records and discharge letters were collected. 
Subsequently, a clinical event committee, blinded to the biomarker results, re-
viewed hospital records and discharge letters and adjudicated the study endpoints.
Study endpoints
The composite endpoint comprised of hospitalization for the management of acute 
or worsened HF, cardiac death, cardiac transplantation, and LVAD implantation, 
whichever occurred first. Cardiac death was defined as death from MI or other 
ischemic heart disease (ICD-10: I20-I25), death from other heart disease includ-
ing HF (I30-I45 and I47-I52), sudden cardiac death (I46), sudden death undefined 
(R96) or unwitnessed or ill-described death (R98, R99). Hospitalization for acute 
or worsened HF was defined as a hospitalization for an exacerbation of HF symp-
toms, in combination with two or more of the following: BNP or NT-proBNP >3x 
upper limit of normal, signs of worsening HF, such as pulmonary rales, raised jugu-
lar venous pressure or peripheral edema, increased dose or intravenous adminis-
tration of diuretics, or administration of positive inotropic agents.24
Study measurements and laboratory analysis 
Blood samples were collected at baseline and at each 3-monthly study follow-
up visit, and were processed and stored at -80oC within two hours after collec-
tion. Treating physicians were unaware of biomarker results as biomarkers were 
measured batchwise after completion of follow-up. All laboratory personnel was 
blinded for clinical data and patients outcomes. Batch analysis of serum was per-
formed at Erasmus MC: NT–proBNP was analysed using an electrochemilumines-
ence immunoassay (Roche Diagnostics, Elecsys 2010, Indianapolis, Indiana, USA) 
and cardiac troponin T was also measured using an electrochemiluminesence im-
munoassay (Roche Diagnostics, Elecsys 2010 immunoassay analyser, Indianapo-
lis, Indiana, USA). Plasma samples were transported at a temperature of -80ºC to 
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HaemoScan BV, Groningen, The Netherlands where creatinine was determined by 
a colorometric test by the Jaffé reaction. 
Thus, the biomarker measurements did not lead to drug adjustments. All pa-
tients received treatment according to the ESC guidelines on CHF.1,24 For efficien-
cy, for the current investigation we selected all baseline samples, the two samples 
closest in time to the composite endpoint, and for patients in whom the primary 
endpoint did not occur during follow-up, the last sample available. Glomerular fil-
tration rate (GFR) was determined by the Chronic Kidney Disease-Epidemiology 
Collaboration (CKD-EPI) equation validated in HF patients.26 
The Olink multiplex PEA platform panel for new biomarkers 
The Olink Cardiovascular (CVD) panel III was used for analysis of high-abun-
dance proteins (Olink Proteomics AB, Uppsala, Sweden). The proteins present in 
this Olink panel were selected because either they have a proven pathophysiologi-
cal role in cardiovascular disease, or because they are promising in this respect 
but yet unexplored.  In the current investigation, biomarkers from the panel were 
chosen and grouped based on their previously described predominant tissue ex-
pression and involvement in renal9,16,27-31 and/or pulmonary32,33 pathophysiology.
The Olink panel is based on PEA (proximity extension assay) technology34 
which uses two oligonucleotide-labeled antibodies to bind to their respective tar-
get proteins in the sample. When the two antibodies are in close proximity, a new 
PCR target sequence is formed by a proximity-dependent DNA polymerization 
event. The resulting sequence is subsequently detected and quantified using stan-
dard real-time PCR. Each sample includes two incubations, one extension, and one 
detection control to determine the lower limit of detection and normalize the mea-
surements.The biomarkers are presented in normalized protein expression (NPX) 
units on a 2log scale. In a validation study, the mean intra-assay and inter-assay 
coefficients of variation were 8% and 12%, respectively.34 
Statistical analysis
For the analysis, we used the Z-score (i.e., the standardized form) of the 2log-
transformed biomarkers to allow for direct comparisons of different biomarkers. 
We used a network analysis35 to assess the relationships between biomarkers with 
Pearson’s correlation coefficients p<0.05 using a clustering coefficient as a measure 
of the degree to which biomarkers tend to cluster together (higher coefficients sug-
gest a certain centrality of a biomarker within the network).36 
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To study the effect of baseline characteristics on repeatedly measured biomarkers, 
linear mixed-effects (LME) models were performed using biomarkers as the depen-
dent variables and baseline characteristics as the independent variables (fixed part). 
The sampling time was entered into the fixed- and random parts of the models. 
To estimate the associations between biomarker levels and survival, we applied 
a joint modeling (JM) prediction analysis that combines LME models for repeated 
measurements, and Cox survival analysis for time-to-event data.37 For both the 
fixed- and random-effects parts of the LME models, linear terms were used for 
sampling times, and both intercepts and slopes were included in the random-ef-
fects design matrix. This allowed the markers’ trajectories to differ at baseline and 
over time. We also estimated the time-dependent slope (i.e., rate of change) of 
each biomarker, indicating whether and by how much the levels are increasing or 
decreasing on a continues scales. 
Besides sampling time, all markers were adjusted as follows: (1) clinical model: 
Cox and LME models were adjusted for age, sex, diabetes, atrial fibrillation, baseline 
NYHA class, diuretics, systolic blood pressure, and eGFR; (2) clinical & time-varying 
HF medication model: after adjusting for clinical characteristics, biomarker values 
were extracted from the joint models and entered simultaneously with repeatedly 
assessed equivalent doses of carvedilol, enalapril, furosemide, and spironolactone 
into a time-dependent Cox analysis to examine the incremental value of the new bio-
markers over clinical characteristics and medication during follow-up; (3) time-de-
pendent Cox model using the marker’s fitted values adjusted for type of HF (HFrEF 
vs. HFpEF), and time-varying NT-proBNP and hs-cTnT collected at the same time 
points during follow-up as the biomarker of interest. Data on all variables were com-
plete, except for systolic blood pressure which was missing in <5% of patients and 
for which imputations were applied using the patients’ clinical and outcome data. 
Results are given as hazard ratios (HR) and 95% confidence intervals (CI) per 1SD 
increase of the marker’s level and per 0.1SD increase of the slope at any time-point 
during follow-up.
To correct for multiple testing, we performed matrix spectral decomposition 
which has been used in genetic studies as it has been demonstrated to be more ef-
fective than Bonferroni correction.38 In this way, we accounted for the correlations 
between the biomarkers by setting a significance level at p <0.008 (0.05/6). 
All tests were two-tailed and were performed with R Statistical Software using 
packages nlme and JMbayes.37 The network analysis was performed using Gephi 
software (https://gephi.org) and the matSpD application (https://gump.qimr.edu.
au/general/daleN/matSpD) available online.
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RESULTS
Baseline characteristics
Patients who experienced the primary endpoint during follow-up were older, more 
frequently had diabetes, atrial fibrillation, lower systolic blood pressure, higher 
NYHA class, higher levels of NT-proBNP and cardiac troponin T, and were more 
frequently on diuretics (Table 1). All biomarkers showed significantly higher levels 
at baseline, except for EGFR which was lower, in patients who later experienced the 
endpoint than in endpoint-free patients (Figure S1).
TAB LE 1 Patients characteristics in relation to the composite endpoint.
Variable Total
        Composite endpoint
p-valueYes No
N (%) 263 (100) 70 (27) 193 (73)
Demographics
Age, years 67±13 69±13 66±12 0.05
Men, n (%) 189 (72) 53 (76) 136 (70) 0.41
Clinical characteristics
BMI, kg/m2 27.5±4.7 27.6±4.8 27.4±4.7 0.80
Heart rate, b.p.m.  67±12 69±13 67±11 0.31
SBP, mmHg 122±20 117±17 124±21 0.02
DBP, mmHg 72±11 70±10 73±11 0.06
Features of heart failure
NYHA class III /IV, n (%) 69 (26) 31 (44) 38 (20) < 0.001
HF-rEF n (%) 250 (95) 66 (94) 184 (95) 0.75
HF-pEF n (%) 13 (5) 4 (6) 9 (5)
LVEF, % 32±11 30±11 33±10 0.18
NT pro-BNP (ng/L) † 1161 (439-2305) 2388 (1492–4376) 806 (268–1757) < 0.001
Hs-TnT (ng/L) † 18.0 (9.5–33.2) 31.9 (20.6–49.7) 13.9 (8.4–26.7) < 0.001
Etiology of heart failure, n (%)
Ischemic 117 (44) 36 (51) 81 (42) 0.17
Hypertension 34 (13) 10 (14) 24 (12) 0.70
Valvular disease 12 (5) 5 (7) 7 (4) 0.23
Cardiomyopathy 68 (26) 15 (21) 53 (28) 0.32
Unknown or Others 32 (12) 4 (6) 28 (15)
Medical history, n (%)
Prior MI 96 (36) 32 (46) 64 (33) 0.06
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Variable Total
        Composite endpoint
p-valueYes No
Prior PCI 82 (31) 27 (39) 55 (28) 0.12
Prior CABG 43 (16) 13 (19) 30 (15) 0.57
Atrial fibrillation 106 (40) 36 (51) 70 (36) 0.03
Diabetes 81 (31) 32 (46) 49 (25) 0.002
Hypercholesterolemia 96 (36) 30 (43) 66 (34) 0.20
Hypertension 120 (46) 38 (54) 82 (42) 0.09
COPD 31 (12) 12 (17) 19 (10) 0.10
Medication use, n (%)
Beta-blocker 236 (90) 61 (87) 175 (91) 0.40
ACE-I or ARB 245 (93) 63 (90) 182 (94) 0.22
Diuretics 237 (90) 68 (97) 169 (88) 0.02
Loop diuretics 236 (90) 68 (97) 168 (87) 0.02
Thiazides 7 (3) 3 (4) 4 (2) 0.28
AA 179 (68) 53 (76) 126 (65) 0.11
Glomerular function
Creatinine, mg/dl 1.18 (0.99–1.49) 1.30(1.02–1.52) 1.17(0.98–1.45) 0.18
eGFR, mL/min/1.73m2 58 (43–76) 53 (40–73) 59 (44–77) 0.16
KDOQI classification, n (%) 0.18
eGFR ≥90 28 (11) 7 (10) 21 (11)
eGFR 60-89 95 (36) 20 (28) 75 (39)
eGFR 30-59 119 (45) 37 (53) 82 (42)
eGFR <30 21 (8) 6 (9) 15 (8)
BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; NYHA 
class, New York Heart Association class; HF-rEF, Heart failure with reduced ejection 
fraction; HF-pEF, heart failure with preserved ejection fraction; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; 
CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; TIA, transitory 
ischemic attack; COPD, chronic obstructive pulmonary disease; ACE-I, angiotensin-
converting enzyme inhibitors; ARB, angiotensin II receptor blockers; AA, aldosterone 
antagonist; eGFR, estimated glomerular filtration rate. 
†Median with inter-quartile range (IQR). Normally distributed continuous variables are 
presented as mean ± standard deviation (SD), and non-normally distributed variables as 
median and interquartile interval. Categorical variables are presented as numbers and 
percentages. 
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Follow-up and study endpoints
During a median (IQR) follow-up of 2.2 (1.4–2.5) years, we collected at fixed 
3-month intervals a median (IQR) of 9 (5–10) blood samples per patient (1984 
samples in total). Seventy (27%) patients reached the composite endpoint: 56 pa-
tients were re-hospitalized for acute or worsened HF, 3 patients underwent heart 
transplantation, 2 patients underwent LVAD placement, and 9 patients died of 
cardiovascular causes. For reasons of efficiency, we set out to select all baseline 
samples, the two samples closest in time to the composite endpoint, and the last 
sample available for event-free patients for biomarker measurement. Some of these 
samples were not available, for example in case an endpoint occurred early after 
baseline or before next scheduled study visit. Ultimately, 567 samples were used for 
biomarker measurement. 
Patients’ clinical profile and biomarkers during follow-up
Table 2 shows the associations between the patients’ baseline clinical profiles and 
the repeatedly-measured levels of candidate biomarkers during follow-up. Further-
more, we found a negative association between time-varying enalapril equivalent 
doses and OPN, OPG, PSP-D, and SCGB3A2 levels during follow-up (Table S1). 
Moreover, a negative association was observed between spironolactone equivalent 
doses and OPG, KLK-6, PSP-D, and SCGB3A2 levels, whereas furosemide equiva-
lent doses correlated positively with OPN, TFF-3, KLK-6, and MEPE levels during 
follow-up.  
Network analysis
The network analysis showed that OPN and TFF3 had the highest clustering coef-
ficients which suggests that these two biomarkers had a certain centrality within 
the network, meaning that a large number of biomarker correlations are mediated 
thought these hubs (Figure 1). 
Temporal trends in biomarkers and relation to study endpoint
Figure 2 shows the average temporal evolutions of candidate biomarkers in patients 
who reached the composite endpoint and those who remained endpoint-free. In 
patients who reached the endpoint, OPN, OPG, HBP, and TFF3, PSP-D, and SC-
GB3A2 showed higher baseline levels that increased further during follow-up as 
the endpoint approached. Patients with the endpoint also had constantly higher 
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FIGU R E 1 Network analysis of candidate biomarkers depicting inter-marker 
correlations and associations with the composite outcome. Node color displays 
crude association with primary outcome, and ranges from the weakest (green) to the 
strongest (red); node size displays clustering coefficient (a measure of the degree to which 
biomarkers tend to cluster together suggesting a certain centrality within the biomarker 
network). Thickness of the line between the biomarkers and line color represent the 
correlation coefficient; correlation coefficient is presented only if p-value <0.05. A ticker 
line represents stronger coefficients and line color ranges from the weakest (green) to the 
strongest (red). OPN, osteopontin; OPG, osteoprotegerin; EGFR, epidermal growth factor 
receptor; HBP, heparin-binding protein; TFF3, trefoil factor 3; PSP-D, pulmonary surfactant-
associated protein D; SCGB3A2, secretoglobulin family 3A member 2; KLK-6, kallikrein-6; 
MEPE, matrix extracellular phosphoglycoprotein.
levels of KLK-6 and MEPE, but without a further increase in the approach to the 
endpoint. Table 3 shows the associations of these biomarkers with the composite 
endpoint. 
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
122
TA
B
LE
 2
 A
ss
o
ci
at
io
n
 o
f 
b
as
el
in
e 
fe
at
u
re
s 
w
it
h
 r
ep
ea
te
d
ly
 m
ea
su
re
d
 l
ev
el
s 
o
f 
ca
n
d
id
at
e 
b
io
m
ar
ke
rs
 d
u
ri
n
g
 f
o
ll
o
w
-u
p
.
D
ep
en
de
nt
 v
ar
ia
bl
e
In
de
pe
nd
en
t 
va
ri
ab
le
 
O
PN
O
PG
EG
FR
H
BP
TF
F3
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
Ag
e 
pe
r 1
0 
yr
s.
ns
ns
-0
.2
9 
(-0
.3
8 
to
 -0
.2
0)
<0
.0
01
ns
ns
M
al
e 
se
x
ns
-0
.2
5 
(-0
.4
7 
to
 -0
.0
4)
0.
02
2
ns
ns
-0
.2
7 
(-0
.4
6 
to
 -0
.0
8)
0.
00
6
N
YH
A
 c
la
ss
 p
er
 1
 
po
in
t i
nc
re
as
e
ns
ns
-0
.1
6 
(-0
.2
8 
to
 -0
.0
4)
0.
00
9
ns
0.
20
 (0
.0
8 
to
 0
.3
1)
0.
00
1
D
M
ns
0.
27
 (0
.0
5 
to
 0
.4
8)
0.
01
5
ns
ns
ns
A
F
0.
28
 (0
.1
0 
to
 0
.4
7)
0.
00
3
0.
37
 (0
.1
8 
to
 0
.5
8)
<0
.0
01
ns
0.
23
 (0
.0
3 
to
 0
.4
4)
0.
02
6
ns
SB
P 
pe
r 1
0 
m
m
H
g
ns
ns
ns
ns
ns
eG
FR
 p
er
 2
0 
m
lm
in
/1
.7
3m
2
ns
-0
.1
2 
(-0
.2
2 
to
 -0
.0
2)
0.
01
5
ns
-0
.1
0 
(-0
.2
0 
to
 -0
.0
1)
0.
03
8
-0
.2
1 
(-0
.3
0 
to
 -0
.1
3)
<0
.0
01
N
T-
pr
oB
N
P 
 
pe
r d
ou
bl
in
g 
0.
10
 (0
.0
4 
to
 0
.1
6)
<0
.0
01
ns
ns
ns
0.
13
 (0
.0
7 
to
 0
.1
8)
<0
.0
01
cT
nT
  
pe
r d
ou
bl
in
g
0.
18
 (0
.0
7 
to
 0
.2
8)
<0
.0
01
0.
12
 (0
.0
1 
to
 0
.2
3)
0.
03
3
ns
ns
0.
17
 (0
.0
7 
to
 0
.2
6)
0.
00
1
Ca
rv
ed
ilo
l  
eq
v.
 p
er
 5
0 
m
g
ns
ns
ns
ns
ns
En
al
ap
ril
  
eq
v.
 p
er
 4
0 
m
g
ns
-0
.2
1 
(-0
.3
8 
to
 -0
.0
4)
0.
01
5
ns
ns
ns
Fu
ro
se
m
id
e 
 
eq
v.
 p
er
 4
0 
m
g
0.
06
 (0
.0
4 
to
 0
.0
9)
<0
.0
01
ns
ns
0.
06
 (0
.0
2 
to
 0
.1
1)
0.
00
9
0.
06
 (0
.0
2 
to
 0
.1
1)
0.
00
2
Sp
iro
no
la
ct
on
e 
 e
qv
. p
er
 2
5 
m
g
-0
.1
6 
(-0
.2
9 
to
 -0
.0
2)
0.
03
ns
ns
-0
.2
1 
(-0
.3
7 
to
 -0
.0
5)
0.
01
2
ns
Cardio-renal and Pulmonary candidate biomarkers in CHF Chapter 6
123
D
ep
en
de
nt
 v
ar
ia
bl
e
In
d
e
p
e
n
d
e
n
t 
va
ri
ab
le
 
KL
K-
6
M
EP
E
PS
P-
D
SC
G
B3
A
2
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
β(
95
%
 C
I)
p-
va
lu
e
Ag
e 
pe
r 1
0 
yr
s.
ns
ns
ns
ns
M
al
e 
se
x
ns
ns
ns
-0
.4
1 
(-0
.6
6 
to
 -0
.1
6)
0.
00
2
N
YH
A
 c
la
ss
 p
er
 1
 
po
in
t i
nc
re
as
e
ns
ns
ns
0.
19
 (0
.0
4 
to
 0
.3
4)
0.
01
3
D
M
ns
ns
ns
-0
.4
6 
(-0
.7
1 
to
 -0
.2
2)
<0
.0
01
A
F
ns
ns
ns
ns
SB
P 
pe
r 1
0 
m
m
H
g
-0
.0
5 
(-0
.1
0 
to
 0
.0
0)
0.
04
7
-0
.0
6 
(-0
.1
1 
to
 0
.0
0)
0.
04
1
ns
ns
eG
FR
 p
er
 2
0 
m
lm
in
/1
.7
3m
2
-0
.2
3 
(-0
.3
3 
to
 -0
.1
4)
<0
.0
01
-0
.1
6 
(-0
.2
7 
to
 -0
.0
6)
0.
00
2
ns
ns
N
T-
pr
oB
N
P 
 
pe
r d
ou
bl
in
g 
0.
08
 (0
.0
2 
to
 0
.1
4)
0.
00
7
ns
0.
09
 (0
.0
2 
to
 0
.1
7)
0.
01
6
0.
03
9
cT
nT
  
pe
r d
ou
bl
in
g
0.
21
 (0
.1
0 
to
 0
.3
1)
<0
.0
01
0.
19
 (0
.0
6 
to
 0
.3
1)
0.
00
3
ns
ns
Ca
rv
ed
ilo
l  
eq
v.
 p
er
 5
0 
m
g
ns
0.
14
 (0
.0
1 
to
 0
.2
7)
0.
03
8
ns
ns
En
al
ap
ril
  
eq
v.
 p
er
 4
0 
m
g
ns
ns
ns
ns
Fu
ro
se
m
id
e 
 
eq
v.
 p
er
 4
0 
m
g
ns
0.
06
 (0
.0
1 
to
 0
.1
1)
0.
01
6
ns
ns
Sp
iro
no
la
ct
on
e 
 e
qv
. p
er
 2
5 
m
g
-0
.4
3 
(-0
.5
9 
to
 -0
.2
8)
<0
.0
01
-0
.1
9 
(-0
.3
6 
to
 -0
.0
1)
0.
03
4
-0
.2
4 
(-0
.4
3 
to
 -0
.0
5)
0.
01
3
ns
O
PN
, o
st
eo
po
nt
in
; O
PG
, o
st
eo
pr
ot
eg
er
in
; E
G
FR
, e
pi
de
rm
al
 g
ro
w
th
 f
ac
to
r 
re
ce
pt
or
; H
BP
, h
ep
ar
in
-b
in
di
ng
 p
ro
te
in
; T
FF
3,
 t
re
fo
il 
fa
ct
or
 3
; P
SP
-D
, p
ul
m
on
ar
y 
su
rf
ac
ta
nt
-a
ss
oc
ia
te
d 
pr
ot
ei
n 
D
; S
CG
B3
A
2,
 s
ec
re
to
gl
ob
ul
in
 fa
m
ily
 3
A
 m
em
be
r 2
; K
LK
-6
, k
al
lik
re
in
-6
; M
EP
E,
 m
at
ri
x 
ex
tr
ac
el
lu
la
r p
ho
sp
ho
gl
yc
op
ro
te
in
.
Th
e 
ef
fe
ct
s 
of
 p
at
ie
nt
s’ 
ba
se
lin
e 
ch
ar
ac
te
ri
st
ic
s 
ar
e 
gi
ve
n 
as
 a
dj
us
te
d 
β 
(9
5%
 c
on
fid
en
ce
 in
te
rv
al
) f
or
 1
SD
 d
iff
er
en
ce
s 
of
 b
io
m
ar
ke
rs
 a
s 
m
ea
su
re
d 
on
 th
e 
2l
og
 
sc
al
e.
 T
hi
s 
m
et
ho
d 
al
lo
w
s 
a 
di
re
ct
 c
om
pa
ri
so
n 
of
 th
e 
ef
fe
ct
s 
on
 d
iff
er
en
t b
io
m
ar
ke
rs
. A
ll 
βs
 a
re
 a
dj
us
te
d 
fo
r a
ge
, s
ex
, d
ia
be
te
s 
m
el
lit
us
 (D
M
), 
at
ri
al
 fi
br
ill
at
io
n 
(A
F)
, b
as
el
in
e 
N
YH
A
 c
la
ss
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e 
(S
BP
), 
es
ti
m
at
ed
 g
lo
m
er
ul
ar
 fi
lt
ra
ti
on
 r
at
e 
(e
G
FR
), 
N
T-
pr
oB
N
P 
le
ve
ls
, c
ar
di
ac
 t
ro
po
ni
n 
T 
le
ve
ls
 (c
Tn
T)
, a
nd
 
eq
ui
va
le
nt
 d
os
es
  o
f c
ar
ve
di
lo
l, 
en
al
ap
ri
l, 
fu
ro
se
m
id
e,
 a
nd
 s
pi
ro
no
la
ct
on
e.
 O
nl
y 
th
e 
as
so
ci
at
io
ns
 w
it
h 
si
gn
ifi
ca
nc
e 
le
ve
l o
f p
-v
al
ue
 <
0.
05
 a
re
 p
re
se
nt
ed
. 
co
nt
in
ue
d
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
124
A
B
C
D
E
F
Cardio-renal and Pulmonary candidate biomarkers in CHF Chapter 6
125
FI
G
U
R
E 
2
 A
ve
ra
g
e 
te
m
p
o
ra
l 
ev
o
lu
ti
o
n
 o
f 
ca
n
d
id
at
e 
b
io
m
ar
ke
rs
 d
u
ri
n
g
 f
o
ll
o
w
-u
p
. 
A
ve
ra
ge
 e
vo
lu
ti
on
 i
n 
pa
ti
en
ts
 w
ho
 
re
ac
he
d 
th
e 
co
m
po
si
te
 e
nd
po
in
t (
so
lid
 re
d 
lin
e)
, a
nd
 in
 e
nd
po
in
t-
fr
ee
 p
at
ie
nt
s 
(s
ol
id
 b
lu
e 
lin
e)
. D
as
he
d 
lin
es
 re
pr
es
en
t t
he
 9
5%
 c
on
fid
en
ce
 
in
te
rv
al
. X
-a
xi
s 
de
pi
ct
s 
th
e 
ti
m
e 
fr
om
 b
as
el
in
e 
(le
ft
 p
ar
t o
f t
he
 x
-a
xi
s)
, a
nd
 ti
m
e 
re
m
ai
ni
ng
 to
 th
e 
ev
en
t (
pa
ti
en
ts
 w
ho
 e
xp
er
ie
nc
ed
 in
ci
de
nt
 
ev
en
ts
) o
r 
la
st
 s
am
pl
e 
m
om
en
t 
(p
at
ie
nt
s 
w
ho
 r
em
ai
ne
d 
ev
en
t-
fr
ee
) (
ri
gh
t 
pa
rt
 o
f t
he
 x
-a
xi
s)
. B
io
m
ar
ke
r 
le
ve
ls
 a
re
 p
re
se
nt
ed
 o
n 
th
e 
y-
ax
is
. 
A
. O
st
eo
po
nt
in
 (O
PN
), 
B.
 O
st
eo
pr
ot
eg
er
in
 (O
PG
), 
C
. E
pi
de
rm
al
 g
ro
w
th
 fa
ct
or
 r
ec
ep
to
r 
(E
G
FR
), 
D
. H
ep
ar
in
-b
in
di
ng
 p
ro
te
in
 (H
BP
), 
E.
 T
re
fo
il 
fa
ct
or
-3
 (
TF
F-
3)
, F
. K
al
lik
re
in
-6
 (K
LK
-6
) G
. M
at
ri
x 
ex
tr
ac
el
lu
la
r 
ph
os
ph
og
ly
co
pr
ot
ei
n 
(M
EP
E)
. H
. P
ul
m
on
ar
y 
su
rf
ac
ta
nt
-a
ss
oc
ia
te
d 
pr
ot
ei
n-
D
 
(P
SP
-D
) I
. S
ec
re
to
gl
ob
ul
in
 fa
m
ily
 3
A
-m
em
be
r-
2 
(S
CG
B3
A
2)
. 
G H
I
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
126
TA
B
LE
 3
 A
ss
o
ci
at
io
n
s 
b
et
w
ee
n
 c
an
d
id
at
e 
b
io
m
ar
ke
rs
 a
n
d
 t
h
e 
co
m
p
o
si
te
 e
n
d
p
o
in
t.
Cr
ud
e 
m
od
el
Cl
in
ic
al
 d
at
a
Cl
in
ic
al
 d
at
a 
&
 
ti
m
e-
va
ry
in
g 
m
ed
ic
at
io
n 
Ti
m
e-
va
ry
in
g 
ca
rd
ia
c 
bi
o-
m
ar
ke
rs
 &
 H
F-
ty
pe
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
Le
ve
ls
 (p
er
 1
SD
 in
cr
ea
se
)
Ca
rd
io
re
na
l b
io
m
ar
ke
rs
 
O
PN
2.
31
 (1
.7
6–
3.
15
)
<0
.0
01
*
2.
45
 (1
.6
4–
3.
68
)
<0
.0
01
*
2.
78
 (2
.0
3–
3.
80
)
<0
.0
01
*
1.
64
 (1
.1
6–
2.
32
)
0.
00
6*
O
PG
2.
23
 (1
.6
9–
3.
00
)
<0
.0
01
*
2.
76
 (1
.9
0–
4.
16
)
<0
.0
01
*
2.
31
 (1
.7
2–
3.
10
)
<0
.0
01
*
1.
68
 (1
.2
1–
2.
32
)
0.
00
2*
EG
FR
0.
77
 (0
.5
4–
1.
08
)
0.
13
x
xx
x
H
BP
1.
36
 (1
.0
9-
1.
70
)
0.
00
6*
1.
49
 (1
.1
5–
1.
88
)
0.
00
2*
1.
65
 (1
.3
2–
2.
06
)
<0
.0
01
*
1.
60
 (1
.2
4–
2.
05
)
<0
.0
01
*
TF
F3
2.
20
 (1
.7
5–
2.
82
)
<0
.0
01
*
2.
38
 (1
.7
3–
3.
33
)
<0
.0
01
*
2.
35
 (1
.8
4–
2.
99
)
<0
.0
01
*
1.
29
 (0
.9
4–
1.
77
)
0.
11
KL
K-
6
1.
60
 (1
.2
5–
2.
04
)
<0
.0
01
*
1.
45
 (1
.0
7–
1.
94
)
0.
01
4
1.
61
 (1
.1
7–
2.
22
)
0.
00
3*
0.
95
 (0
.7
0–
1.
29
)
0.
74
M
EP
E
1.
35
 (1
.0
4–
1.
75
)
0.
02
1.
06
 (0
.7
9–
1.
42
)
0.
66
xx
0.
76
 (0
.5
7–
1.
01
)
0.
05
Pu
lm
on
ar
y 
bi
om
ar
ke
rs
PS
P-
D
1.
66
 (1
.2
8–
2.
12
)
<0
.0
01
*
1.
51
 (1
.1
5–
1.
95
)
0.
00
2*
1.
63
 (1
.2
3–
2.
16
)
0.
00
1*
1.
16
 (0
.8
9–
1.
50
)
0.
26
SC
G
B3
A
2
1.
44
 (1
.1
7–
1.
77
)
<0
.0
01
*
1.
32
 (1
.0
2–
1.
69
)
0.
03
2
1.
37
 (1
.0
8–
1.
73
)
0.
00
8
1.
06
 (0
.8
1–
1.
40
)
0.
67
Sl
op
e 
(p
er
 0
.1
SD
 in
cr
ea
se
/y
ea
r)
a
Ca
rd
io
re
na
l b
io
m
ar
ke
rs
O
PN
1.
14
 (1
.0
3–
1.
29
)
0.
01
0
1.
12
 (1
.0
0–
1.
29
)
0.
04
6
1.
08
 (1
.0
3–
1.
14
)
0.
00
3*
1.
05
 (1
.0
0–
1.
12
)
0.
07
O
PG
1.
24
 (1
.1
4–
1.
38
)
<0
.0
01
*
1.
48
 (1
.1
9–
1.
88
)
0.
00
4*
1.
15
 (1
.0
8–
1.
23
)
<0
.0
01
*
1.
09
 (1
.0
3–
1.
16
)
0.
00
3*
EG
FR
x
x
xx
x
H
BP
0.
87
 (0
.7
7–
1.
08
)
0.
19
0.
92
 (0
.7
3–
0.
19
)
0.
62
xx
1.
03
 (0
.9
9–
1.
07
)
0.
13
TF
F3
1.
31
 (1
.1
7–
1.
49
)
<0
.0
01
*
1.
55
 (1
.3
0–
1.
87
)
<0
.0
01
*
1.
19
 (1
.1
1–
1.
28
)
<0
.0
01
*
1.
15
 (1
.0
7–
1.
23
)
<0
.0
01
*
Cardio-renal and Pulmonary candidate biomarkers in CHF Chapter 6
127
Cr
ud
e 
m
od
el
Cl
in
ic
al
 d
at
a
Cl
in
ic
al
 d
at
a 
&
 
ti
m
e-
va
ry
in
g 
m
ed
ic
at
io
n 
Ti
m
e-
va
ry
in
g 
ca
rd
ia
c 
bi
o-
m
ar
ke
rs
 &
 H
F-
ty
pe
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
H
R 
(9
5%
 C
I)
p-
va
lu
e
KL
K-
6
1.
01
 (0
.7
6–
1.
38
)
0.
99
1.
05
 (0
.6
6–
1.
77
)
0.
90
xx
1.
02
 (0
.9
5–
1.
10
)
0.
58
M
EP
E
0.
96
 (0
.8
6–
1.
10
)
0.
57
1.
03
 (0
.9
1–
1.
16
)
0.
66
xx
1.
02
 (0
.9
5–
1.
09
)
0.
61
Pu
lm
on
ar
y 
bi
om
ar
ke
rs
PS
P-
D
1.
32
 (1
.2
1–
1.
47
)
<0
.0
01
*
1.
52
 (1
.3
2–
1.
78
)
<0
.0
01
*
1.
12
 (1
.0
4–
1.
19
)
0.
00
1*
1.
10
 (1
.0
4–
1.
16
)
<0
.0
01
*
SC
G
B3
A
2
1.
33
 (1
.1
8–
1.
53
)
<0
.0
01
*
1.
39
 (1
.1
9–
1.
67
)
<0
.0
01
*
1.
10
 (1
.1
02
–1
.2
0)
0.
02
0
1.
08
 (1
.0
0–
1.
17
)
0.
05
O
PN
, o
st
eo
po
nt
in
; O
PG
, o
st
eo
pr
ot
eg
er
in
; E
G
FR
, e
pi
de
rm
al
 g
ro
w
th
 fa
ct
or
 re
ce
pt
or
; H
BP
, h
ep
ar
in
-b
in
di
ng
 p
ro
te
in
; T
FF
3,
 tr
ef
oi
l f
ac
to
r 3
; P
SP
-D
, 
pu
lm
on
ar
y 
su
rf
ac
ta
nt
-a
ss
oc
ia
te
d 
pr
ot
ei
n 
D
; S
CG
B3
A
2,
 s
ec
re
to
gl
ob
ul
in
 fa
m
ily
 3
A
 m
em
be
r 
2;
 K
LK
-6
, k
al
lik
re
in
-6
; M
EP
E,
 m
at
ri
x 
ex
tr
ac
el
lu
la
r 
ph
os
ph
og
ly
co
pr
ot
ei
n.
H
az
ar
d 
ra
ti
os
 (H
Rs
) a
nd
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
s 
(C
Is
) a
re
 g
iv
en
 p
er
 1
SD
 in
cr
ea
se
 o
f t
he
 le
ve
l a
nd
 p
er
 0
.1
SD
 in
cr
ea
se
 o
f t
he
 a
nn
ua
l s
lo
pe
 
at
 a
ny
 p
oi
nt
 in
 t
im
e 
du
ri
ng
 fo
llo
w
-u
p.
 C
ru
d
e 
m
od
el
: C
ox
 m
od
el
 u
na
dj
us
te
d,
 L
M
E 
m
od
el
 a
dj
us
te
d 
fo
r 
sa
m
pl
in
g 
ti
m
e.
 C
lin
ic
al
 m
od
el
: C
ox
 
an
d 
LM
E 
m
od
el
s 
ad
ju
st
ed
 f
or
 a
ge
, s
ex
, d
ia
be
te
s,
 a
tr
ia
l 
fib
ri
lla
ti
on
, b
as
el
in
e 
N
YH
A
 c
la
ss
, d
iu
re
ti
cs
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 a
n 
eG
FR
, a
nd
 
sa
m
pl
in
g 
ti
m
e 
(L
M
E)
; C
lin
ic
al
 &
 t
im
e-
va
ry
in
g 
m
ed
ic
at
io
n 
m
od
el
: t
im
e-
de
pe
nd
en
t 
Co
x 
m
od
el
 u
si
ng
 m
ar
ke
r’s
 f
it
te
d 
va
lu
es
 f
ro
m
 c
lin
ic
al
 
m
od
el
 a
dj
us
te
d 
fo
r t
ot
al
 d
ai
ly
 d
os
es
 o
f e
qu
iv
al
en
ts
 o
f c
ar
ve
di
lo
l, 
en
al
ap
ri
l, 
fu
ro
se
m
id
e,
 a
nd
 s
pi
ro
no
la
ct
on
e 
du
ri
ng
 fo
llo
w
-u
p.
 T
im
e-
va
ry
in
g 
ca
rd
ia
c 
b
io
m
ar
ke
rs
 &
 H
F-
ty
p
e 
m
od
el
: t
im
e-
de
pe
nd
en
t 
Co
x 
m
od
el
 u
si
ng
 m
ar
ke
r’s
 fi
tt
ed
 v
al
ue
s 
ad
ju
st
ed
 fo
r 
ty
pe
 o
f H
F 
(H
Fr
EF
 v
s.
 H
Fp
EF
) 
an
d 
ti
m
e-
va
ry
in
g 
N
T-
pr
oB
N
P 
an
d 
ca
rd
ia
c 
tr
op
on
in
 T
 c
ol
le
ct
ed
 a
t 
th
e 
sa
m
e 
ti
m
e 
po
in
ts
 d
ur
in
g 
fo
llo
w
-u
p 
as
 t
he
 b
io
m
ar
ke
r 
of
 in
te
re
st
. C
ox
 
an
d 
LM
E 
m
od
el
s 
ad
ju
st
ed
 fo
r b
as
el
in
e 
N
T-
pr
oB
N
P 
an
d 
hs
-c
Tn
T,
 a
nd
 s
am
pl
in
g 
ti
m
e 
(L
M
E)
.
 a  
A
nn
ua
l s
lo
pe
s 
w
er
e 
ad
di
ti
on
al
ly
 a
dj
us
te
d 
fo
r t
he
 le
ve
ls
 o
f r
ep
ea
te
dl
y 
m
ea
su
re
d 
m
ar
ke
r d
ur
in
g 
fo
llo
w
-u
p;
 
* 
p
-v
al
ue
 b
el
ow
 th
e 
co
rr
ec
te
d 
si
gn
ifi
ca
nc
e 
le
ve
l f
or
 m
ul
ti
pl
e 
te
st
in
g 
(p
<
0.
00
7)
; 
x,
 n
ot
 p
er
fo
rm
ed
 b
ec
au
se
 re
pe
at
ed
ly
 m
ea
su
re
d 
le
ve
l w
as
 n
ot
 s
ig
ni
fic
an
t; 
xx
, n
ot
 p
er
fo
rm
ed
 b
ec
au
se
 m
ar
ke
r’s
 le
ve
ls
/s
lo
pe
 w
as
 n
ot
 s
ig
ni
fic
an
t i
n 
th
e 
cl
in
ic
al
 m
od
el
.  
co
nt
in
ue
d
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
128
After adjustment for clinical characteristics and repeatedly assessed CHF phar-
macological treatment, OPN, OPG, HBP, TFF3, KLK-6, and PSP-D independently 
predicted the endpoint (per 1SD increase of marker levels: hazard ratio [95%CI] 
2.78 [2.03–3.08], 2.31 [1.72–3.10], 1.65 [1.32–2.06], 2.35 [1.84–2.99], 1.61 [1.17–
2.22], 1.12 [1.04–1.19], each p<0.008). Levels of these biomarkers, except for KLK-
6 and PSP-D, remained significant predictors after adjustment for time-varying 
levels of two established cardiac biomarkers (NT-proBNP and hs-cTnT). Indepen-
dently of their absolute levels, the slopes of OPG, TFF3, and PSP-D remained ro-
bust clinical predictors after adjusting for clinical characteristics and repeatedly 
assessed CHF pharmacological treatment and cardiac biomarkers (Table 3). 
DISCUSSION
This study is the first to demonstrate that temporal trends in levels of OPN, OPG, 
and HBP strongly predict clinical outcome in CHF. Moreover, independent of the 
absolute level of the biomarker, higher slopes of OPG, TFF-3, and PSP-D trajecto-
ries were also strong clinical predictors. Importantly, all associations with adverse 
outcomes were independent of patients’ clinical profiles, CHF pharmacological 
treatment and known cardiac biomarkers measured repeatedly during follow-up. 
Therefore, these candidate biomarkers may become relevant for clinical practice as 
they might further define a patient’s risk, but also for future HF trials as they might 
help design more effective biomarker-guided therapy.  
Recently, we have demonstrated in the same cohort that temporal patterns of 
NT-proBNP, troponin T and C-reactive protein are associated with adverse out-
come.23 Our current investigation extends these findings to several novel cardio-re-
nal and pulmonary candidate biomarkers. OPN was previously found to be signifi-
cantly increased in critically ill patients with AKI compared to those without AKI.27 
Moreover, both animal and human studies have shown that OPN is upregulated in 
left ventricular hypertrophy, diabetic and dilated cardiomyopathy.39-42 Interestingly, 
a small-scale study of CHF patients undergoing cardiac resynchronization therapy 
(CRT) showed that CRT-responders had significantly lower circulating OPN levels 
than non-responders.43 Thus, it is apparent that OPN is involved both in cardiac 
and renal damage. However, up till now, there have been insufficient data to ad-
dress the temporal relationship of OPN with adverse clinical outcomes. To this end, 
our results demonstrate that repeatedly measured OPN levels, but not the slope, are 
clinically relevant for risk stratification of CHF patients. Taken together, the re-as-
sessment of OPN levels might not only help to update a patient’s risk estimates, but 
may also serve as a potential response-indicator to HF therapy, However, the latter 
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application of OPN levels warrants confirmation in subsequent clinical studies.   
OPG levels predicted progression of vascular calcification and survival in pre-
dialysis, dialysis, and renal-transplant patients.11 In CKD patients, OPG levels 
were found to be markedly increased in those who had diabetes, which was also 
observed in our CHF patients.28 In patients with post-infarction or chronic HF, 
OPG levels predicted death after acute coronary syndrome and HF-hospitaliza-
tions.29,30,44 However, it is here that our study extends existing evidence by showing 
that OPG levels dynamically increase as the adverse event such as HF-hospitaliza-
tion or death approaches. Importantly, the patient’s risk entailed by this temporal 
increase (i.e., higher slope of the OPG trajectory) was independent of OPG levels. 
In other words, in two patients who have the same “high” OPG levels, it is impor-
tant whether the OPG levels were high but steady (zero slope) or were increasing 
prior to assessment (increasing slope). In the latter case, our study shows that ev-
ery 0.1SD increase in the slope will translate into a 24% higher risk of the event. 
This information may be used to additionally refine the patients’ risk assessment. 
Interestingly, we also found that patients who were on higher doses of renin-angio-
tensin-system (RAS) blockers had lower OPG levels. This is indirectly supported 
by Tsuruda et al. who demonstrated that OPG levels increase in response to cardiac 
damage during angiotensin II-induced hypertrophy in mice.45 Therefore, the ques-
tion is raised whether serial assessment of circulating OPG may be used to identify 
patients who respond poorly to RAS inhibition. In case OPG does not decrease 
after RAS inhibition, therapy might be intensified in order to prevent pathological 
cardiac remodeling.
TFF-3 was found to be upregulated after ischemic myocardial injury in mice.46 
The same authors showed that administration of TFF-3 significantly reduced the 
infarct size suggesting a cardioprotective effect. In CKD, TFF-3 was found to pre-
dict onset of CKD and poor survival.31 However, data on the prognostic role of 
TFF-3 in CHF is currently lacking. Hence, this study is the first to demonstrate 
that increasing slope of the TFF-3 trajectory is a strong clinical predictor in CHF. 
The importance of TFF-3 in the pathophysiology of CHF is also supported by the 
network analysis that showed that TFF-3 was the hub within the currently investi-
gated biomarker network. Still, the exact mechanisms of the actions of TFF-3 and 
its potential use for targeting HF therapy remain to be investigated.
In critically ill patients, HBP was found to be associated with respiratory and 
circulatory failure, infection-related organ dysfunction, and mortality.47,48 Howev-
er, to our best knowledge, there is no previous publication on the role of HBP in 
CHF. Our study provides strong evidence that HBP is also implicated in CHF by 
showing a significant association with cardiac decompensation and mortality. Al-
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though HBP was independently associated with eGFR, it is unclear whether renal 
dysfunction is the only factor that contributes to the pool of circulating HBP in 
CHF. Nevertheless, this study establishes a basis for further investigations on the 
role of HBP in CHF. 
Finally, the pulmonary biomarkers were increased and associated with the pri-
mary endpoint independently of the patients’ clinical profiles and pharmacological 
treatment during follow-up. However, only higher slope of PSP-D remained sig-
nificant predictor after adjustment for time-varying cardiac biomarkers. The fact 
that the current study population was in a relatively good condition (74% was in 
NYHA class I-II) may have contributed to the inability to demonstrate robust asso-
ciations, as lung damage may be expected to manifest itself prominently only with 
more advanced stages of CHF.3 Taken together, PSP-D and SCGB3A2 are promis-
ing markers and warrant further exploration in more severe stages of CHF.
We found that the new candidate biomarkers studied here are related to the 
patients’ clinical characteristics. Limited data are available on this topic in patients 
with CHF.  Secondly, in this study we utilized a network analysis which may help 
us to further specify the role of emerging biomarkers in heart failure by analyz-
ing their inter-biomarker relations. In this regard, OPN and TFF-3 were identi-
fied as the hubs within the current network, and these findings were subsequently 
strengthened by the fact that these biomarkers also carried the highest crude risk of 
adverse events. Thirdly, this study is unique in showing that not only the levels, but 
also the slopes of biomarker trajectories (i.e., information on how much a marker 
was increasing, decreasing, or was stable in approach to a subsequent adverse car-
diac event) are relevant for risk assessment. As such, temporal biomarker profiles 
may potentially help to identify the patients who respond poorly to treatment. This 
may enable timely adaptation of therapy, thereby preventing future events to occur. 
Finally, our results indicate a promising role of these new biomarkers in defining 
more effective biomarker-guided therapy, rather than the current approach where 
therapy is largely based on symptoms and ejection fraction.49 
Study limitations
Firstly, this cohort consisted mainly of HFrEF patients. The low number of HFpEF 
patients is most likely attributable to the fact that in the Netherlands, most HFpEF pa-
tients are followed in secondary referral centres or by the general practitioner, while 
the current study was performed in two tertiary referral centres. Potential inclusion 
bias is not a likely reason for the low HpEF rate, because all consecutive patients were 
screened in both participating centres. Secondly, enrolled CHF patients were in a 
Cardio-renal and Pulmonary candidate biomarkers in CHF Chapter 6
131
better health condition than previously reported CHF populations. Yet, we were able 
to demonstrate, even in this ‘less sick’ CHF population, that several biomarkers are 
strongly associated with the clinical outcomes. Third, re-hospitalization for HF rep-
resented the majority of the composite endpoint. Investigation of individual, ‘harder’ 
endpoints such as cardiovascular mortality is advisable, but warrants larger numbers 
of such endpoints. Finally, future research should focus on better standardization of 
the assays and reproducibility in other CHF cohorts in order to successfully translate 
these emerging biomarkers into daily clinical practice. 
CONCLUSION
Repeatedly-measured levels of OPN, OPG, and HBP, and slopes of OPG, TFF-3, 
and PSP-D strongly predict clinical outcome during outpatient follow-up in CHF. 
The use of these candidate markers may be clinically relevant as they may fur-
ther refine a patient’s risk assessment and provide additional pathophysiological 
insights into CHF.
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SUPPLEMENTARY INFORMATION
FIGU R E S1 Baseline levels of candidate biomarkers in relation to the 
occurrence of the composite endpoint. T-test was applied to test the differences in 
baseline levels between the patients who later reached the composite endpoint and those 
who did not. OPN, osteopontin; OPG, osteoprotegerin; EGFR, epidermal growth factor 
receptor; HBP, heparin-binding protein; TFF3, trefoil factor 3; PSP-D, pulmonary surfactant-
associated protein D; SCGB3A2, secretoglobulin family 3A member 2; KLK-6, kallikrein-6; 
MEPE, matrix extracellular phosphoglycoprotein.
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ABSTRACT
Background
Multiple hormonal and metabolic alterations occur in chronic heart failure (CHF), 
but their proper monitoring during clinically silent progression of CHF remains 
challenging. Hence, our objective was to explore whether temporal patterns of six 
emerging cardiometabolic biomarkers predict future adverse clinical events in sta-
ble patients with CHF.
Methods
In 263 CHF patients, we determined the risk of a composite endpoint of HF-hos-
pitalization, cardiac death, LVAD-implantation and heart transplantation in rela-
tion to serially assessed blood biomarker levels and slopes (i.e., rate of biomarker 
change per year). During 2.2 years of follow-up, we repeatedly measured insulin-
like growth binding protein 1, 2, and 7 (IGFBP-1, IGFBP-2, IGFBP-7), adipose fatty 
acid-binding protein 4 (FABP-4), resistin, and chemerin (567 samples in total). 
Results
Serially measured IGFBP-1, IGFBP-2, IGFBP-7, and FABP-4 levels predicted the 
endpoint (univariable HR [95% confidence interval] per 1SD increase: 3.34 [2.43–
4.87], 2.86 [2.10–3.92], 2.45 [1.91–3.13], and 2.46 [1.88–3.24], respectively). Inde-
pendently of the biomarkers’ levels, their slopes were also strong clinical predic-
tors (per 0.1SD increase/year: 1.20 [1.11–1.31], 1.27 [1.14–1.45], 1.23 [1.11–1.37], 
and 1.27 [1.12–1.48]). All associations persisted after multivariable adjustment for 
patient baseline characteristics, baseline NT-proBNP and cardiac troponin T, and 
pharmacological treatment during follow-up. 
Conclusions
The temporal patterns of IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4 predict 
adverse clinical outcomes during outpatient follow-up of CHF patients, and may be 
clinically relevant as they could help detect more aggressive CHF forms and assess 
patient prognosis, and ultimately aid in designing more effective biomarker-guided 
therapy.
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INTRODUCTION
Chronic heart failure (CHF) is a clinical syndrome characterized by recurrent epi-
sodes of decompensation that require constant therapeutic interventions.1 After 
occurrence of initial cardiac alterations in heart failure, the failing heart also in-
duces abnormalities in peripheral organs including the lungs, liver, kidneys, gas-
trointestinal tract, skeletal muscles, and endocrine system.2 Together, these abnor-
malities cause the overall energy balance to shift towards a catabolic state, leading 
to exercise intolerance and weight loss, both of which strongly determine poor 
outcome.3,4 In this context, circulating biomarkers could be an effective clinical 
tool, as these cellular signals naturally precede the patient’s functional decline, and 
may therefore provide early tissue-specific information on CHF. Similarly, their 
temporal patterns could help in monitoring disease progression even in the pre-
symptomatic phase, potentially enabling physicians to timely modify therapy to 
prevent impending decompensation. 
Although it has long been known that multiple hormonal and metabolic altera-
tions occur in CHF5, the biomarkers that reflect these alterations have only recently 
received increasing attention with the upcoming use of modern -omics technolo-
gies that allow us to discover new highly sensitive proteins.6 To date, ongoing con-
troversy exists concerning the role of these cardiometabolic biomarkers in CHF. 
Studies have suggested that insulin-like growth factor binding proteins (IGFBPs) 
1, 2, and 7 are increased in CHF and are associated with adverse outcomes after 
myocardial infraction.7-9 IGFBPs regulate insulin-like growth factor (IGF) activ-
ity which is crucial for indirect effects of growth hormone (GH).10 Of note is that 
IGFBPs also exhibit IGF-independent effects on the cardiovascular system.11 In 
this way, the IGF-IGFBPs system has an important role in the regulation of cardiac 
remodeling, myocardial contractility, and vascular system function.10 Similarly, 
the adipose tissue acts as an endocrine organ by secreting adipokines which are 
involved in a plethora of metabolic functions including glucose and lipid metabo-
lism, inflammation, atherosclerosis, and cardiac remodeling.12 Among secreted ad-
ipokines, fatty acid-binding protein (FABP)-4, resistin, and chemerin have recently 
been linked to CHF.13-15 Nevertheless, the scientific evidence on these biomarkers 
in CHF is limited, and their potential utility remains undetermined. 
Therefore, we investigated the associations of the temporal patterns of cardio-
metabolic biomarker levels and biomarker slopes (i.e., rates of biomarker change per 
year) with adverse clinical events in CHF patients who had undergone 3-monthly 
repeated blood sampling during their outpatient follow-up.
HEART-KIDNEY INTERACTIONS · M. Brankovic
PART II
140
METHODS 
CHF cohort 
The Serial Biomarker Measurements and New Echocardiographic Techniques in 
Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-
SHiFT) is a prospective cohort study of stable patients with CHF, conducted in 
Erasmus MC, Rotterdam, and Noordwest Ziekenhuisgroep, Alkmaar, the Nether-
lands.16 Patients were included if aged ≥18 years, capable of understanding and sign-
ing informed consent, and if CHF had been diagnosed ≥3 months ago according to 
European Society of Cardiology guidelines.1,17,18 Patients were ambulatory and sta-
ble, i.e., they had not been hospitalized for HF in the past three months. The study 
was approved by the medical ethics committees, conducted in accordance with 
the Declaration of Helsinki, and registered in ClinicalTrials.gov (NCT01851538). 
Written informed consent was obtained from all patients. This investigation com-
prised 263 CHF patients enrolled during the first inclusion round period (October 
2011 until June 2013). 
Baseline assessment
All patients were evaluated by research physicians, who collected information on 
HF-related symptoms, NYHA class, and performed a physical examination. Infor-
mation on HF etiology, left ventricular ejection fraction, cardiovascular risk fac-
tors, medical history and treatment was retrieved primarily from hospital records 
and was checked in case of ambiguities. History of cardiovascular and other co-
morbidities was defined as their clinical diagnosis as recorded in the medical file.
Follow-up and study endpoints
During the study, all patients were routinely followed at the outpatient clinic by 
treating physicians who were blinded for biomarker sampling. Additionally, study 
follow-up visits were predefined and scheduled every 3 months (±1 month). This 
3-month interval was chosen to ensure that blood sampling occurred as often as 
possible during a relatively long follow-up period (>2 years), while keeping the 
study burden acceptable for this CHF population. At each study follow-up visit, 
a short medical evaluation was performed and samples were collected. During 
follow-up, all medication changes and occurrence of hospitalizations for HF, MI, 
PCI, CABG, arrhythmias, and CVA, cardiac transplantation, left ventricular assist 
device (LVAD) implantation and mortality, were recorded in the electronic case 
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report forms, and associated hospital records and discharge letters were collected. 
Subsequently, a clinical event committee, blinded to the biomarker results, re-
viewed hospital records and discharge letters and adjudicated the study endpoints.
The composite endpoint comprised cardiac death, cardiac transplantation, 
LVAD implantation, and hospitalization for the management of acute or worsened 
HF, whichever occurred first. Cardiac death was defined as death from MI or other 
ischemic heart disease (ICD-10: I20-I25), death from other heart disease includ-
ing HF (I30-I45 and I47-I52), sudden cardiac death (I46), sudden death undefined 
(R96) or unwitnessed or ill-described death (R98, R99). Hospitalization for acute 
or worsened HF was defined as a hospitalization for an exacerbation of HF symp-
toms, in combination with two of the following: BNP or NT-proBNP >3x upper 
limit of normal, signs of worsening HF, such as pulmonary rales, raised jugular ve-
nous pressure or peripheral edema, increased dose or intravenous administration 
of diuretics, or administration of positive inotropic agents.1
Study measurements and laboratory analysis 
Blood samples were collected at baseline and at each study follow-up visit, and 
were processed and stored at -80oC within two hours after collection. Treating phy-
sicians were unaware of biomarker results as biomarkers were measured batch-wise 
after completion of follow-up. Thus, the biomarker measurements did not lead to 
drug adjustments. All patients received usual care. All laboratory personnel was 
blinded for clinical data and patient outcomes. 
For efficiency, for the current investigation we selected all baseline samples, 
the two samples closest in time to the primary composite endpoint, and the last 
sample available for patients in whom the primary endpoint did not occur during 
follow-up. 
Glomerular filtration rate (GFR) was determined by the Chronic Kidney Dis-
ease-Epidemiology Collaboration (CKD-EPI) equation validated in HF patients.19 
The Olink multiplex PEA platform for new biomarkers 
The Cardiovascular (CVD) panel III (Olink Proteomics AB, Uppsala, Sweden) was 
used for analysis of high-abundance proteins. The proteins present in this Olink 
panel were selected because either they have a proven pathophysiological role in 
cardiovascular disease, or because they are promising in this respect but yet un-
explored. This assay is based on PEA (proximity extension assay) technology.6 In 
brief, the assay uses two oligonucleotide-labeled antibodies to bind to their respec-
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tive target proteins in the sample. When the two antibodies are in close proximity, 
a new PCR target sequence is formed by a proximity-dependent DNA polymer-
ization event. The resulting sequence is subsequently detected and quantified us-
ing standard real-time PCR. Each sample includes two incubations, one extension, 
and one detection control to determine the lower limit of detection and normalize 
the measurements. The biomarkers are presented in normalized protein expres-
sion (NPX) units on a 2log scale. In a validation study, the mean intra-assay and 
inter-assay coefficients of variation were 8% and 12%, respectively.6 For the cur-
rent investigation, six emerging cardiometabolic biomarkers (IGFBP-1, IGFBP-2, 
IGFBP-7, FABP-4, resistin, and chemerin) were examined. 
Statistical analysis
For the analysis, we used the Z-score (i.e., the standardized form) of the 2log-trans-
formed biomarkers to allow for direct comparisons of different biomarkers. For the 
network analysis we used only the biomarkers that showed significant correlations 
based on Pearson’s correlation coefficients (p<0.05). We assessed the clustering co-
efficient as a measure of the degree to which biomarkers tend to cluster together, 
where higher coefficients suggest a certain centrality of a biomarker within the 
network.20 
To study the effect of baseline characteristics on repeatedly measured biomark-
ers, linear mixed-effects (LME) models were performed using biomarkers as the 
dependent variables and baseline characteristics as the independent variables 
(fixed part). The sampling time was entered into the fixed- and random parts of 
the models. 
To estimate the associations between patient-specific biomarker levels and sur-
vival, we applied a joint modeling (JM) analysis that combines LME models for re-
peated measurements, and Cox survival analysis for time-to-event data.21 For both 
the fixed- and random-effects parts of the LME models, linear terms were used 
for sampling times, and both intercepts and slopes were included in the random-
effects design matrix. This allowed the markers’ trajectories to differ at baseline 
and over time. We also estimated the time-dependent slope (i.e., rate of change) of 
each biomarker from these joint models, indicating whether and by how much the 
levels are increasing or decreasing and how they relate to patient prognosis. The 
slope mathematically corresponds to the first derivative of a marker’s trajectory, 
and is presented as an annual change in Z-scores (i.e., delta Z-scores per year). 
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Besides sampling time, all markers were adjusted as follows: (1) clinical mod-
el: Cox and LME models were adjusted for age, sex, diabetes, atrial fibrillation, 
baseline NYHA class, diuretics, systolic blood pressure, and eGFR; (2) clinical & 
time-varying HF medication model: after adjusting for clinical characteristics, bio-
marker values were extracted from the joint models and entered simultaneously 
with equivalent doses of carvedilol, enalapril, furosemide, and spironolactone (re-
peatedly assessed during follow-up) into a time-dependent Cox analysis to exam-
ine the incremental value of the new biomarkers over clinical characteristics and 
medication during follow-up; (3) cardiac biomarker model: Cox and LME mod-
els were adjusted for biomarkers of myocardial stretch and damage (NT-proBNP 
and c-TnT). Data on all variables were complete, except for systolic blood pressure 
which was missing in <5% of patients and for which imputations were applied us-
ing the patients’ clinical and outcome data. Results are given as hazard ratios (HR) 
and 95% confidence intervals (CI) per 1SD increase of the marker’s level and per 
0.1SD increase of the slope at any time-point during follow-up.
To correct for multiple testing, we performed matrix spectral decomposition 
which has previously been demonstrated to be more effective than Bonferroni 
correction.22 Consequently, the corrected significance level was set at p <0.0127 
(0.05/4). 
All analyses were performed with R Statistical Software using packages nlme 
and JMbayes.21 The network analysis was performed using Gephi software (https://
gephi.org) and the matSpD application (https://gump.qimr.edu.au/general/daleN/
matSpD) available online.
RESULTS
Baseline characteristics
Table 1 displays the patients’ baseline characteristics. Specifically, the patients who 
reached the composite endpoint were older, more frequently had diabetes, atrial 
fibrillation, lower systolic blood pressure, higher NYHA class, higher levels of NT-
proBNP and cardiac troponin T, and were more frequently on loop diuretics. 
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TAB LE 1 Baseline characteristics in relation to the occurrence of the composite 
endpoint.
Variable Total         Composite endpoint p-value
Yes No
n (%) 263 (100) 70 (27) 193 (73)
Demographics
Age, years (mean ± SD) 67±13 69±13 66±12 0.05
Men, n (%) 189 (72) 53 (76) 136 (70) 0.41
Clinical characteristics
BMI, kg/m2 27.5±4.7 27.6±4.8 27.4±4.7 0.80
Heart rate, b.p.m. 67±12 69±13 67±11 0.31
SBP, mmHg 122±20 117±17 124±21 0.02
DBP, mmHg 72±11 70±10 73±11 0.06
Features of heart failure
NYHA class III or IV, n (%) 69 (26) 31 (44) 38 (20) < 0.001
HF-rEF n (%) 250 (95) 66 (94) 184 (95) 0.75
HF-pEF n (%) 13 (5) 4 (6) 9 (5)
LVEF, % 32±11 30±11 33±10 0.18
NT pro-BNP (pmol/L) † 137.3 (51.7–272.6) 282.4 (176.4–517.4) 95.3 (31.72–207.7) < 0.001
Hs-TnT (ng/L) † 18.0 (9.5–33.2) 31.9 (20.6–49.7) 13.9 (8.4–26.7) < 0.001
Etiology of heart failure, n (%)
Ischemic 117 (44) 36 (51) 81 (42) 0.17
Hypertension 34 (13) 10 (14) 24 (12) 0.70
Valvular disease 12 (5) 5 (7) 7 (4) 0.23
Cardiomyopathy 68 (26) 15 (21) 53 (28) 0.32
Unknown or Others 32 (12) 4 (6) 28 (15)
Medical history, n (%)
Prior MI 96 (36) 32 (46) 64 (33) 0.06
Prior PCI 82 (31) 27 (39) 55 (28) 0.12
Prior CABG 43 (16) 13 (19) 30 (15) 0.57
Atrial fibrillation 106 (40) 36 (51) 70 (36) 0.03
Diabetes 81 (31) 32 (46) 49 (25) 0.002
Hypercholesterolemia 96 (36) 30 (43) 66 (34) 0.20
Hypertension 120 (46) 38 (54) 82 (42) 0.09
COPD 31 (12) 12 (17) 19 (10) 0.10
Medication use, n (%)
Beta-blocker 236 (90) 61 (87) 175 (91) 0.40
ACE-I or ARB 245 (93) 63 (90) 182 (94) 0.22
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Variable Total         Composite endpoint p-value
Yes No
Diuretics 237 (90) 68 (97) 169 (88) 0.02
Loop diuretics 236 (90) 68 (97) 168 (87) 0.02
Thiazides 7 (3) 3 (4) 4 (2) 0.28
Aldosterone antagonist 179 (68) 53 (76) 126 (65) 0.11
Glomerular function
Creatinine, mg/dl † 1.18 (0.99–1.49) 1.30(1.02–1.52) 1.17(0.98–1.45) 0.18
eGFR, mL/min/1.73m2 † 58 (43–76) 53 (40–73) 59 (44–77) 0.16
KDOQI classification, n (%) 0.18
eGFR ≥90 28 (11) 7 (10) 21 (11)
eGFR 60-89 95 (36) 20 (28) 75 (39)
eGFR 30-59 119 (45) 37 (53) 82 (42)
eGFR <30 21 (8) 6 (9) 15 (8)
BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; NYHA 
class, New York Heart Association class; HF-rEF, Heart failure with reduced ejection fraction; 
HF-pEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass grafting; CVA, cerebrovascular accident; TIA, transitory ischemic attack; COPD, 
chronic obstructive pulmonary disease; ACE-I, angiotensin-converting enzyme inhibitors; 
ARB, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate.†Median 
with inter-quartile range (IQR).
Follow-up and study endpoints
During a median of 2.2 (IQR: 1.4–2.5) years of follow-up, we collected a total of 
1984 blood samples at fixed 3-month intervals (per patient: 9 [IQR: 5–10] sam-
ples), and measured biomarkers in all samples collected at baseline, the two sam-
ples closest in time to the composite endpoint, and the last sample available for 
event-free patients (567 samples in total). During the follow-up, 70 (27%) patients 
experienced the composite endpoint. Specifically, 56 patients were re-hospitalized 
for acute or worsened HF, 3 patients underwent heart transplantation, 2 patients 
underwent LVAD placement, and 9 patients died of cardiovascular causes. 
Network analysis
Figure 1 displays baseline inter-marker correlations and crude associations of their 
serially measured levels with the composite endpoint (for HRs see Table 3). Of 
note is that all biomarkers correlated with each other and no clustering was pres-
ent. The strongest correlations were present within the IGFBP biomarker family, 
continued
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and between these biomarkers and NT-proBNP. Similarly, adipokines correlated 
strongly with each other. 
FIGU R E 1 Network analysis of cardiometabolic biomarkers depicting inter-
marker correlations and associations with the composite endpoint. Node color 
represents the crude association with the composite endpoint, and ranges from white (the 
weakest) to black (the strongest). Node size represents the clustering coefficient (a measure 
of the degree to which biomarkers tend to cluster together suggesting a certain centrality 
within the biomarker network). The thickness of the line between the biomarkers represents 
the correlation coefficient (presented only if p<0.05); a thicker line represents stronger 
coefficients.
Patients’ clinical characteristics and cardiometabolic 
biomarkers during follow-up
Table 2 shows the associations between  the patients’ baseline characteristics and the 
biomarkers’ temporal trends; the  reported associations were independent of each other. 
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IGFBPs
Higher serially measured IGFBP-1 levels during follow-up were associated with in-
creased baseline NT-proBNP and c-TnT, and lower baseline BMI values (per dou-
bling of NT-proBNP: adjusted β [95% confidence interval CI] 0.15SD [0.09; 0.22], 
p<0.001; c-TnT: 0.13SD [0.02; 0.24], p=0.018; BMI: -0.95SD [-1.38; -0.53], <0.001). 
Likewise, patients with increased baseline cardiac markers and lower BMI had 
higher IGFBP-2 levels during follow-up (for regression coefficients see Table 2). 
The IGFBP-2 levels were also positively associated with older age, higher baseline 
NYHA class, and impaired baseline eGFR. Similarly, higher IGFBP-7 levels were 
found in patients with increased baseline cardiac markers and decreased eGFR, 
and in those who were on higher loop diuretic doses. Patients with atrial fibrilla-
tion (AF) also had markedly increased IGFBP-7 levels.
Adipokines
Higher serially measured FABP-4 levels were associated with increased baseline 
cardiac biomarkers, higher BMI, female sex, and impaired eGFR. Moreover, pa-
tients who were on higher baseline β-blockers and loop diuretic doses had high-
er FABP-4 levels during follow-up. Higher serially measured resistin levels were 
found in patients with AF, and in those with increased NT-proBNP and decreased 
eGFR levels. During follow-up, higher serially measured chemerin levels were as-
sociated with female gender, higher baseline BMI, decreased eGFR, and higher 
loop diuretic doses.   
Temporal evolutions of IGFBPs and adipokines in relation to 
study endpoints
Average temporal trajectories of cardiometabolic biomarkers in patients who ex-
perienced an incident endpoint and those who did not are displayed in Figure 2. 
In patients with an incident endpoint, all biomarkers showed increasing patterns 
to various degrees, with the steepest rise seen in IGFBP-1, IGFBP -2, IGFBP-7, and 
FABP-4 levels prior to the occurrence of the endpoint. 
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FIGU R E 2 Average temporal evolution of IGFBP-1, IGFBP-2, IGFBP-7, FABP-4, 
resistin, chemerin during follow-up. Average evolution in patients who reached the 
composite endpoint (solid black line), and in endpoint-free patients (solid gra line). Dashed 
lines represent the 95% confidence interval. X-axis depicts the time from baseline (BL: left 
part of the x-axis), and time remaining to the event (patients who experienced incident 
events) or last sample moment (patients who remained event-free) (right part of the x-axis). 
Biomarker levels are presented on the y-axis. (a) IGFBP-1 (b) IGFBP-2, (c) IGFBP-7, (d) FABP-4, 
(e) resistin, (f ) chemerin. 
Table 3 summarizes the associations of the cardiometabolic biomarkers with 
the composite endpoint. After adjustment for baseline clinical characteristics and 
HF pharmacological treatment during follow-up, IGFBP-1, IGFBP-2, IGFBP-7, and 
FABP-4 independently predicted the endpoint (per 1SD increase of biomarker lev-
els HR [95%CI]: 4.21 [2.96; 6.01], 2.93 [2.11; 4.08], 2.72 [2.06; 3.60], 3.15 [2.36; 
4.21], respectively, each p<0.001). These biomarkers remained significant predic-
tors even after controlling for baseline NT-proBNP and cTnT levels.  Notably, their 
higher slopes were strong predictors independently of their absolute levels, baseline 
clinical characteristics and cardiac biomarkers, and HF medication during follow-
up. Serially measured resistin predicted the endpoint independently of the patients’ 
clinical characteristics and pharmacological treatment, but lost significance after 
controlling for cardiac markers. The chemerin did not show clear prognostic value 
after multivariable adjustments (Table 3).
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DISCUSSION
This study is the first to demonstrate that temporal patterns of IGFBP-1, IGFBP-2, 
IGFBP-7, and FABP-4 strongly predict adverse clinical outcomes in CHF. Inde-
pendently of the absolute biomarker levels, their higher slopes (i.e., higher rates 
of change) were also strong clinical predictors. All aforementioned associations 
were robust to the multivariable adjustment for  baseline clinical characteristics 
and cardiac natriuretic peptide and troponin levels, as well as CHF pharmacologi-
cal treatment during follow-up.
IGFBPs in CHF
In CHF, an impaired anabolic drive with increased GH levels but peripheral GH 
resistance, and elevated IGFBPs, has been reported.8,23,24 In this regard, studies 
have suggested that elevated IGFBPs, especially high-affinity IGF binders such 
as IGFBP-1 and IGFBP-2, indirectly control anabolic activity via their inhibitory 
function on the GH–IGF-1 axis.11 The IGFBPs also directly control cell growth 
and survival which may also contribute to adverse CHF outcomes.11 Our study 
confirms that patients who experienced adverse clinical events had higher levels of 
all three IGFBPs than event-free patients, which rose during the follow-up. These 
elevated IGFBPs might also explain the conflicting results of clinical trials on GH 
therapy in CHF.25 A meta-analysis on GH treatment showed that CHF patients who 
had a reduced IGF-1 response to GH administration were less likely to benefit from 
this treatment. Thus, it may be speculated that elevated IGFBPs may be responsible 
for the “non-responsiveness” to GH treatment in these patients, but further inves-
tigations are needed to confirm this hypothesis. 
Besides higher levels, the rise of IGFBP-1, IGFBP-2, and IGFBP-7 over the 
time-course of CHF strongly predicted adverse outcome. In other words, we found 
elevated risk in patients in whom the levels were increasing (i.e., a higher slope 
was present) compared to patients with similar IGFBP levels, but in whom levels 
remained constant (for details see Figure 3). These new insights into IGFBPs’ tem-
poral dynamics is important considering the dynamic nature of myocardial remod-
eling itself, which has a pivotal role in CHF progression. These findings are novel 
and carry clinical implications for the monitoring of CHF patients.
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FIGU R E 3 An illustration of different aspects of the underlying trajectory of 
a serially assessed biomarker that may be relevant for a patient’s prognosis. 
Figure illustrates biomarker trajectories of three distinct patients. Their biomarker levels are 
measured on the y-axis and their follow-up time on the x-axis. At the time of assessment, 
patient C has lower biomarker levels than patients A and B. Corresponding risk in  patient C 
is lower than in patients A and B. By comparing patients A and B, we observe that they have 
the same biomarker levels. Thus, if we would like to compare these two patients we have 
to look at their slopes and relate them to the risk of event. In other words, for two patients 
with the same biomarker levels, increase in slope provides us with risk estimates related to 
the adverse event independently of their levels. These risk estimates are provided in Table 3 
under “Slope (per 0.1SD increase / year)”. The dots represent actual biomarker levels.  
All three IGFBPs correlated independently with CHF severity as assessed by 
cardiac natriuretic peptide and troponin levels. However, IGFBPs differed with 
respect to their associations with other patient characteristics. Specifically, we 
found an independent inverse relation between the patients’ BMI and IGFBP-1 and 
IGFBP-2. This has been consistently reported.7,26 Thus, it may be speculated that the 
“obesity paradox”, in which higher BMI is associated with better survival in CHF27, 
might be (partially) mediated through the suppressed adverse effects of IGFBP-1 
and IGFBP-2. Yet, this association could not be demonstrated between BMI and 
IGFBP-7. On its part, IGFBP-7 correlated independently with higher prevalence of 
atrial fibrillation. In this context, IGFBP-7 has previously been linked to left ven-
tricular (LV) diastolic dysfunction28 and to increased collagen deposition29, both of 
which may contribute to atrial fibrillation. Taking these findings together with the 
fact that IGFBP-7 belongs to the category of low-affinity IGF binders30, it appears 
that direct effects of IGFBP-7 on the myocardium may predominate in the setting 
of CHF. 
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Altogether, based on our findings we may tentatively hypothesize that prevent-
ing alterations in IGFBPs, by means of lowering IGFBP levels, might potentially 
help protect the myocardium from further damage.
Adipokines in CHF
Adipose tissue has been identified not only as an energy deposit, but also as a 
hormonally active organ that releases numerous bioactive molecules called adi-
pokines.12 Among them, adipose FABP-4 has been linked to metabolism-related 
cardiac alterations including LV hypertrophy and systolic dysfunction.31,32 Animal 
models suggest that adipose FABP-4 causes these cardiac alterations by reducing 
shortening amplitude and the intracellular systolic Ca2+ peak in cardiomyocytes.33 
FABP-4  also predicted the onset of HF among elderly population within the Car-
diovascular Health Study.13 The present study extends these findings by showing 
that higher FABP-4 levels and higher rate of change in these levels predict adverse 
clinical events, also in patients with prevalent CHF.
Resistin and chemerin are two other adipokines which are mainly involved in 
the inflammatory activity underlying cardiovascular diseases.12 Resistin is largely 
secreted by mononuclear cells in response to inflammatory stimuli.34 Animal ex-
periments have demonstrated that in the heart, resistin alters glucose handling, 
herewith leading to hypertrophy and impaired cardiomyocyte contractility.35 In 
murine cardiomyocytes, chemerin was found to induce apoptosis through the ac-
tivation of several apoptotic mediators.36 In humans, both resistin and chemerin 
correlated with LV mass and systolic dysfunction15,37 but their prognostic role in 
CHF is less firmly established. In this regard, we found increased levels of both 
biomarkers in CHF patients who reached adverse events compared to those who 
did not, but we could not demonstrate their independent prognostic value in CHF.
Cardiometabolic markers as a new link for cardio-renal 
interaction
We found that repeatedly measured IGFBP-7, FABP-4, resistin, and chemerin are 
associated with impaired baseline eGFR independently of the patients’ charac-
teristics, cardiac markers, and CHF pharmacological treatment. In this context, 
increased urinary IGFBP-7 has been identified in the settings of acute kidney in-
jury38, and FABP-4 has been correlated with renal dysfunction and progression of 
proteinuria.39 Similarly, resistin and chemerin have been linked to impaired kidney 
functioning.14,40 Altogether, this raises the question whether these cardiometabolic 
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biomarkers also represent another link underlying cardiorenal interaction respon-
sible for worse CHF prognosis. However, additional studies including animal ex-
periments exclusively focusing on this subject are needed to elucidate this promis-
ing concept.
Clinical implications 
Our findings, together with previous reports, indicate that the use of cardiometa-
bolic biomarkers for monitoring of CHF progression is a rapidly growing area of 
interest. The current study explores a potential clinical role of these biomarkers to 
assist in the care of CHF patients through better phenotyping of CHF. We found 
that CHF patients with higher levels and slopes of IGFBP-1, IGFBP-2, IGFBP-7, 
and FABP-4 had a more aggressive form of CHF ultimately leading to adverse out-
comes such as re-hospitalization or death. This may be important in practice to 
enable timely adjustment of therapy in patients without clinically overt CHF. These 
results provide a basis for future studies to further explore this hypothesis. Be-
sides their prognostic role, these biomarkers are bioactive proteins as they activate 
distinct cell signaling pathways within the IGF-IGFBPs system and adipose-relat-
ed tissue. Therefore, targeting these biomarkers may be a promising approach in 
designing more effective biomarker-guided CHF therapy. Finally, future research 
should focus on better standardization of the assays, and combining the results 
with genetic analyses may further help to successfully translate these biomarkers 
into clinical practice.
Study limitations
Firstly, this cohort consisted mainly of HFrEF patients. The low number of HFpEF 
patients can most likely be attributed to the fact that in the Netherlands, most 
HFpEF patients are followed in secondary referral centres or by their primary care 
provider, while our study was performed in two tertiary referral centres. Poten-
tial selection bias is not a likely reason for the low rate of HpEF patients, because 
all consecutive patients were screened in both participating centres. Secondly, al-
though we had trimonthly blood samples available for all patients, because of ef-
ficiency reasons only two sampling moments were selected for event-free patients, 
and three sampling moments for patients with a PE. In previous investigations 
within this cohort, we have used all available sampling moments to determine NT-
proBNP, cTnT, CRP as well as glomerular and tubular renal biomarkers.16 Those 
investigations demonstrated that most of these biomarkers show an increase short-
ly prior to the incident adverse event. Thus, we believe that by selecting baseline 
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samples, as well as the last two samples prior to the incident endpoint, we retain the 
most informative measurements while enhancing efficiency. 
CONCLUSION
The temporal patterns of IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4 strong-
ly predict adverse clinical outcomes during outpatient follow-up of CHF patients. 
These biomarkers may, therefore, be relevant for clinical practice as they could help 
detect more aggressive forms of CHF and assess patient prognosis, and ultimately 
aid in designing more effective biomarker-guided therapy.  
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ABSTRACT 
Background
We investigated whether plasma cystatin C (CysC) and neutrophil gelatinase-as-
sociated lipocalin (NGAL) are associated with intravascular ultrasound (IVUS)-
derived characteristics of coronary atherosclerosis and 1-year adverse coronary 
events in patients with normal and mildly-to-moderately impaired kidney func-
tion.
Methods 
Between 2008-2011, virtual histology (VH)-IVUS of a non-culprit coronary ar-
tery was performed in 581 patients undergoing coronary angiography. Creatinine, 
CysC and NGAL were measured in pre-procedural blood samples. Presence of VH-
IVUS-derived thin-cap fibroatheroma (TCFA) lesions, lesions with plaque burden 
(PB)≥70% and lesions with minimal luminal area (MLA)≤4 mm2 was assessed. Ma-
jor adverse coronary events (MACE) comprised the composite of all-cause mortal-
ity, acute coronary syndrome, or unplanned coronary revascularization. Analyses 
were stratified using eGFRCr of 90 ml/min/1.73m2 as the cut-off.
Results 
In patients with normal kidney function, those with higher CysC levels had fewer 
lesions with PB≥70% and fewer VH-TCFA lesions (adjusted odds ratios(ORs) and 
95% confidence intervals(CIs): 0.46 [0.30-0.69] and 0.59 [0.44-0.83], respectively, 
per standard deviation(SD) ln[ng/mL] CysC). Those with higher NGAL levels also 
had fewer lesions with PB≥70% (adjusted OR [95%CI]: 0.49 [0.29-0.82]) In pa-
tients with impaired kidneys, no differences in high-risk lesions were observed 
for CysC or NGAL. However, those with higher CysC had higher risk of MACE 
(hazard ratio(HR): 1.4, 95%CI [1.03–1.92]). This was not the case in patients with 
normal kidney function. NGAL did not influence risk of MACE. 
Conclusions 
Mild-to-moderate kidney dysfunction modifies the relationship between CysC and 
high-risk coronary lesions. This has not been established before, and offers an ex-
planation for the difference in findings between experimental and epidemiologic 
studies.
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INTRODUCTION
Kidney impairment, as assessed by creatinine-based equations of glomerular filtra-
tion rate (eGFRCr), is associated with cardiovascular disease independently of estab-
lished cardiovascular risk factors.1 In persons with mild kidney dysfunction (eGFRCr 
in the range of 60-89 ml/min/1.73m2), cystatin C (CysC) may outperform eGFRCr 
as a predictor of adverse outcome. This is illustrated by the fact that CysC displays 
a linear association with mortality in patients with such mild GFR reduction, while 
eGFRCr has a J-shaped association with mortality, and risk only starts to rise when 
eGFRCr falls beneath 60 ml/min/1.73m2.2,3  Although some studies have shown linear 
associations of eGFRCr with adverse outcome, these associations were linear only in 
particular ranges of eGFRCr (specifically, eGFRCr above 60).4
CysC is a cysteine protease inhibitor produced by most nucleated cells, and can be 
detected in serum or plasma.5 In in-vitro and animal experiments, a reduction of CysC 
correlated with increased activity of cysteine proteases cathepsins K and S, which led to 
breakdown of the elastic lamina in the blood vessel wall.6 Altered CysC expression has 
been identified in diseases which progress by extracellular proteolysis, such as athero-
sclerosis and aortic aneurysms, and metastasis.7,8 These experiments, pointing towards 
a favourable role for CysC, do not concur with the positive associations of CysC with 
adverse outcomes found in epidemiological studies. Studies on the in-vivo association 
between plasma CysC and coronary atherosclerosis may provide further insight into this 
discrepancy, but have not yet been performed.  
Neutrophil gelatinase-associated lipocalin (NGAL) is a clinically relevant biomark-
er in acute kidney injury9 due to its marked increase in plasma and urine after tubulo-
interstitial  kidney damage.10 Recently, overexpression of plasma NGAL has been found 
in coronary plaques, where NGAL inhibits elimination of matrix metalloproteinase–9 
(MMP-9).11,12 MMP-9 is involved in extracellular matrix degradation, herewith increas-
ing the risk of plaque rupture.13 NGAL and NGAL/MMP-9 complex have been shown 
to predict major adverse cardiovascular events in epidemiological studies.14,15 
In spite of the above-described associations that have been demonstrated between 
CysC, NGAL and adverse cardiac events, the presence and shape of a relationship be-
tween plasma CysC, NGAL, and coronary atherosclerosis have not yet been investigated 
in-vivo. To the best of our knowledge, we are the first to perform such an investigation, 
and to herewith provide a link between fundamental experiments and epidemiological 
studies. Specifically, our study aimed to investigate whether plasma CysC and NGAL are 
associated with IVUS-derived characteristics of in-vivo coronary atherosclerosis and 
1-year adverse coronary events in patients with normal and mildly-to-moderately im-
paired kidney function.
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MATERIALS AND METHODS
Study population
We have previously described the design of The European Collaborative Project 
on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascu-
lar Ultrasound (ATHEROREMO-IVUS).16 In this study, we included 581 patients 
undergoing diagnostic coronary angiography or percutaneous coronary interven-
tion (PCI) for acute coronary syndrome (ACS) or stable angina pectoris (SAP) be-
tween 2008 and 2011 in the Erasmus MC, Rotterdam, the Netherlands. Following 
coronary angiography, intravascular ultrasound (IVUS) of a non-culprit coronary 
artery was performed. The human research ethics committee of Erasmus MC, Rot-
terdam, the Netherlands has approved this study. All included patients have signed 
informed consent, and the study protocol conformed to the Declaration of Hel-
sinki. This study is registered in ClinicalTrials.gov (number: NCT01789411).
Kidney function assessment
Estimated Glomerular Filtration Rate (eGFRCr) was assessed by the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI) equation.17 Patients were cat-
egorized according to eGFR by using the modified definition from the National 
Kidney Foundation – Kidney Disease Outcome Quality Initiative (K/DOQI) clini-
cal practice guidelines18: normal (GFR≥90 ml/min/1.73m2), mild (GFR 60-89 ml/
min/1.73m2), moderate (GFR 30-59 ml/min/1.73m2), and severe (GFR 15-29 ml/
min/1.73m2) kidney dysfunction, and kidney failure (GFR<15 ml/min/1.73m2). No 
patients with kidney failure were present in this study, and only one patient had 
eGFRCr <30 ml/min/1.73m2. The latter was excluded from further analyses. Patients 
were stratified into those with normal kidney function and those with mildly-to-
moderately impaired kidney function, using an eGFRCr of 90 ml/min/1.73m2 as the 
cut-off value. 
Biomarkers
Arterial blood was taken before the procedure and stored at -80ºC within two 
hours. Samples were available in 570 patients. An immunoturbidimetric high sen-
sitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Roche Cobas 
8000 modular analyser platform was used in the Erasmus MC clinical laboratory to 
measure the level of C-reactive protein (CRP) in serum samples. The plasma EDTA 
samples were transported at a temperature of -80ºC to Myriad RBM, Austin, Texas, 
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USA, where cystatin C and NGAL concentrations were assessed by a validated mul-
tiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). As a result 
of the batch-wise handling of the samples, with an update of the composition of 
the multiplex assay by the manufacturer in-between two batches, cystatin C was 
measured in the full cohort of 570 patients, and NGAL in a random subset of 473 
patients. Both laboratories were blinded to clinical and imaging data.
Grayscale and radiofrequency intravascular ultrasound (IVUS)
The degree (plaque volume and plaque burden) and composition of the athero-
sclerotic plaque were assessed.  Plaque volume was defined as the total volume of 
the external elastic membrane occupied by atheroma.19 Plaque burden was defined 
as the plaque and media cross-sectional area divided by the external elastic mem-
brane cross-sectional area and is presented as a percentage (Figure 1). A coronary 
lesion was defined as a segment with a plaque burden of more than 40% in at 
least three consecutive frames.16 The composition of the atherosclerotic plaque was 
characterized into fibrous, fibro-fatty, dense calcium and necrotic core.20 Subse-
quently, three types of VH-IVUS high-risk lesions were identified: 1. thin-cap fi-
broatheroma (TCFA) lesion: a lesion with the presence of >10% confluent necrotic 
core in direct contact with the lumen; 2. lesion with a plaque burden of ≥70%; 
3. lesion with a minimal luminal area (MLA) of ≤4.0mm2.21
Follow-up
Clinical follow-up started at inclusion and lasted one year. The primary clinical 
endpoint – MACE – was the composite of all-cause mortality, ACS, or unplanned 
coronary revascularization. ACS was defined as the clinical diagnosis of ST-seg-
ment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina 
pectoris using the guidelines of the European Society of Cardiology.22,23 Unplanned 
coronary revascularizations were defined as unplanned coronary artery bypass 
grafting or repeat percutaneous coronary intervention. The secondary endpoint 
was the composite of all-cause mortality or ACS. The endpoints were adjudicated 
by a clinical event committee blinded for biomarker and IVUS data.
Statistical analysis
The Kolmogorov-Smirnov test was used to test distributions of continuous vari-
ables for normality. CysC and CRP were not normally distributed and were ln-
transformed for further analyses. Categorical variables are presented as numbers 
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and percentages. Continuous variables that were normally distributed are presented 
as mean±standard deviation (SD); non-normally distributed continuous variables 
are presented as median and interquartile range (IQR). For reasons of uniformity, 
all biomarkers are presented as median (IQR).
We examined the associations of plasma CysC and NGAL levels with plaque bur-
den, plaque volume, and the presence of high-risk coronary lesions. Plaque volume 
was normalized for the imaged segment length. We used linear regression and logis-
tic regression analyses with continuous ln-transformed CysC and NGAL concentra-
tions consecutively as independent variables. To assess the effect of kidney function, 
we included interaction terms (ln-transformed CysC or NGAL, respectively, with di-
chotomized eGFRCr (above or below 90 ml/min/1.73m2)) into the logistic regression 
models. Subsequently, we stratified all analyses on eGFRCr of 90 ml/min/1.73m2. To 
test whether effect estimates differed between patients with ACS and patients with 
SAP, Z-tests for heterogeneity were performed. 
Cox proportional hazards regression analyses were performed to evaluate the 
associations between CysC and NGAL and the clinical study endpoints. 
Age, gender, indication for coronary angiography, diabetes mellitus, hypertension, 
and CRP concentration were considered as potential confounders , and were therefore 
entered into the multivariable linear and logistic regression models. Multivariable ad-
justment of Cox proportional hazards models was constrained due to the number of 
clinical endpoints, and was therefore performed in two steps. For MACE, in the first 
step the adjustment included age, gender, and indication for angiography; in the sec-
ond step, diabetes mellitus, hypertension and CRP were added.
Finally, we determined the cut-off values of CysC and NGAL that carry the op-
timal discriminative ability with respect to presence of high-risk coronary lesions 
and occurrence of MACE. For this purpose, we drew receiver operating character-
istic (ROC) curves and calculated the Youden index (highest sum of sensitivity and 
specificity -1).24 We considered only statistically significant associations.
All data were analysed with SPSS software (SPSS 20.0; IBM Corp., Armonk, NY). 
All statistical tests were two tailed, and p values <0.05 were considered statistically 
significant.
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FIGU R E 1 Plasma cystatin C and presence of VH-IVUS high-risk coro-
nary lesions. A. Lesion with plaque burden (PB) ≥70%. Plaque burden is defined as 
plaque and media cross-sectional area (i.e., area between yellow contour and red con-
tour) divided by external elastic membrane cross-sectional area (contoured in red); 
B. VH-IVUS derived thin-cap fibroatheroma lesion (VH-TCFA), defined as a lesion (i.e., plaque 
with a plaque burden >40%) with presence of confluent necrotic core >10% in direct contact 
with the lumen in at least three frames; C. Odds ratio (OR) per standard deviation increase 
in ln-transformed cystatin C with 95% confidence interval (CI) for lesions with PB ≥70%. 
D.  Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C with 95% 
confidence interval (CI) for VH-TCFA lesions. 
FI, fibrous; FF, fibro-fatty; NC, necrotic core, DC, dense calcium. 
a adjusted for age, gender. diabetes, hypertension, indication for angiography, C-reactive 
protein.
A
C
B
D
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RESULTS
Baseline characteristics
Mean age was 61.6±11.4 years, 75.7% were men, 54.6% had ACS, and 45.4% had SAP 
(Table 1). The imaged coronary segment had a median length of 44.3(33.8-55.4)mm. 
A total of 239 (41.5%) patients had at least one TCFA lesion, 120 (21.0%) had lesions 
with PB ≥70%, and 175 (30.7%) had lesions with MLA ≤4 mm2. Median eGFRCr 
was 90 (77-98) ml/min/1.73mm2 in the full cohort with similar values in the subset 
of ACS patients (91[78-100] ml/min/1.73mm2) and SAP patients (89 [77-97] ml/
min/1.73mm2). A total of 291 (51.8%) patients had normal kidney function and 271 
(48.2%) patients had mild-to-moderate kidney dysfunction. ACS patients exhibited 
significantly higher NGAL levels compared to patients with SAP, regardless of kidney 
function, whereas plasma CysC levels were similar in both eGFRCr groups (Table 1).
TAB LE 1 Baseline characteristics.
Variable Total(n=570)
ACS patients
(n= 309)
SAP patients
(n=261)
Patient characteristics 
Age, years (mean ± SD) 61.5±11.4 59.7±11.9 63.6±10.3
Men, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes Mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.5) 140 (45.5) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Indication for coronary angiography 
Acute coronary syndrome, n (%) 309 (54.2) 309 (100.0) 0 (0.0)
      Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0.0)
      Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0.0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0.0) 261 (100.0)
 Cystatin C, NGAL, and Coronary Atherosclerosis on IVUS
Chapter 10 
215
Variable Total(n=570)
ACS patients
(n= 309)
SAP patients
(n=261)
Coronary artery disease a 
  No signiﬁcant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.5) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
IVUS characteristics 
Segment length (mm), median (IQR) 44.2 (33.7-55.4) 43.9 (32.9-54.1) 44.8 (34.2-57.2)
Plaque burden (%), median (IQR) 39.2 (29.9-46.4) 37.2 (28.0-45.5) 40.1 (31.8-47.7)
Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.5) 99 (37.9)
Presence of PB ≥70%, n (%) 120 (21.0) 56 (18.1) 64 (24.5)
Presence of MLA ≤4 mm2 175 (30.7) 87 (28.2) 88 (33.7)
Renal function
eGFR (ml/min/1.73m2) median (IQR) b,c 90 (77-98) 91 (78-100) 89 (77-97)
KDOQI classificationa, n (%)
GFR ≥90 ml/min/1.73m2 291 (51.8) 165 (54.3) 126 (48.8)
GFR 60-89 ml/min/1.73m2 231(41.1) 115 (37.8) 116 (45.0)
GFR 30-59 ml/min/1.73m2 39 (6.9) 23 (7.6) 16 (6.2)
GFR <30 ml/min/1.73m2 1 (0.1) 1 (0.3) 0 (0.0)
Serum biomarkers
NGAL (ng/mL) median (IQR) d 197.0 (143.0-254.0) 204.0 (148.2-274.5) 177.0 (141.5-239.0)
eGFRCr ≥90 ml/min/1.73m
2 e 183.0 (143.0-227.0) 193.0 (143.0-243.0) 174.0 (125.0-223.0)
eGFRCr 30-89 ml/min/1.73m
2 e 216.0 (148.0-293.2) 228.5 (149.0-307.0) 197.0 (143.5-257.7)
Cystatin C (ng/ml) median (IQR) 796.0 (691.0-923.0) 791.0 (674.5-915.5) 802.0 (712.5-935.5)
eGFRCr ≥90 ml/min/1.73m
2 732. 0 (644.0-834.0) 729.0 (637.5-841.5 734.5 (650.7-822.5)
eGFRCr 30-89 ml/min/1.73m
2 872.0 (775.7-1032.5) 863.0 (745.0-1040.0) 879.0 (781.0-1030.0)
Creatinine (umol/l), median (IQR) c 77 (66-86) 77 (65-877) 76 (67-86)
C-reactive protein (mg/l), median (IQR) 2.1 (0.8-5.3) 2.8 (1.1-6.9) 1.4 (0.6-3.1)
ACS, acute coronary syndrome; SAP, stable angina pectoris; CABG, coronary artery bypass 
grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; CKD, chronic 
kidney disease; NGAL, neutrophil gelatinase-associated lipocalin; PB, plaque burden; 
MLA, minimal luminal area. a significant stenosis was defined as a stenosis >50% of the 
vessel diameter by visual assessment on the coronary angiogram. b estimated Glomerular 
Filtration Rate (eGFRCr) using CKD-EPI equation: GFR = 141 × min (Scr /κ, 1)α × max(Scr 
continued
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/κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] where: Scr is serum creatinine 
in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, 
min indicates the minimum of Scr /κ or 1, and max indicates the maximum of Scr /κ or 1. 
c Creatinine available in 99%, Total n=562, ACS n=304, SAP n=258; d Measurable in sample 
of  total n=473, ACS n=257, SAP n=216. e A statistically significant difference in plasma 
NGAL levels between ACS and SAP patients (for total population, p=0.002; if eGFRCr ≥90 
ml/min/1.73 m2, p=0.01; if eGFRCr 30-89 ml/min/1.73 m
2, p=0.03).
Cystatin C, NGAL and degree of atherosclerosis on grayscale 
IVUS 
Numbers of lesions with plaque burden (PB) ≥70% and minimal luminal area 
(MLA) ≤4mm2 according to categories of kidney function are depicted in Fig-
ure S3. Significant interactions were found between CysC and eGFRCr in crude 
(p=0.007) and multivariable (p=0.010) models predicting lesions with PB ≥70%. 
In patients with normal kidney function, those with higher CysC had lower risk 
of lesions with PB ≥70% (per SD increase in ln-transformed CysC: OR[95%CI]: 
0.56 [0.39-0.82], p=0.002) (Table 2, Figure 1, Figure S1). After multivariable 
adjustment including CRP levels, risk remained significantly lower (adjusted 
OR[95%CI]: 0.46 [0.30-0.69], p<0.001). A CysC level of 773.0 ng/ml was the op-
timal cut-off value to identify patients who did not have lesions with PB≥70% 
(CysC ≥773.0 ng/ml) (Figure S4). Conversely, in patients with mild-to-moderate 
kidney dysfunction risk did not differ significantly according to CysC levels (ad-
justed OR[95%CI]:0.95 [0.69-1.30], p=0.75). Risk of lesions with PB ≥70% dis-
played a similar pattern in patients with higher NGAL (Table 2). In patients with 
normal kidney function, an NGAL level of 180.0 ng/ml was the optimal cut-off 
value to identify patients without lesions with PB ≥70% (NGAL ≥180.0 ng/ml) 
(Figure S5). Risk of lesions with MLA ≤4mm2 was not different for patients with 
higher CysC or NGAL (Table 2).
Overall, no differences could be demonstrated between CysC and NGAL in 
either plaque burden or normalized plaque volume of the entirely imaged seg-
ment (Table 3 and Table S2). Nevertheless, CysC showed a tendency towards low-
er normalized segment plaque volume (per SD increase in ln-transformed CysC: 
β [95%CI]: -0.43 [-1.02-0.16], p=0.16) in patients with normal kidney function; 
whereas no differences were observed in patients with mild-to-moderate kidney 
dysfunction.
There was no heterogeneity between ACS and SAP patients regarding the dif-
ferences in IVUS grayscale parameters according to CysC or NGAL levels. 
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Cystatin C, NGAL and composition of atherosclerosis on 
radiofrequency VH-IVUS 
Absolute numbers of thin-cap fibroatheroma  lesions (VH-TCFAs) according to cat-
egories of kidney function are depicted in Figure S3. Significant interactions were 
found between CysC and eGFRCr in crude (p=0.002) and multivariable (p=0.003) 
models predicting VH-TCFAs. In patients with normal kidney function, those with 
TAB LE 2 Plasma cystatin C, NGAL and presence of thin-cap fibroatheroma  
( VH-TCFA) lesions, lesions with plaque burden (PB) ≥70% and lesions with 
minimal luminal area (MLA) ≤4mm2 stratified according to kidney function. 
 
Unadjusted model Multivariable model
OR (95% CI) p-value OR (95% CI) p-value
eGFRCr ≥90 ml/min/1.73m
2
VH-TCFA
Cystatin C a 0.63 (0.46-0.85) 0.002 0.59 (0.44-0.83) 0.002
NGAL b 0.77 (0.57-1.04) 0.090 0.72 (0.52-0.98) 0.040
Plaque Burden ≥70%
Cystatin C a 0.56 (0.39-0.82) 0.002 0.46 (0.30-0.69) <0.001
NGAL b 0.56 (0.35-0.89) 0.015 0.49 (0.29-0.82) 0.007
MLA ≤4mm2
Cystatin C a 0.97 (0.72-1.32) 0.88 0.92 (0.67-1.25) 0.59
NGAL b 1.03 (0.77-1.37) 0.84 1.07 (0.79-1.45) 0.67
eGFRCr 30-89 ml/min/1.73m
2
VH-TCFA
Cystatin C a 1.14 (0.89-1.45) 0.30 1.09 (0.83-1.42) 0.55
NGAL b 1.01 (0.78-1.29) 0.97 0.96 (0.74-1.24) 0.74
Plaque Burden ≥70%
Cystatin C a 1.06 (0.80-1.40) 0.68 0.95 (0.69-1.30) 0.75
NGAL b 1.20 (0.88-1.63) 0.25 1.21 (0.87-1.67) 0.25
MLA ≤4 mm2
Cystatin C a 0.84 (0.64-1.10) 0.19 0.73 (0.53-0.99) 0.042
NGAL b 0.98 (0.74-1.29) 0.90 1.05 (0.78-1.41) 0.75
a Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C with 95% 
confidence interval (CI); b Odds ratio (OR) per standard deviation increase in NGAL with 95% 
confidence interval (CI); Multivariable model: adjusted for age, gender, diabetes mellitus, 
hypertension, indication for angiography, C-reactive protein.
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higher CysC levels had lower risk of VH-TCFA lesions (per SD increase in ln-trans-
formed CysC: OR[95%CI]: 0.63 [0.46-0.85], p=0.002) (Table 2, Figure 1, Figure 
S1). After multivariable adjustment including CRP levels, risk remained signifi-
cantly lower (adjusted OR[95%CI]: 0.59 [0.44-0.83], p=0.002). CysC of 678.5 ng/ml 
was the optimal cut-off value to identify patients without VH-TCFA lesions (CysC 
≥678.5 ng/ml) (Figure S6). Conversely, in patients with mild-to-moderate kidney 
dysfunction, risk did not differ significantly according to CysC levels (adjusted 
OR[95%CI]: 1.09[0.83-1.42],  p=0.55). The interaction between NGAL and eGFRCr 
was not statistically significant. A tendency towards lower risk of VH-TCFA lesions 
was observed for higher NGAL, but only in patients with normal kidney function 
(Table 2). There was no heterogeneity between ACS and SAP patients regarding 
the difference in VH-TCFA lesions (CysC, p=0.29, NGAL, p=0.57) (Table S1). At 
the level of the entire segment, no differences were present in radiofrequency VH-
tissue types between CysC or NGAL (Table 3 and Table S2). 
TAB LE 3 Plasma cystatin C, NGAL and segment characteristics (degree of 
atherosclerosis: plaque volume and plaque burden; composition of coronary 
atherosclerosis: 4 components) as determined by VH-IVUS stratified according 
to kidney function.
Cystatin C b NGAL c
β coefficient (95% CI) p-value β coefficient (95% CI) p-value
eGFRCr ≥90 ml/min/1.73m
2
Plaque burden a -0.02 (-0.16 – 0.12) 0.77 -0.05 (-0.18 – 0.09) 0.50
Plaque volume a -0.43 (-1.02 – 0.16) 0.16 -0.19 (-0.77 – 0.38) 0.51
FI (%) 0.52 (-1.11 – 2.15) 0.53 0.60 (-0.98 – 2.19) 0.45
FF (%) a 0.03 (-1.10 – 0.17) 0.65 0.12 (-0.02 – 0.25) 0.09
NC (%) -0.65 (-1.84 – 0.53) 0.28 -0.85 (-2.00– 0.30) 0.15
DC (%) a 0.00 (-0.17 – 0.17) 0.99 -0.12 (-0.28 – 0.04) 0.15
eGFRCr 30-89 ml/min/1.73m
2
Plaque burden a 0.00 (-0.11 – 0.12) 0.94 -0.03 (-0.15 – 0.09) 0.66
Plaque volume a 0.16 (-0.37 – 0.68) 0.55  -0.04 (-0.59 – 0.51) 0.89
FI (%) -1.04 (-2.45 – 0.37) 0.15 0.60 (-0.89 – 2.09) 0.42
FF (%) a -0.02 (-0.13 – 0.10) 0.76 -0.01 (-0.12 – 0.11) 0.92
NC (%) 0.44 (-0.47 – 1.35) 0.34 -0.27 (-1.23 – 0.68) 0.57
DC (%) a 0.11 (-0.04 – 0.25) 0.15  -0.06 (-0.21 – 0.09) 0.44
FI, fibrous; FF, fibro-fatty; NC, necrotic core, DC, dense calcium. a Square root transformed 
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b  Unadjusted β coefficient per standard deviation increase in ln-transformed Cystatin C with 
95% confidence interval (CI). 
c Unadjusted β coefficient per standard deviation increase in NGAL with 95% confidence 
interval (CI). 
Cystatin C, NGAL and 1-year MACE 
Vital status was acquired for 569 (99.8%) patients. During the 1-year follow-up, 56 
patients experienced the primary endpoint (MACE; Figure S3), and 30 patients en-
dured the secondary composite endpoint of all-cause mortality or ACS. In the full 
cohort, patients with higher CysC had higher risk of MACE (per SD increase in ln-
transformed CysC: HR[95% CI]:1.41[1.10-1.79], p=0.006) (Figure 2, Figure S2). After 
multivariable adjustment, the risk estimate lost statistical significance. For NGAL, 
significant differences in risk of MACE were not found (Figure 2, and Figure S2).  
FIGU R E 2 Plasma cystatin C, NGAL and occurrence of the 1-year MACE. MACE, 
major adverse coronary event; Hazard ratio (HR) per standard deviation increase in ln-
transformed cystatin C and per standard deviation increase in NGAL with 95% confidence 
interval (CI). a unadjusted model; b  adjusted for age, gender, indication for angiography; 
c adjusted for age, gender, indication for angiography, diabetes mellitus, hypertension, 
C-reactive protein; Multivariable adjustment was constrained by the limited number of 
clinical endpoint.
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In patients with normal kidney function, those with higher CysC levels did not 
have higher risk of MACE (Figure 2, Figure S2). In patients with mild-to-moderate 
kidney dysfunction, those with higher CysC levels had higher risk of MACE in 
univariable analysis (HR[95%CI]:1.40[1.03-1.92], p=0.03) (Figure 2, Figure S2). In 
multivariable analysis, the HR lost statistical significance, but did not materially 
change (HR[95%CI]:1.31 [0.92-1.87], p=0.12). 
Both in the total population and in patients with mild-to-moderate kidney dys-
function, a CysC of 849.0 ng/ml was the optimal cut-off value to identify patients 
who developed MACE (CysC ≥849.0 ng/ml) (Figure S7). Patterns of risk of the sec-
ondary endpoint (all-cause mortality and ACS) according to CysC and NGAL levels 
were similar to those of MACE (Table S3). Finally, stratification on the indication for 
angiography confirmed the risk patterns which were found in the full cohort (Table 
S4). 
DISCUSSION 
We found that in patients with normal kidney function, those with higher CysC 
levels had fewer high-risk coronary lesions (VH-TCFA and lesions with PB ≥70%), 
while risk of MACE was not different. Conversely, when kidney function was mild-
ly-to-moderately impaired, no differences in high-risk lesions were observed, but 
those with higher CysC levels had higher risk of MACE. Therefore, with regard to 
prediction of cardiovascular risk, CysC appears to carry potential only when eG-
FRCr is below 90 ml/min/1.73m2. Furthermore, patients with higher NGAL levels 
had fewer lesions with PB≥70%, but only when they had normal kidney function. 
No differences in MACE were found for NGAL, and thus its use for cardiovascular 
risk prediction could not be substantiated. Altogether, our results on CysC suggest 
novel pathophysiological insights, because they offer an explanation for the differ-
ence in findings observed in experimental and epidemiologic studies so far, and 
imply that the association between CysC and cardiovascular disease may not be 
solely explained through its correlation with GFR. 
Higher CysC levels have been associated with occurrence of cardiovascular 
events in various epidemiological studies.25 Conversely, animal experiments sug-
gest that higher CysC may be favourable. Atherosclerotic mice deficient in CysC 
display increased plaque size and macrophage content, increased elastic lamina 
degradation and accumulation of smooth muscle cells.26,6 Studies in humans have 
also found reduced CysC in atherosclerotic and aneurysmatic aortic lesions.7 Xu et 
al. have demonstrated that immune cells (CD8+ dendritic cells (DC) and macro-
phages), which are involved in atherosclerotic processes, are major contributors to 
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the circulating CysC pool.27,28 However, besides a correlation with GFR, the mecha-
nisms that may explain the link between CysC and cardiovascular disease are still 
unclear. Our study provides additional insights. We found that in patients with 
normal kidney function, those with higher CysC levels had fewer high-risk coro-
nary lesions, and did not have higher risk of MACE.  This is in accordance with a 
potential ‘athero-protective’ effect. 
Conversely, in patients with mild-to-moderate kidney dysfunction, differences 
in high-risk lesions according to CysC level were not present. This could possibly 
be explained by the changes in CysC physiology that occur in impaired kidneys. 
When kidney function deteriorates, circulating plasma CysC increases and oxida-
tive stress advances, both of which stimulate Cys to form homodimers.28,29 When 
CysC forms homodimers, it cannot inhibit cysteine proteases, because the inhibi-
tory region is hidden within the dimer interface. Thus, it may no longer be able to 
exhibit ‘athero-protective’ properties.30 Although these hypotheses are compelling, 
additional clinical and experimental studies are necessary to further substantiate 
the effect modification by kidney function that we observed. 
Our findings suggest that NGAL may act on coronary artery disease through 
a different mechanism than currently investigated. A potential lack of predictive 
precision due to a limited number of MACE may explain the difference between 
the current results and previous studies.15,31 On the other hand, a recent meta-
analysis that investigated NGAL as a predictor of cardiovascular disease concluded 
that strong evidence for independent predictive value of NGAL is still lacking.32 
Notably, we found higher plasma NGAL levels in ACS patients compared to SAP 
patients, independently of kidney function. This could possibly be explained by 
neutrophilia as a consequence of more severe cardiac damage in ACS patients com-
pared to SAP patients.33 However, no heterogeneity between ACS and SAP patients 
was observed in the relationship between NGAL and IVUS-features of coronary 
atherosclerosis. 
Study limitations
Some limitations of this study merit consideration. This study is currently the larg-
est cohort in which the associations between IVUS plaque characteristics, CysC 
and NGAL were investigated. Yet, we cannot exclude the possibility of a chance 
finding with regard to effect modification by kidney function. However, both the 
cut-off value (based on K/DOQI guidelines) and the study population (no kidney 
failure/eGFR<30) were chosen a priori. Still, our findings should be considered 
hypothesis-generating and warrant external validation. Second, kidney function 
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was determined by the creatinine-based CKD-EPI formula, without direct mea-
surement of GFR. Although the CKD-EPI formula has displayed better perfor-
mance than the Modification of Diet in Renal Disease (MDRD) equation,17 it is 
still possible that a few patients are misclassified. Third, VH-IVUS imaging was 
limited to a pre-specified target segment of a non-culprit coronary artery. This 
study design was chosen based on the hypothesis that such a non-stenotic seg-
ment reflects coronary wall pathophysiology of the larger coronary tree.34,35 This 
hypothesis, on its part, was based on ex-vivo, as well as in-vivo studies using IVUS 
in patients with myocardial infarction. These studies have demonstrated the pres-
ence of TCFAs in places other than the culprit lesion or even culprit artery.16,36 In 
fact, we were subsequently able to confirm this hypothesis, by demonstrating that 
imaging characteristics of the non-culprit artery are associated with increased risk 
of MACE within the current study population.34 Therefore, this study design allows 
us to investigate whether the patient’s burden and vulnerability of atherosclerotic 
disease – as reflected by the phenotype of a non-culprit artery segment – is associ-
ated with blood biomarkers.16 Finally, although the spatial resolution of IVUS-VH 
is formally too low to detect thin caps, we have demonstrated that VH-IVUS de-
rived TCFA lesions strongly and independently predict the occurrence of MACE 
within the current study population.34 
CONCLUSION
This study provides new insights into the role of plasma CysC and NGAL in coro-
nary atherosclerosis. Most importantly, it shows that in patients with normal kid-
ney function, those with higher CysC levels have fewer high-risk coronary lesions, 
while in patients with impaired kidneys, those with higher CysC have higher risk of 
MACE. Thus, this study implies that mild-to-moderate kidney dysfunction modi-
fies the relationship between plasma CysC and coronary artery disease. This has 
not been established before, and it offers an explanation for the difference in find-
ings observed in experimental and epidemiologic studies.With regard to cardiovas-
cular risk prediction, CysC showed predictive capacities when eGFRCr was below 90 
ml/min/1.73m2, whereas NGAL levels were not predictive of MACE. 
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SUPPLEMETARY INFORMATION 
FIGU R E S1 Relative number of thin-cap fibroatheroma ( VH-TCFA) lesions and 
lesions with plaque burden (PB)≥70% per strata of kidney function (eGFRCr) 
and plasma cystatin C (CysC) levels above and below median. 
FIGU R E S2 1-year cumulative incidence of major adverse coronary events 
(MACE). A. 1-year MACE per strata of kidney function (eGFRCr) and plasma cystatin C (CysC) 
levels above and below median. B. 1-year MACE per strata of kidney function (eGFRCr)  and 
plasma NGAL levels above and below median.
A
B
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TAB LE S1 Plasma cystatin C, NGAL and presence of thin-cap fibroatheroma 
( VH-TCFA) lesions, lesions with plaque burden (PB)≥70%, and lesions with 
minimal luminal area (MLA) ≤4 mm2.
Unadjusted Multivariable model
OR (95% CI) p-value OR (95% CI) p-value
Total population
VH-TCFA
Cystatin Ca 0.93 (0.78-1.10) 0.38 0.89 (0.74-1.08) 0.25
NGAL b 0.92 (0.76-1.10) 0.36 0.88 (0.72-1.07) 0.19
Plaque Burden ≥70%
Cystatin C a 0.93 (0.76-1.14) 0.50 0.75 (0.59-0.95) 0.018
NGAL b 0.95 (0.74-1.21) 0.67 0.92 (0.71-1.19) 0.51
MLA ≤4mm2
Cystatin C a 0.90 (0.75 - 1.08) 0.27 0.79 (0.65-0.98) 0.028
NGAL b 1.00 (0.82 - 1.21) 0.95 1.01 (0.82-1.24) 0.90
ACS patients 
VH-TCFA
Cystatin C a 0.86 (0.69-1.07) 0.18 0.80 (0.62-1.03) 0.085
NGAL b 0.86 (0.67-1.09) 0.21 0.85 (0.66-1.08) 0.18
Plaque Burden  ≥70% 
Cystatin C a 0.81 (0.61-1.09) 0.17 0.57 (0.40-0.81) 0.002
NGAL b 0.87 (0.62-1.24) 0.45 0.81 (0.56-1.17) 0.26
MLA ≤4mm2
Cystatin C a 1.04 (0.79-1.28) 0.97 0.86 (0.65-1.14) 0.30
NGAL b 1.11 (0.85-1.44) 0.44 1.10 (0.84-1.44) 0.50
SAP patients
VH-TCFA
Cystatin C a 1.05 (0.81-1.37) 0.70 1.06 (0.79-1.42) 0.70
NGAL b 0.96 (0.70-1.30) 0.78 0.95 (0.69-1.31) 0.75
Plaque Burden ≥70% 
Cystatin C a 1.04 (0.78-1.40) 0.77 1.00 (0.72-1.38) 0.97
NGAL b 1.01 (0.77-1.58) 0.60 1.05 (0.73-1.52) 0.79
MLA ≤4mm2
Cystatin C a 0.77 (0.58-1.02) 0.071 0.73 (0.53-0.99) 0.044
NGAL b 0.91 (0.67-1.24) 0.55 0.90 (0.65-1.24) 0.51
ACS, acute coronary syndrome; SAP, stable angina pectoris. Multivariable model:  adjusted 
for age, gender, diabetes mellitus, hypertension, indications for angiography, C-reactive 
protein. a Odds ratio (OR) per standard deviation increase ln-transformed cystatin C with 
95% confidence interval (CI). b Odds ratio (OR) per standard deviation increase in NGAL with 95% 
confidence interval (CI). 
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TAB LE S2 Plasma cystatin C, NGAL and segment plaque volume, burden 
and VH-tissue types as determined by VH-IVUS, in the total population and 
stratified by indication for angiography.
Cystatin C a NGAL b
β coefficient (95% CI) p-value β  coefficient (95% CI) p-value
Total population 
Plaque burden c 0.03 (-0.05 – 0.11) 0.44 -0.02 (-0.11 – 0.07) 0.67
Plaque volume c 0.04 (-0.31 – 0.39) 0.83 -0.05 (-0.44 – 0.34) 0.79
FI (%) -0.46 (-1.42 – 0.50) 0.35 0.52 (-0.54 – 1.58) 0.33
FF (%) c 0.01 (-0.07 – 0.09) 0.86 0.05 (-0.04 – 0.13) 0.29
NC (%) -0.17 (-0.83 – 0.50) 0.62 -0.56 (-1.29– 0.17) 0.13
DC (%) c 0.09 (-0.01 – 1.19) 0.072 -0.07 (-0.18 – 0.04) 0.22
ACS patients 
Plaque burden c 0.01 (-0.10 – 0.12) 0.89 -0.05 (-0.16 – 0.07) 0.43
Plaque volume c -0.22 (-0.68 – 0.24) 0.35 -0.27 (-0.77 – 0.23) 0.29
FI (%) -0.20 (-1.50 – 1.10) 0.76 0.54 (-0.87 – 1.95) 0.45
FF (%) c -0.05 (-0.16 – 0.06) 0.39 0.08 (-0.04 – 0.20) 0.18
NC (%) -0.19 (-1.12– 0.74) 0.69 -0.98 (-1.98 – 0.02) 0.055
DC (%) c 0.12 (-0.01 – 0.24) 0.079 -0.06 (-0.20 – 0.08) 0.39
SAP patients
Plaque burden c 0.05 (-0.07 – 0.16) 0.41 0.07 (-0.06 – 0.21) 0.29
Plaque volume c 0.35 (-0.20 – 0.90) 0.21 0.39 (-0.25 – 1.02) 0.23
FI (%) -0.66 (-2.09 – 0.76) 0.36 0.03 (-1.61 – 1.67) 0.97
FF (%) c 0.71 (-0.04 – 0.18) 0.22 0.03 (-0.10 – 0.16) 0.64
NC (%) -0.08 (-1.03 – 0.86) 0.86 -0.09 (-1.18 – 1.00) 0.87
DC (%) c 0.04 (-0.12 – 0.19) 0.64 -0.02 (-0.20 – 0.16) 0.85
ACS, acute coronary syndrome; SAP, stable angina pectoris. FI, fibrous, FF; fibro fatty; NC, 
necrotic core; DC, dense calcium. a Unadjusted β per standard deviation increase in ln-
transformed cystatin C with 95% confidence interval (CI) b Unadjusted β per standard 
deviation increase in NGAL with 95% confidence interval (CI). c  Square root transformed.
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FIGU R E S3 Absolute numbers of thin-cap fibroatheroma ( VH-TCFA) lesions, 
lesions with plaque burden (PB)≥70%, lesions with minimal luminal area 
(MLA)≤4 mm2, and 1-year major adverse coronary events (MACE) per strata of 
kidney function (eGFRCr).
TAB LE S3 Plasma cystatin C, NGAL and composite endpoint of all-cause 
mortality/acute coronary syndrome(ACS) in total population and stratified by 
kidney function (eGFRCr).
All-cause 
mortality/
ACS
Unadjusted Model 1 Model 2
HR (95%CI) p-value HR (95%CI) p-valueHR (95%CI) p-value
Total population
Cystatin C a 1.67(1.24-2.27) <0.001 1.51 (1.08-2.10) 0.015 1.24 (0.88-1.77) 0.19
NGAL b 1.20 (0.85-1.71) 0.30 1.17 (0.81-1.70) 0.40 1.11 (0.77-1.61) 0.56
eGFRCr ≥90 ml/min/1.73m
2
Cystatin C a 1.39 (0.72 – 2.65) 0.32 1.33 (0.72 – 2.48) 0.36 1.11 (0.54-2.25) 0.78
NGAL b 1.04 (0.57-1.89) 0.89 1.12 (0.63-1.98) 0.69 1.08 (0.56-2.11) 0.81
eGFRCr 30-89 mL/min/1.73 m
2
Cystatin C a 1.81 (1.23-2.66) 0.003 1.73 (1.17-2.55) 0.006 1.59  (1.01-2.50) 0.04
NGAL b 1.26 (0.80-1.98) 0.31 1.22 (0.77-1.94) 0.39 1.18 (0.74-1.87) 0.48
Model 1: adjusted for the age, gender, indication for angiography; Model 2: model 1 
+ diabetes mellitus, hypertension, C-reactive protein. Multivariable adjustment was 
constrained by the limited number of clinical endpoints. 
a  Hazard ratio (HR) per standard deviation increase in ln-transformed cystatin C with 95% 
confidence interval (CI). 
b  Hazard ratio (HR) per standard deviation increase in NGAL with 95% confidence interval (CI). 
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TAB LE S4 Plasma cystatin C, NGAL and major adverse coronary events (MACE) 
and the composite of all-cause mortality/acute coronary syndrome (ACS), 
stratified by indication for angiography.
Unadjusted Model 1 Model 2
HR (95%CI) p-valueHR (95%CI) p-value HR (95%CI) p-value
ACS patients
MACE
Cystatin C a 1.41 (1.01-1.98) 0.047 1.24 (0.85-1.81) 0.27 1.10 (0.73 – 1.65) 0.66
NGAL b 1.17 (0.80 – 1.70) 0.43 1.17 (0.80 – 1.72) 0.42 1.14 (0.76 – 1.69) 0.53
All-cause mortality/ACS
Cystatin C* 1.61 (1.15 –  2.40) 0.007 1.47 (0.98 – 2.20) 0.06 1.23 (0.79 – 1.91) 0.37
NGAL b 1.33 (0.89 – 1.98) 0.16 1.35 (0.89 – 2.03) 0.15 1.33 (0.86 – 2.06) 0.20
SAP patients
MACE
Cystatin C a 1.39 (0.98 – 1.97) 0.07 1.35 (0.92-1.98) 0.12 1.25 (0.85-1.84) 0.26
NGAL b 1.18 (0.77 – 1.80) 0.44 1.10 (0.72 – 1.69) 0.66 1.08 (0.70 – 1.64) 0.73
All-cause mortality/ACS
Cystatin C a 1.71 (1.02 – 2.88) 0.042 1.61 (0.90 – 2.87) 0.11 1.40 (0.76 – 2.59) 0.28
NGAL b 0.84 (0.42 – 1.70) 0.64 0.79 (0.39 – 1.61) 0.52 0.78 (0.38 – 1.58) 0.49
ACS, acute coronary syndrome; SAP, stable angina pectoris. Model 1: adjusted for the age, 
gender; Model 2: model 1 + diabetes mellitus, hypertension, C-reactive protein. 
a Hazard ratio (HR) per standard deviation increase in ln-transformed cystatin C with 95% 
confidence interval (CI). 
b  Hazard ratio (HR) per standard deviation increase in NGAL with 95% confidence interval (CI). 
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FIGU R E S5 Receiver operator characteristic (ROC) curve of plasma NGAL for 
the prediction of absence of lesion with plaque burden (PB)≥70% in patients 
with eGFRCr ≥90 ml/min/1.73m
2. NGAL of 180.0 ng/ml is optimal cut-off value, based on 
Youden index (highest sum of sensitivity and specificity -1), discriminating between patients 
who did not have lesion with PB≥70% (NGAL ≥180.0 ng/ml) and those who had (NGAL <180.0 
ng/ml). AUC (95%CI), area under the ROC curve with corresponding 95% confidence interval.
FIGU R E S4 Receiver operator characteristic (ROC) curve of plasma cystatin C 
(CysC) for  the prediction of absence of lesion with plaque burden (PB)≥70% 
in patients with eGFRCr ≥90 ml/min/1.73m
2. CysC of 773.0 ng/ml is optimal cut-off 
value, based on Youden index (highest sum of sensitivity and specificity -1), discriminating 
between patients who did not have lesion with PB ≥70% (CysC ≥773.0 ng/ml), and those 
who had (CysC <773.0 ng/ml). AUC (95%CI), area under the ROC curve with corresponding 
95% confidence interval.
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FIGU R E S7 Receiver operator characteristic (ROC) curve for plasma cystatin C 
(CysC) for the prediction of the occurrence of major adverse coronary events 
(MACE) in total population and in patients with eGFRCr 30-89 ml/min/1.73m
2. 
CysC of 849.0 ng/ml is optimal cut-off value, based on Youden index (highest sum of 
sensitivity and specificity -1), discriminating between patients who developed MACE (CysC 
≥849.0 ng/ml) and those who did not (CysC <849.0 ng/ml). AUC (95%CI), area under the ROC 
curve with corresponding 95% confidence interval.
BA
FIGU R E S6 Receiver operator characteristic (ROC) curve of plasma cystatin 
C (CysC) for the prediction of absence of thin-cap fibroatheroma ( VH-TCFA) 
lesion in patients with eGFRCr ≥90 ml/min/1.73m
2. CysC of 678.5 ng/ml is optimal 
cut-off value, based on Youden index (highest sum of sensitivity and specificity -1), 
discriminating between patients who did not have VH-TCFA lesion (CysC ≥678.5 ng/ml), 
and those who had (CysC <678.5 ng/ml). AUC (95%CI), area under the ROC curve with 
corresponding 95% confidence interval. 
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ABSTRACT 
Background 
We determined the temporal effects of neurohormonal antagonists and loop di-
uretics on serially assessed cardio-renal biomarkers, functional status, and clinical 
outcomes in patients with chronic heart failure (CHF) with reduced ejection frac-
tion. 
Methods
In 250 CHF patients, we measured 3-monthly in blood: NT-proBNP, troponin T, 
C-reactive protein, creatinine, cystatin C;  and in urine: N-acetyl-beta-D-glucosa-
minidase and kidney-injury-molecule-1. 
Results
ACE-inhibitors/ARB were inversely associated with cardiac impairment, inflam-
mation and renal tubular damage, but not with glomerular dysfunction. Diuretics 
were associated with worse biomarker profiles and with a hazard ratio for adverse 
clinical outcome of 1.12 (95%CI:1.03–1.22) per 40 mg higher doses. ACE-inhibi-
tors/ARBs were more frequently down-titrated and diuretics more frequently up-
titrated in patients who experienced endpoints than in those who did not. 
Conclusions
In conclusion, decrease or withholding of ACE-inhibitors/ARBs solely based on 
glomerular function is not justified because of the beneficial effects on the heart, 
inflammation, and renal tubules. Higher and increase in diuretic doses mark pro-
gression towards end-stage CHF. 
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INTRODUCTION
In randomized clinical trials (RCTs), neurohormonal antagonists significantly re-
duce mortality in chronic heart failure (CHF) with reduced ejection fraction.1-4 
In clinical practice, however, optimization of neurohormonal antagonist doses to 
guideline recommendations is often not reached.5 Moreover, the temporal effects 
of dose adjustments of these agents during clinical follow-up of “real-life” patients 
with CHF are uncertain. 
Although guidelines also recommend the use of loop diuretics due to their ben-
eficial effect on symptoms and signs of congestion, no large RCTs have been con-
ducted to prove their efficacy on survival.6 While longitudinal data on the temporal 
effects of loop diuretics are absent, studies using cross-sectional data have suggest-
ed that the loop diuretics are associated with reduced survival.7-9 Yet, it is unclear 
whether this association between poor survival and non-randomized use of diuret-
ics is causal or a reflection of the progressive underlying disease with progressive 
congestion.7 Hence, higher doses of loop diuretics will be given to the patients with 
more severe CHF. However, excessive diuresis may also lead to excessive neurohor-
monal activation and renal dysfunction, thereby potentially increase mortality.10,11
For these reasons identifying the temporal effects of neurohormonal antago-
nists and loop diuretics on serially assessed patients’ functional status and multiple 
cardio-renal biomarkers, could help to better use of these agents and potential-
ly improve outcomes. The multiple-biomarker strategy enables us to investigate 
simultaneously the effects of HF medication doses on the evolution of different 
pathophysiological processes (myocardial stretching and damage, inflammation, 
renal injury and dysfunction) that occur in CHF regardless of its underlying cause. 
Similarly, serial measures enable us to control for time-varying health status of 
patients, thereby providing less biased risk estimates.
In this prospective longitudinal study, our aim was (1) to determine the tem-
poral effects of neurohormonal antagonists and loop diuretics on serially assessed 
New York Heart Association (NYHA) functional classification, natriuretic peptide 
NT-proBNP, cardiac troponin T (hs-cTnT), C-reactive protein (CRP), creatinine 
and cystatin C, and urinary N-acetyl-ß-D glucosaminidase (NAG) and kidney-
injury-molecule (KIM)-1, at predefined 3-month intervals during ≥ 2-year outpa-
tient follow-up; (2) to investigate the temporal associations between dose adjust-
ments of these HF medications and clinical outcomes.
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MATERIALS AND METHODS 
The Serial Biomarker Measurements and New Echocardiographic Techniques in 
Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-
SHiFT) is a prospective observational cohort of patients with CHF, conducted in 
Erasmus MC, Rotterdam, and Noordwest Ziekenhuisgroep, Alkmaar, The Neth-
erlands. Patients were included if aged ≥18 years, capable of understanding and 
signing informed consent, and if CHF had been diagnosed ≥3 months ago accord-
ing to European Society of Cardiology guidelines (Figure S1).12,13 Patients were am-
bulatory and stable, i.e., they had not been hospitalized for HF in the past three 
months. The study was approved by the medical ethics committees, conducted in 
accordance with the Declaration of Helsinki, and registered in ClinicalTrials.gov 
(NCT01851538). Written informed consent was obtained from all patients. This 
investigation comprised 263 stable CHF patients enrolled during the first inclu-
sion period (October 2011 until June 2013). Since the effect of certain HF medica-
tions, such as RAAS inhibitors, is less firmly established in HFpEF patients than in 
HFrEF patients, and since 95% of the study population had HFrEF, in this paper we 
focused on the HFrEF patients (n=250). However, all analyses were also repeated 
in the full cohort (n=263).
Baseline assessment
All patients were evaluated by research  physicians, who collected information on 
HF-related symptoms, NYHA classification, and performed a physical examina-
tion, including blood pressure, heart rate and body mass index. Information on 
HF etiology, left ventricular ejection fraction, cardiovascular risk factors, medical 
history and medical treatment was retrieved primarily from hospital records and 
was checked in case of ambiguities. History of myocardial infarction (MI), per-
cutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), 
valvular heart disease, atrial fibrillation or other arrhythmias, cerebrovascular ac-
cident (CVA), diabetes mellitus, hypercholesterolemia, hypertension, and COPD 
were defined as a clinical diagnosis of these conditions, as reported by the treating 
physician in the medical chart. 
Study follow-up and endpoints
Study follow-up visits were predefined and scheduled every 3 months (±1 month 
was allowed), with a maximum of 10 study follow-up visits (for details see Figure 
1 and Table S2). At each study follow-up visit, a research physician performed a 
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short medical evaluation and collected samples. In parallel, all patients completed 
their standard outpatient clinic visits at their treating physicians’ offices. Treating 
physicians were unaware of the biomarker results. All medication changes and oc-
currence of adverse cardiovascular events since the previous visit were recorded in 
electronic case report forms.
FIGU R E 1 Schematic depiction of the analysis of the temporal lagged effects 
of HF medication doses on NYHA functional classification and biomarker 
profiles during follow-up. Study follow-up visits were predefined and scheduled every 
3 months (X-axis). At these visits a research physician performed a medical evaluation, 
assessing NYHA functional class (green rectangle), and collecting blood and urine samples 
for biomarker measurement (red dots). All HF medication changes that had occurred after 
the previous visit were recorded and calculated as total daily equivalent doses (light blue 
area); subsequently these doses were related to NYHA class and biomarker profiles at the 
next outpatient visit (dark blue arrows; temporal lagged effect). All patients were followed 
until they reached the composite endpoint or until they were censored. To account for 
differences in the moments in time at which sampling was performed in individual patients 
and the fact that some patients reached the event  and some did not, analyses were adjusted 
for sampling time and whether or not the patient had an event (for details see statistical 
analyses). 
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 During follow-up, hospitalizations for HF, MI, PCI, CABG, arrhythmias, CVA, 
cardiac transplantation, left ventricular assist device (LVAD) implantation and mor-
tality were recorded and associated hospital records and discharge letters were col-
lected. Subsequently, a clinical event committee, blinded to the biomarker results, 
reviewed hospital records and discharge letters and adjudicated the study endpoints.
The primary endpoint comprised the composite of cardiac death, cardiac trans-
plantation, LVAD implantation, and hospitalization for the management of acute or 
worsened HF, whichever occurred first. Secondary endpoints included individual 
components of the primary endpoint, and also MI, PCI, CABG, CVA, and all-cause 
mortality. Cardiac death was defined as death from MI or other ischemic heart 
disease (ICD-10: I20-I25), death from other heart disease including HF (I30-I45 
and I47-I52), sudden cardiac death (I46), sudden death undefined (R96) or unwit-
nessed or ill-described death (R98, R99). Hospitalization for acute or worsened HF 
was defined as a hospitalization for an exacerbation of HF symptoms, in combina-
tion with two of the following: BNP or NT-proBNP >3x ULN, signs of worsening 
HF, such as pulmonary rales, raised jugular venous pressure or peripheral edema, 
increased dose or intravenous administration of diuretics, or administration of 
positive inotropic agents.12
Blood and urine analysis
Blood and urine samples were collected and stored at -80oC. Biomarkers were 
measured batchwise after follow-up was completed. Laboratory personnel was 
blinded for clinical data and patients outcomes. Serum NT–proBNP and cardiac 
troponin T were analyzed by electrochemiluminesence immunoassays (Roche 
Diagnostics, Elecsys 2010, Indianapolis, Indiana, USA) (LLD: 0.6 pmol/L and 
3 ng/L respectively). Serum CRP was measured by immunoturbidimetric assay 
(Roche Hitachi 912 chemistry analyser, Basel, Switzerland) (LLD: 0.3 mg/L). 
Creatinine was determined by a colorometric test by the Jaffe reaction (LLD: 
plasma 0,14 mg/dl,  urine: 1.56 mg/ml). Plasma CysC was determined by ELISA 
(R&D systems, Minneapolis, MN) (LLD: 0.1066 µg/mL). Urinary KIM-1 was 
determined by ELISA (R&D systems, Minneapolis, MN, USA) (LLD: 0.146 ng/
mL), and NAG was determined using a substrate p-nitrophenyl N-acetyl-β-D-
glucosaminidase at pH 4.5 (Sigma, St Louis, MO, USA) (LLD: 0.485 U/L). All 
urinary biomarker were normalized to urinary creatinine concentrations to cor-
rect for concentration or dilution of urine. Glomerular filtration rate (GFR) was 
determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation that has been validated in HF patients.14 
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Statistical analyses
Categorical data are summarized by numbers and percentages; continuous data 
when normally distributed by mean ± standard deviation (SD) and when skewed 
by median and interquartile range (IQR). Differences between patients with the 
event and event-free patients were evaluated by the Mann-Whitney U test or Stu-
dent T test.
The total daily doses (TDD) were converted to equivalents according to ESC 
guidelines6 (Table S1). Furosemide equivalent dose above 500 mg (n=7) were ex-
cluded from the analysis. To calculate per patient the relative number of up-titra-
tions and down-titrations, the number of times the dose was changed (compared 
with the previous visit) of a particular patient was divided by the total number of 
this patient’s outpatient visits. 
Linear mixed-effects (LME) models were applied to estimate the evolution of 
HF medication doses over time. Intercept and slope were included in the random-
effects design matrix. To achieve normal distributions, biomarkers were 2log-trans-
formed and TDD were √-transformed for the analyses. 
LME models were also applied to assess the temporal effects of HF medica-
tion doses at the current visit on NYHA class and biomarkers at the subsequent 
outpatient visit (i.e., temporal lagged effect) during follow-up (Figure 1). For this 
analysis, we used only complete data on all variables (medication, NYHA class, and 
biomarkers) at corresponding time points during follow-up (per patient: a median 
of 8 time points). The models were adjusted for sampling time (in the fixed- and 
random-effects part), and whether or not the patient had an event (in the fixed-
effect part). To allow direct comparison of the effects of HF medication on differ-
ent biomarkers, we used Z-scores (i.e., standard deviation differences from their 
means). Thus, the effects are depicted as per 1SD increase of HF medication.
Time-dependent Cox survival analysis was applied to investigate the associations 
between HF medication doses and the study endpoints. Analyses were performed 
univariably, and then adjusted for potential confounders: age, gender, diabetes, and 
repeatedly assessed NYHA class, NT-proBNP and eGFR during follow-up. Covari-
ates were chosen based on pathophysiological considerations and were limited in 
number because we took into account the number of events that occurred during 
follow-up (and required minimum of 10 outcome events per covariate).
All analyses were performed with R Statistical Software Version 3.15 All tests 
were two-tailed and p-values <0.05 were considered statistically significant.
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RESULTS
Baseline characteristics, Follow-up, and Clinical Outcomes
Table 1 shows baseline clinical and biomarker characteristics of the 250 HFrEF 
patients. Patients who later experienced the endpoint, at baseline were older, more 
frequently had diabetes, atrial fibrillation, and history of myocardial infraction, 
and had lower systolic blood pressure, higher NYHA class, and higher levels of 
NT-proBNP, cardiac troponin T, CRP, cystatin C, and urinary NAG  than patients 
who remained endpoint-free. 
During a median (IQR) follow-up of 2.2 (1.4–2.5) years, we drew a median of 9 
blood (IQR: 5–10) and 8 urine (IQR: 5–10) samples per patient, and assessed NYHA 
functional classification and HF medication 9 (IQR: 5–11) times. Of the HFrEF pa-
tients, a total of 66 (26%) patients reached the composite endpoint: 53 patients were 
re-hospitalized for acute or worsened HF, 8 patients died of cardiovascular causes, 3 
underwent heart transplantation, and 2 underwent LVAD placement.  
TAB LE 1 Baseline characteristics. 
Total Composite endpoint reached p-value
Yes No
n = 250 66 184
Demographics
Age, years* 66 ± 13 69 ± 13 65 ± 12 0.042
Men, n (%) 184 (74) 52 (79) 132 (72) 0.27
Clinical characteristics
BMI, kg/m2 * 27.4 ± 4.7 27.3 ± 4.7 27.5 ± 4.7 0.78
Heart rate, b.p.m.* 67 ± 11 68 ± 13 66 ± 11 0.26
SBP, mmHg* 122 ± 21 116 ± 18 123 ± 21 0.021
DBP, mmHg* 72 ± 11 70 ± 10 73 ± 11 0.052
Features of heart failure
NYHA class III/IV, n (%) 62 (25) 29 (44) 33 (18) <0.001
LVEF, % * 30 ± 10 29 ± 9 31 ± 10 0.52
Etiology of heart failure, n (%)
Ischemic 116 (46) 36 (54) 80 (43) 0.12
Hypertension 31 (13) 8 (12) 23 (12) 0.94
Valvular disease 10 (4) 5 (8) 5 (3) 0.08
Cardiomyopathy 63 (25) 13 (20) 50 (27) 0.23
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Total Composite endpoint reached p-value
Yes No
n = 250 66 184
Unknown or Others 30 (12) 4 (6) 26 (14)
Medical history, n (%)
Prior MI 95 (38) 32 (48) 63 (34) 0.041
Prior PCI 81 (32) 26 (39) 55 (30) 0.16
Prior CABG 42 (17) 12 (18) 30 (16) 0.73
Atrial fibrillation 97 (39) 33 (50) 64 (35) 0.030
Diabetes 77 (31) 29 (44) 48 (26) 0.007
Hypercholesterolemia 94 (38) 29 (44) 65 (35) 0.22
Hypertension 113 (45) 34 (51) 79 (43) 0.23
COPD 31 (12) 12 (18) 19 (10) 0.10
NT-proBNP (pmol/L) † 133.1(44.9–274.4) 297.4 (176.4–524.6) 93.9 (29.1–205.0) <0.001
Hs-TnT (ng/L) † 17.7 (9.3–32.8) 30.1 (19.7–48.6) 13.8 (8.2–27) <0.001
C-reactive protein mg/L † 2.2 (0.9–4.9) 2.9 (1.4–5.4) 1.8 (0.7–4.3) 0.016
Glomerular function markers †
Creatinine, mg/dl 1.18 (0.99–1.49) 1.32 (1.02–1.51) 1.17 (0.97–1.48) 0.14
eGFR, mL/min/1.73m2 58 (42–77) 53 (39–73) 60 (44–78) 0.24
Cystatin C, mg/L 0.73 (0.57–0.97) 0.86 (0.70–1.02) 0.70 (0.52–1.18) <0.001
KDOQI classification, n (%)
eGFR ≥90 28 (11) 7 (11) 21 (11) 0.59
eGFR 60-89 92 (37) 20 (30) 72 (39)
eGFR 30-59 110 (44) 33 (50) 77 (42)
eGFR <30 20 (8) 6 (9) 14 (8)
Tubular markers †
NAG, U/gCr [urine] 5.8 (3.7–9.1) 7.9 (5.9–10.8) 5.1 (3.2–8.0) <0.001
KIM-1, ng/gCr [urine] 488.6 (246.6–935.2) 589.0 (259.6–1802.7)462.8 (236.2–900.6) 0.14
BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; NYHA 
class, New York Heart Association class; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; 
CVA, cerebrovascular accident; TIA, transitory ischemic attack; COPD, chronic obstructive 
pulmonary disease; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin 
II receptor blockers; eGFR, estimated glomerular filtration rate. * Normally distributed 
continuous variables are presented as mean±standard deviation (SD), and non-normally 
distributed variables as median and interquartile range (IQR). Categorical variables are 
presented as numbers and percentages.†All biomarkers levels were presented as median 
and interquartile range (IQR).
continued
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Associations of temporal changes in repeatedly assessed 
HF medication doses with temporal changes in NYHA 
classification and biomarker profiles during follow-up
Figure 2 shows average temporal lagged effects of repeatedly assessed HF medication 
doses on subsequent NYHA classification and biomarkers profiles during follow-up.
NYHA functional classification
Higher repeatedly assessed furosemide equivalent doses were associated with higher 
(i.e., worse) NYHA class values during follow-up. At any time-point during follow-
up, one SD increase in equivalent dose of furosemide was related to a 0.10 (95% 
CI: 0.04–0.15) points higher NYHA class (p<0.001) at the next follow-up visit. Con-
versely, higher doses of carvedilol and enalapril equivalents were associated with 
lower (i.e., better) NYHA class values during follow-up: one SD increase in equiva-
lent dose of carvedilol with a 0.06 (0.01–0.12) points lower value (p=0.036), and one 
SD increase in equivalent dose of enalapril with a 0.07 (0.02–0.13) points lower value 
(p=0.011).  
FIGU R E 2 Associations of temporal changes in repeatedly assessed 
HF medication doses with temporal changes in NYHA classification and 
biomarker profiles in HFrEF patients. The HF medication effects are giv-
en as β (95% confidence interval) SD change in 2log-biomarkers levels per 1SD in-
crease in HF medication √-dose. This method of standardization (i.e., per SD) allows 
BA
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a direct comparison of the effects of HF medication doses on different biomarkers. 
A. Carvedilol equivalent doses, B. Enalapril equivalent doses, C. Furosemide equivalent doses, 
D. Spironolactone equivalent doses,  E. Table shows conversion factors for HF medication 
doses and biomarker levels from logarithmic to linear scale
Scale: HFrEF patients Mean-1SD Mean Mean+1SD
HF medication - independent variable
Carvedilol eqv., mg. 8 32 71
Enalapril eqv., mg. 4 17 39
Furosemide eqv., mg. 9 52 131
Spironolactone eqv., mg. 1 11 30
Biomarkers - dependent variable
NT-proBNP, pmol/L 24.2 92.4 353.8
hs-cTnT, ng/L 7.4 17.0 39.3
CRP, mg/L 0.7 2.4 7.6
Creatinine, mg/L 0.87 1.21 1.69
eGFR, mL/min/1.73m2 37 56 84
Cystatin C, µg/mL 0.50 0.74 1.10
NAG, U/gCr [urine] 2.2 4.9 11.1
KIM-1, ng/gCr [urine] 197.2 457.8 1062.7
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Myocardial stretching and damage
At any time-point during follow-up, one SD increase in equivalent dose of furose-
mide was related to a 0.10 SD (0.04–0.15) higher NT-proBNP value (p<0.001) at the 
next follow-up visit, as measured on the 2log scale. As an example on the linear scale, 
these findings read as follows: in HFrEF patients an increase in furosemide dose 
from 52 (mean value) to 131 mg (mean+1SD) at the current visit corresponds to an 
increase in NT-proBNP from 92.4 (mean value) to 118.5 pmol/L (mean value + 0.10 
SD) at the next visit. Similarly, one SD increase in equivalent dose of furosemide was 
also related to a 0.09 SD (0.04–0.13) higher hs-cTnT value (p<0.001),  as measured 
on the 2log scale (Figure 2).
At any time-point during follow-up, an increase in equivalent dose of enalapril 
was associated with lower NT-proBNP and hs-cTnT at the next follow-up visit (one 
SD higher dose: 0.10 SD [0.04–0.15] lower NT-proBNP values, p<0.001; and 0.08 
SD [0.04–0.13] lower hs-cTnT values, p<0.001) (for details on linear scale see Fig-
ure 2).
Inflammation 
At any time-point during follow-up, one SD increase in equivalent dose of furo-
semide dose was related to a 0.13 SD (0.06–0.20) higher CRP value (p<0.001) at 
the next follow-up visit, as measured on the 2log scale. Conversely, higher enalapril 
equivalent doses were associated with lower CRP levels (one SD higher dose: 0.19 SD 
[0.12–0.27] lower CRP values, p<0.001) (for details on the linear scale see Figure 2).
Renal function and injury
At any time-point during follow-up, one SD increase in equivalent dose of furose-
mide was related to a 0.13 SD (0.05–0.20) lower eGFR (p=0.001), and to 0.17 SD 
(0.10–0.25) higher cystatin C (p<0.001) at the next follow-up visit, as measured on 
the 2log scale. Associations were also present with greater tubular damage (one SD 
higher dose: 0.20 SD [0.13–0.28] higher NAG values, p<0.001; and 0.12 SD [0.04–
0.20] higher KIM-1 values, p<0.001) at the next follow-up visit.
At any time-point during follow-up, increase in equivalent dose of enalapril was 
associated with less tubular damage at the next follow-up visit (one SD higher dose: 
0.10 SD [0.03–0.17] lower NAG values, p=0.008; and 0.11 SD [0.03–0.19] lower KIM-
1 values, p=0.005) (for details on the linear scale see Figure 2). Of note, glomerular 
function improved numerically with higher doses of enalapril equivalents, but this 
was not statistically significant (Figure 2). 
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HF medication and clinical outcomes: prevalence of use and 
frequency of change 
At baseline, loop diuretics were given more frequently to patients who experienced 
adverse events than to event-free patients (97 vs. 89%, p=0.021) (Figure 3).  During 
follow-up, patients who experienced the event had more than twice as many up-
titrations of diuretics than event-free patients (8 vs. 3%, p=0.038) (Figure 4). The 
frequency of unchanged dose during follow-up was numerically, but not statisti-
cally, higher in event patients (11 vs. 5%, p=0.10). Importantly, such patients also 
had more than twice as many down-titrations of ACE-inhibitors/ARBs (5 vs. 2%, 
p=0.018). In contrast, event-free patients had more up-titrations of ACE-inhibi-
tors/ARBs (0.2 vs. 1.5%, p=0.047). 
HF medication and clinical outcomes: average evolutions of 
total daily doses
At baseline, patients who later experienced adverse events were given significantly 
higher doses of loop diuretics than patients who remained event-free (94 vs. 43 mg, 
p<0.001). This difference in average dose remained significant during follow-up 
(p<0.001), and further increased in the time-period prior to event (Figure 5). 
At baseline, the average dose of ACE-inhibitors/ARBs was numerically, but not sta-
tistically, lower in patients who experienced the event than in event-free patients (15 vs. 
19 mg, p=0.12). However, the average dose significantly decreased in the time-period 
prior to the event (p=0.015 for the difference during follow-up between patients with 
events and without events). We also found a tendency towards a simultaneous decrease 
in ACE-inhibitor/ARB doses and increase in loop diuretic doses in the same patient 
over time preceding the event. However, this was not the case in event-free patients 
(Figure S2).
At baseline, patients who experienced adverse events were given, on average, nu-
merically higher doses of mineralocorticoid receptor antagonists (MRAs) than event-
free patients (13 vs. 11 mg, p=0.11). However, a decrease in average MRAs dose was 
observed during follow-up in event patients (Figure 5). 
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FIGU R E 3 Prevalence of HF medication use. Mann-Whitney U test was applied to 
test the difference between patients who experienced the event and event-free patients. A. HF 
medication use at baseline B. HF medication use during follow-up. 
FIGURE 4 Frequency of HF medication change (up-titration/down-titration/no 
change) during follow-up. Mann-Whitney U test was applied to test the difference be-
tween patients who experienced the event and event-free patients. A.  β-blockers, B.  ACE-
inhibitors/ARBs, C. Diuretics, D. Mineralocorticoid receptor antagonist (MRAs).
B
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FIGU R E 5 Average evolutions of HF medication total daily doses at baseline 
and during 1-year preceding the event (patients with incident endpoints) or 
last sample moment (event-free patients). X-axis displays baseline (BL) and the time 
(months) preceding the event or last sampling moment (time 0). Y-axis displays estimated 
mean of HF medication total daily dose at each time moment during follow-up. T-test was 
applied to test the differences at baseline, and mixed-effects models were used to test the 
difference during follow-up.  
HF medication and clinical outcomes: time-dependent 
survival analysis
Table 2 displays the results of the time-dependent survival analysis. Higher doses 
of diuretics are independently associated with higher risk of events (per 40 mg in-
crease: HR (95%CI) 1.12 (1.03–1.22), p=0.009). In addition, lower enalapril equiv-
alent doses were univariably associated with increased risk (per 40 mg decrease: 
2.41 [1.19–4.88], p=0.014), which did not persist after multivariable adjustment. 
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TAB LE 2 Time -dependent survival analysis of total daily doses in HF medication 
and the risk of clinical events during follow-up. 
HF medication
Unadjusted Model 1 Model 2
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
β-blockers
per 50 mg 
increase:
0.79 (0.53–1.19) 0.27 0.80 (0.52–1.23) 0.32 0.92 (0.62–1.36) 0.67
ACEi/ARBs
per 40 mg  
decrease:
2.41 (1.19–4.88) 0.014 2.44 (1.20–4.97) 0.014 1.27 (0.65–2.48) 0.48
Loop diuretics
per 40 mg  
increase:
1.24 (1.16–1.33) <0.001 1.25 (1.17–1.34) <0.001 1.12 (1.03–1.22) 0.009
MRAs
per 25 mg  
increase:
0.91 (0.58–1.43) 0.68 0.97 (0.61–1.55) 0.90 0.94 (0.59–1.51) 0.81
β-blockers, β-adrenergic receptor blockers; ACE-inhibitors/ARBs, angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers; MRAs, mineralocorticoid receptor 
antagonists. Hazard ratios (HR) with 95% confidence intervals (CI) are given for unadjusted 
model; Model 1: HF medications adjusted for one another; and Model 2: HF medications 
adjusted for age, sex, diabetes + repeatedly assessed: NYHA classification, NT-proBNP and 
eGFR. 
Sensitivity analysis
All above-described analyses were also performed in the full cohort (n=263) which 
additionally included the HFpEF patients. Results were essentially the same (data 
not shown).
DISCUSSION 
This study is the first to investigate the temporal relationship between medical 
therapy for HF and detailed biomarker profiles in patients with CHF with reduced 
ejection fraction. We found that higher ACE-inhibitor/ARB doses are associated 
with less cardiac impairment, lower inflammation, and less renal tubular dam-
age. No association was observed between higher ACE-inhibitor/ARB doses and 
glomerular impairment. In contrast, higher loop diuretic doses were associated 
with worsening of the biomarkers profiles and poor prognosis. We also found that 
patients who experienced incident clinical events had significantly more down-
titrations of ACE-inhibitors/ARBs, and more up-titrations of loop diuretics in the 
time-period prior to the event. Altogether, these findings challenge the down-titra-
tion or withholding of ACE-inhibitors/ARBs solely based on creatinine or eGFR, 
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and thus carry potential implications for treatment of patients with CHF. Likewise, 
“renoprotective” treatment targeted at the tubules may be even more effective than 
treatment aiming at improving renal function in terms of GFR. 
CHF and renal dysfunction are highly prevalent, share many risk factors (dia-
betes, hypertension, hyperlipidemia), and interact to worsen the prognosis.10,16 
Yet, patients with CHF and eGFR <30 ml/min/1.73m2 have systematically been 
excluded from RCTs that showed efficacy of ACE-inhibitors/ARBs in reversing 
cardiac remodeling and improving outcome.6 Moreover, some reports indicated 
that use of ACE-inhibitors/ARBs might precipitate acute renal failure.17,18 This 
may result in suboptimal dosing of ACE-inhibitors/ARBs in clinical practice as 
eGFR declines.19,20 In a recent multicenter study including 11 European coun-
tries, lower eGFR remained an independent predictor for suboptimal dosing of 
ACE-inhibitors/ARBs.21  In contrast, nephrology guidelines recommend the use 
of ACE-inhibitors/ARBs in patients with eGFR <30 ml/min/1.73m2.22,23 In fact, 
a pooled analysis of 11 randomized clinical trials has demonstrated a consistent 
protective effect of ACE-inhibitors on progression of kidney disease.24 Impor-
tantly, ACE-inhibitors impede progression of proteinuria independently of their 
antihypertensive effect.25,26 Our study extends these findings by exclusively show-
ing that ACE-inhibitors/ARBs reduce renal tubular damage in patients with CHF. 
This was demonstrated by two tubular markers (urinary NAG and KIM-1) that 
were previously found to be strongly associated with tubular damage in patients 
with acute renal injury,27 but were also associated with adverse clinical outcomes 
such as HF re-hospitalisation and mortality in patients with CHF.28,29 In line with 
this, our findings indicate that these urinary biomarkers may also be clinically 
useful for monitoring the kidney’s response to ACE-inhibitors/ARBs in patients 
with CHF. Furthermore, we found, although not significantly, a tendency towards 
improvement of glomerular function with higher ACE-inhibitor/ARB doses. 
This is indirectly supported by Frohlich et al., who found that down-titration of 
ACE-inhibitors/ARBs from higher doses does not improve renal function.30 Our 
results also suggest that higher ACE-inhibitors/ARBs doses are associated with 
lower inflammation in CHF, as shown by repeatedly measured CRP levels. This 
anti-inflammatory effect of ACE-inhibitors/ARBs,31,32 although not consistently 
proven, may be an additional link to improved survival in CHF. This raises the 
question whether a decrement in renin-angiotensin-aldosterone system (RAAS) 
blockage is justified solely based on creatinine or eGFR. This issue is especially 
important in subgroups of patients in whom we found that decrease in ACE-
inhibitors/ARBs and increase in diuretics dose occurs in parallel. 
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As for the effects of diuretics, our time-dependent survival analysis showed 
that every 40 mg increase in furosemide equivalent dose independently increases 
the instantaneous risk for 13% (4–19%). This corresponds well with 11% (8–14%) 
found by Damman et al. in their propensity-matched study of 5011 CHF pa-
tients.7 Yet a 50% reduction in the risk after correction for time-varying health 
status of patients indicates that substantial confounding by severity of HF is pres-
ent in the crude risk estimates of loop diuretics.This study is not the first to re-
port an association between these agents and poor prognosis in CHF. However, 
a unique advantage of this study is frequent repeated assessment both of NYHA 
functional classification and different cardio-renal biomarkers, which allowed us 
to thoroughly evaluate the temporal effect of HF medication dosage adjustments 
in CHF. To this end, we found that higher loop diuretics doses were associated 
with a deterioration of the complete biomarker profiles, with the largest effect 
being on the kidneys (glomeruli and tubules). This temporal association between 
loop diuretics and the levels of glomerular and tubular markers might be of par-
ticular importance for optimizing diuretic therapy in such a way that congestion 
is treated adequately but at the same time, renal injury is not caused. However, 
in-depth studies on these tubular markers, preferably interventional in nature, 
are needed to provide definite recommendations on the potential use of biomark-
er-guided loop diuretic treatment in CHF. Taken together, it is clear that higher, 
and increase in, loop diuretic doses during follow-up mark progression of CHF. 
Notably, the effects we found for potassium-sparing diuretics differed from those 
found for loop diuretics. Higher MRA doses were not significantly associated 
with adverse biomarker profiles or adverse clinical outcomes. This may in part 
be attributed to the differences in the mechanisms of action between loop diuret-
ics and MRAs. While the former have been shown to up-regulate the RAAS, the 
latter result in (beneficial) RAAS blockage. Yet, although efficacy of MRAs has 
been demonstrated in trials, in our study higher doses only showed a statistically 
significant association with lower cardiac troponin levels over follow-up; other 
beneficial effects could not be demonstrated. To this end, in other CHF cohorts, 
under-prescription of MRAs was found to be a stumbling stone for observing 
beneficial effects33-35  
Study limitations 
First, although this study was not randomized, its repeated-measures design allows 
for stronger claims of causality than can be made in previous observational studies. 
Nevertheless, risk assessment may have been biased by unmeasured confounding 
although we adjusted for several time-varying variables. Second, our analysis could 
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not take into account reasons for the dose adjustments. Yet, it is likely that reasons 
are similar to those identified  by  Ouwerkerk et al., since our patients were re-
cruited from Dutch hospitals as was the majority of patients in their study.21 Third, 
we cannot comment on the anti-proteinuric effect of ACE-inhibitors/ARBs in CHF 
since we did not measure proteinuria. However, we showed that these agents were 
associated with less tubular damage which may share similar mechanisms. Impor-
tantly, a protective tubular effect was shown by NAG and also by KIM-1, which 
was qualified as the biomarker for kidney toxicity in preclinical settings (i.e, safety 
assessment in rats) by the Food and Drug Administration and European Medicines 
Agency.36 While we examined a wide array of biomarkers, other biomarkers that 
were not assessed here may also be relevant and should be investigated in future 
studies. With the rise of modern –omics technologies, multiple biomarkers that 
carry potential for heart failure are expected to emerge in the near future. Finally, 
of note is that the proportion of patients with HFpEF in the current study was low. 
This may most likely be attributed to the fact that in the Netherlands, most HFpEF 
patients are treated by the general practitioner or in secondary referral centres, 
while the current study was performed in two centres which were both tertiary 
referral centres. We do not deem potential inclusion bias a likely reason for the low 
proportion HFpEF, because all consecutive patients were screened in both partici-
pating centres. 
CONCLUSION
In conclusion, decrease or withholding of ACE-inhibitors/ARBs solely based on glo-
merular function is not justified because of the beneficial effects on the heart, inflam-
mation, and renal tubules. Furthermore, higher and increase in loop diuretic doses 
during follow-up mark progression towards end stage CHF. 
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SUPPLEMENTARY INFORMATION
FIGU R E S1 Inclusion and exclusion criteria.
 Neurohormonal Antagonists and Loop Diuretics in Heart Failure Chapter 11
257
FIGU R E S2 Average evolutions of furosemide equivalent doses in relation to 
equivalent doses of carvedilol, enalapril,  and spironolactone within the same 
patient at the same time during follow-up, stratified by event status. 
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TAB LE S1 Total daily dose equivalents and conversion factors for ACE-
inhibitors/ARBs, β-blockers, MRAs and loop diuretics/thiazides.
Drug Category Maximal Dose(Target  Dose) Equivalency Conversion
ACE-inhibitors Total Daily Dose (mg) Enalapril Dose Conversion Factor
Enalapril 40 x 1
Lisinopril 40 x 1
Captopril 150 / 3.75
Quinapril 40 x 1
Ramipril 10 x 4
Fosinopril 40 x 1
Perindopril 16 x 2.5
Trandolapril 4 x 10
ARB Total Daily Dose (mg) Enalapril Dose Conversion Factor
Candesartan 32 x 1.25
Losartan 50 / 1.25
Valsartan 320 / 8
Irbesartan 150 /3.75
β-lockers Total Daily Dose (mg) Carvedilol Dose Conversion Factor
Carvedilol 50 x 1
Bisprolol 10 x 5
Metoprolol tartrate 100 / 2
Atenolol 50 x 1
Celiprolol 200 / 4
Labetalol 100 / 2
Nebivolol 10 x 5
Aldosterone Antagonists Total Daily Dose (mg) Spironolactone Dose Conversion Factor
Spironolactone 25 x 1
Eplerenone 50 / 2
Loop Diuretic/thiazides Total Daily Dose (mg) Furosemide Dose Conversion Factor
Furosemide 40 x 1
Bumetanide 1 x 40
Torsemide 20 x 2
Hydrochlorothiazide 12.5 x 3.2
Chlorothiazide 36 x 1.44
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ABSTRACT
Background
Acute kidney injury (AKI) frequently occurs after heart transplantation (HTx), but 
its relation to preoperative right heart hemodynamic (RHH) parameters remains 
unknown. Therefore, we aimed to determine their predictive properties for post-
operative AKI severity within 30 days after HTx.
Methods
From 1984 to 2016, all consecutive HTx recipients (n=595) in our tertiary referral 
center were included and analyzed for the occurrence of postoperative AKI staged 
by the Kidney Disease Improving Global Outcome Criteria. The effects of preop-
erative RHH on postoperative AKI were calculated using logistic regression, and 
predictive accuracy was assessed using integrated discrimination improvement 
(IDI), net reclassification improvement (NRI), and area under the receiver operat-
ing characteristics curves (AUC). 
Results
Postoperative AKI occurred in 430 (72%) patients including 278 (47%) stage-1, 
66 (11%) stage-2, and 86 (14%) stage-3. Renal replacement therapy (RRT) was ad-
ministered in 41 (7%) patients. Patients with higher AKI stages had also higher 
baseline right atrial pressure (RAP) (median: 7, 7, 8, 11 mmHg, p-trend=0.021), 
RAP-to-pulmonary capillary wedge pressure (PCWP) ratio (0.37, 0.36, 0.40, 0.47, 
p-trend=0.009), and lower pulmonary artery pulsatility index (PAPi) values (2.83, 
3.17, 2.54, 2.31, p-trend=0.012). Higher RAP and lower PAPi values indepen-
dently predicted AKI severity (adjusted OR per doubling of RAP 1.16[1.02–1.32], 
p=0.029; of PAPi 0.85[0.75–0.96], p=0.008). Based on IDI, NRI, and delta AUC, 
inclusion of these parameters improved the models’ predictive accuracy. 
Conclusions
Preoperative PAPi and RAP strongly predict the development of AKI early after 
HTx and can be used as early AKI predictors. 
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INTRODUCTION 
Heart transplantation (HTx) remains the gold standard therapy for patients with 
end-stage heart failure (HF) improving both their survival and quality of life.1 Re-
cent advances in immunosuppressive therapy and treatment protocols have signifi-
cantly improved the long-term outcome in HTx recipients despite the propensity 
for accepting older donors.2 However, the short-term outcome during the early 
postoperative phase has remained complex, affecting both morbidity and mortal-
ity.2,3
Acute kidney injury (AKI) occurs frequently after HTx ranging from 22 to 76% 
and carries unfavorable prognosis.4-7 In addition to anesthesia- and surgery-relat-
ed factors that can precipitate AKI, postoperatively used nephrotoxic drugs (e.g., 
CNI) and hemodynamic instability may also lead to AKI.4
It is known that the preexisting pulmonary hypertension increases the right 
ventricular afterload that can lead to the right ventricular failure (RVF).8 Im-
portantly, RVF can critically diminish renal function by increasing renal venous 
pressure causing congestive AKI.9,10 Consequently, the right heart hemodynamic 
(RHH) parameters have been routinely assessed in all HTx candidates.11 However, 
it is unclear how these RHH parameters relate to RVF and, more importantly to 
AKI early after HTx. Finally, the question remains whether and to what extent 
is the relationship between preoperative RHH parameters and the occurrence of 
postoperative AKI explained by the occurrence of RVF along that pathway. 
Recently, new composite hemodynamic parameters such as the pulmonary 
artery pulsatility index (PAPi), the right atrial pressure-to-pulmonary capillary 
wedge pressure ratio (RAP/PCWP), and diastolic pulmonary gradient (DPG) are 
considered to be the predictors of RVF.12-15 However, their relationships with post-
operative AKI early after HTx remain unknown. 
The aim of this study was to determine the predictive properties of the routine 
and the novel RHH parameters measured at the time of transplantation listing in 
relation to AKI early after HTx. Preliminary results have been previously reported.16
METHODS
Study population
Data of all consecutive HTx in the Erasmus Medical Center, Rotterdam, have been 
collected prospectively since the first transplantation in June 1984.2,4 We included all 
adult (≥18 years) patients transplanted between 1984 and December 2016. Patients 
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were excluded if age <18 years at the time of transplantation, were on renal replacement 
therapy (RRT) before transplantation, died within 48 hours or were re-transplanted 
within 7 days after transplantation (Figure 1). No patients underwent simultaneous 
heart-kidney transplantation. Patient data were obtained from the hospital database, 
electronic records and by chart review. 
Immunosuppressive protocol
From 1984 to 1999, the immunosuppressive therapy consisted of calcineurin in-
hibitor (CNI) cyclosporine A and tacrolimus thereafter. In patients who did not 
receive induction therapy, CNI was initiated peri-operatively or immediately after 
HTx. The induction therapy was used to delay the starting of CNI, especially in pa-
tients with already impaired kidneys and/or postoperative hemodynamic instabil-
ity, to postpone the CNI nephrotoxicity.4 The induction therapy consisted of anti-
CD3 (1987-1994), anti-IL2 (1987-1994), horse polyclonal anti-thymocyte globulin 
(1987-2008), and rabbit anti-thymocyte globulin (2008 and thereafter).
Preoperative right heart catheterization parameters
All HTx candidates underwent right heart catheterization during the screening for 
transplantation listing. If a patient’s clinical status deteriorated with suspicion of 
pulmonary hypertension while on the waiting list, an additional catheterization was 
performed where the most recent data prior to HTx were used for our analysis. Pro-
cedural data were extracted from the catheterization reports and included the fol-
lowing parameters: RAP, PCWP, pulmonary artery (PA) systolic, diastolic and mean 
pressures, systemic arterial systolic, diastolic and mean pressures, cardiac output, 
pulmonary vascular resistance, and systemic vascular resistance, PAPi, transpulmo-
nary gradient (TPG), and DPG (Figure 2).13,15
Renal function assessment
Serum creatinine was measured as part of routine clinical care at baseline, daily from 
postoperative day 0 until day 7, and at 1, 3, 6, 9 and 12 months. Baseline creatinine 
was defined as the most recent outpatient value up to 6 months before transplan-
tation. If unavailable, creatinine values at hospital admission were accepted as the 
baseline. Estimated glomerular filtration rate (eGFR) was assessed by the CKD-EPI 
equation17, and categorization was performed by National Kidney Foundation–Kid-
ney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines.18
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Follow-up and study endpoints
The primary endpoint was AKI severity as defined by Kidney Disease Improving 
Global Outcome (KDIGO) criteria during the first month after HTx. AKI stage 1 was 
defined as serum creatinine increased by ≥0.3 mg/dl (≥26.5 µmol/l) within 48 hours 
or by 1.5–1.9 times baseline; AKI stage 2 as serum creatinine increased 2.0–2.9 times 
from baseline; and AKI stage-3 as serum creatinine increased 3.0 times from baseline 
or by ≥4.0 mg/dl (≥353.6 µmol/l) or starting RRT.19 The time interval between HTx 
and the RRT was recorded within the first month. RRT requirement at 1-year was 
evaluated in all survivors. 
The secondary endpoints were postoperative RVF and 1-year survival. RVF was 
defined as need of postoperative RVAD or as reported in the medical reports by the 
attending physicians. Post-discharge survival status was obtained from our hospital’s 
electronic patient file and was completed for all patients. 
Statistical analysis
For reasons of uniformity all continuous variables are presented as median (inter-
quartile range, IQR), and  categorical variables are presented as numbers and per-
centages. The distributions of continuous variables were tested for normality by the 
Kolmogorov-Smirnov test, and if skewed were  2log-transformed. For continuous 
variables, the linear trend across AKI stages was performed by analysis of variance 
(ANOVA) or the Kruskal-Wallis test, when appropriate; categorical variables were 
tested by the χ2-trend test.
Ordinal logistic regression analysis was performed to relate perioperative data to 
postoperative AKI severity (i.e., deterioration to any level of AKI). Covariates that were 
univariably associated with AKI severity (exploratory p<0.10) were entered into a mul-
tivariable model, applying proportional odds ordinal regression with full likelihood 
ratio method. All analyses were performed in the total cohort, and subsequently in the 
subgroup of patients with RAP≥6 mmHg (previously determined as the cut-off for the 
opening of the collapsed vein).20,21 A multiplicative interaction between dichotomized 
RAP and PAPi was also explored. 
We assessed predictive accuracy for the most severe AKI (stage 3) before and 
after adding significant hemodynamic parameters (p<0.05) into the clinical model 
using delta between the areas under the two receiver operating characteristic curves 
(ROC-AUC), integrated discrimination improvement (IDI), and net reclassification 
improvement (NRI).22,23 Clinical variables found to be univariably associated with 
AKI stage 3 (exploratory p<0.10) were entered into a multivariable model using step-
wise backward likelihood ratio method. Only clinical predictors with p<0.05 in the 
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multivariable model were used to assess the models’ predictive accuracy.
Binary logistic regression analysis was applied to assess the association between 
RRT administration within 30 days after HTx and chronic RRT dependency at first 
year, and to relate preoperative data to the onset of RVF. 
For 1-year survival, we performed the log-rank test and estimated event-time 
distributions across AKI stages and temporal RRT requirements using the Kaplan–
Meier method. Cox regression analysis was performed to assess hazard ratios with 
95% confidence intervals for 1-year survival. 
All analyses were performed with a complete dataset using SPSS software (SPSS 
20.0; IBMCorp., Armonk, NY) and R-statistical software using packages ‘pROC’, 
“Hmisc”, and “effects”.22,24,25 All tests were two-tailed, and p-values <0.05 were con-
sidered statistically significant. 
RESULTS
Incidence and temporal trends of postoperative AKI
From 1984 to 2016, 682 patients underwent HTx at the Erasmus MC, of which 
595 patients were included in this study (Figure 1). Of 595 patients, 430 (72%) 
developed AKI, including 278 (47%) stage 1, 66 (11%) stage 2, and 86 (14%) stage 
3 AKI. Of those who developed AKI stage 3, 41 (7%) required RRT which lasted 
for a median of 7 days (IQR: 5–13) and had a 3.3-times (95%CI: 1.6–6.6, p=0.001) 
higher crude risk of chronic RRT in the first year than those who did not require 
such treatment. Figure S1 displays the time distribution for the occurrence of AKI 
with the highest peaks for all three stages on the seventh day.
We found a tendency towards a higher incidence of overall AKI noticeable in recent 
years. This tendency was accompanied by a trend in a lower baseline eGFR (median 
eGFR per six 5-year intervals: 69, 67, 67, 56, 69, 56 years, p-trend <0.001), an increasing 
incidence of diabetes (0, 3, 10, 9, 13, 13%, p-trend <0.001), and older donors (24, 28, 35, 
38, 45, 46 years, p-trend <0.001). We also found a tendency towards a higher incidence 
of AKI stage 3, but only when defined as a requirement for RRT (Figure S2).
Demographic and perioperative data
Table 1 shows baseline characteristics and perioperative data stratified by AKI 
stages. Patients who had a higher AKI stage also had a higher baseline BMI (me-
dian: 22.6, 23.2, 22.9, 24.2 kg/m2, p-trend<0.001), a lower baseline eGFR (71, 
60, 67, 56 ml/min/1.73 m2, p-trend<0.001), and more frequent diabetes (4, 7, 8, 
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13%, p-trend=0.015). They also received a heart from older donors (31, 34, 37, 
39 years, p-trend<0.001) with more frequently female gender (46, 46, 58, 59%, p-
trend=0.019) and postoperatively were more frequently diagnosed with RVF (7, 5, 
12, 28%, p-trend<0.001). These patients had a longer hospital stay (20, 24, 24, 37 
days, p-trend<0.001) and were less likely to have received induction therapy (90, 
80, 71, 67%, p-trend<0.001). A trend was also seen in higher in-hospital mortality 
with higher AKI stages (2, 5, 14, 9%, p-trend=0.003). 
FIGU R E 1 Flowchart of study population according to postoperative AKI 
severity. AKI, acute kidney injury ; RRT, renal replacement therapy.
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TAB LE 1 Baseline characteristics and perioperative data according to postop-
erative AKI stages.
n (%) No AKI165 (28)
AKI Stage 1
278 (48)
AKI Stage 2
66 (11)
AKI Stage 3
86 (14)
p-value
Demographics
Age, yrs. 51 (45–56) 51 (43–57) 51 (43–57) 48 (41–55) 0.23
Male sex 127 (77) 208 (75) 49 (74) 67 (78) 0.95
BMI, kg/m2 22.6 (20.1–24.5) 23.2 (21.0–25.2) 22.9 (20.8–25.8) 24.2 (22.1–26.8) <0.001*
Renal function
eGFR, ml/min/1.73m2 71 (58–88) 60 (47–79) 67 (60–79) 56 (43–70) <0.001*
eGFR ≥90 38 (23) 37 (13) 11 (17) 2 (2) <0.001*
eGFR 60–89 79 (48) 103 (37) 40 (60) 33 (38)
eGFR <60 48 (29) 138 (50) 15 (23) 51 (60)
eGFR 45–59 31 (19) 81 (29) 11 (17) 27(32)
eGFR <45 17 (10) 57 (21) 4 (6) 24 (28)
Medical history
Prior cardiac surgery 45 (27) 89 (32) 15 (23) 25 (29) 0.90
Diabetes mellitus 7 (4) 19 (7) 5 (8) 11 (13) 0.015*
Hypertension 17 (10) 29 (10) 5 (8) 8 (9) 0.65
Donor characteristics 
Age, yrs. 31 (20–42) 34 (22–45) 37 (24–45) 39 (27–49) <0.001*
Male sex 89 (54) 149 (54) 28 (42) 35 (41) 0.019*
Cause of death 0.61
Trauma 74 (45) 117 (42) 26 (39) 36 (42)
CVA 83 (50) 149 (54) 38 (58) 4 (51)
Other 6 (4) 11 (4) 2 (3) 6 (7)
Unknown 2 (1) 1 (0) 0 (0) 0 (0)
Time of donor heart 
ischemia, minutes 165 (139–196) 171 (143–206) 170 (147–195) 176 (150–210) 0.09
Urgency status on waiting list 0.78
Elective 78 (47) 166 (60) 41 (62) 38 (44)
Urgent 58 (35) 73 (26) 14 (21) 31 (36)
Unknown 29 (18) 39 (14) 11 (17) 17 (20)
Preoperative hemodynamic parameters at the time of transplantation listing 
Days before HTx 182 (81–331) 275 (123–545) 273 (117–505) 213 (100–534) 0.15
Heart rate, beats/min 80 (68–100) 80 (70–92) 73 (61–94) 72 (67–90) 0.06
Systolic AP, mmHg 99 (90–106) 97 (90–105) 95 (84–105) 97 (87–107) 0.27
Diastolic AP, mmHg 63 (57–70) 61 (56–69) 62 (54–69) 62 (56–72) 0.91
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n (%) No AKI165 (28)
AKI Stage 1
278 (48)
AKI Stage 2
66 (11)
AKI Stage 3
86 (14)
p-value
Mean AP, mmHg 74 (68–80) 73 (67–81) 73 (64–81) 75 (66–83) 0.61
CO, L/min 3.8 (3.1–4.6) 4.0 (3.3–4.7) 3.8 (3.2–4.5) 3.8 (3.0–4.5) 0.98
PVR, dynes sec/cm5 172 (115–230) 149 (96–224) 154 (93–245) 144 (82–226) 0.44
SVR, dynes sec/cm5 1442 (1192–1764) 1286 (1086–1671) 1398 (1216–1605) 1333 (1042–1630) 0.14
RAP, mmHg 7 (5–12) 7 (4–11) 8 (5–13) 11 (5–17) 0.021*
PA systolic,  mmHg 44 (32–55) 42 (30–52) 44 (34–53) 45 (29–59) 0.93
PA diastolic,  mmHg 23 (15–30) 21 (14–29) 21 (15–30) 23 (15–29) 0.78
PA mean,  mmHg 30 (21–39) 28 (19–36) 27 (21–37) 31 (20–38) 0.84
PCWP,  mmHg 21 (14–29) 20 (13–26) 20 (14–27) 22 (13–29) 0.81
TPG,  mmHg 8.3 (5.0–11.0) 7.7 (4.3–10.7) 7.2 (4.4–10.3) 7.3 (4.3–10.3) 0.25
DPG,  mmHg 1.0 (-2.0–4.0) 1.0 (-2.0–4.0) 0.0 (-2.0–3.0) 0.0 (-2.0–4.0) 0.93
PAPi 2.83 (1.89–5.81) 3.17 (1.61–5.67) 2.54 (1.82–5.60) 2.31 (1.01–4.57) 0.012*
RAP/PCWP ratio 0.37 (0.24–0.57) 0.36 (0.23–0.52) 0.40 (0.25–0.53) 0.47 (0.29–0.74) 0.009*
Preoperative hemodynamic support
Inotropes 41 (25) 59 (21) 15 (23) 29 (34) 0.16
IABP / ECMO 16 (10) 20 (7) 5 (8) 10 (12) 0.68
LVAD 14 (8) 15 (5) 1 (1) 5 (6)
Postoperative complications
Right ventricle failure 11 (7) 14 (5) 8 (12) 24(28) <0.001*
Re-thoracotomy 12 (7) 18 (6) 9 (14) 12 (14) 0.06
Primary graft failure 3 (2) 4 (1) 4 (6) 2 (2) 0.14
Other a 7 (4) 14 (5) 1 (1) 7 (8)
Immunosuppressive  therapy
Induction therapy 148 (90) 222 (80) 47 (71) 58 (67) <0.001*
ATG use 89 (54) 151 (54) 29 (44) 46 (53) 0.58
Anti-CD3 45 (27) 41 (15) 5 (7) 5 (6) <0.001*
Anti-IL2 14 (9) 30 (11) 13 (20) 7 (8) 0.49
Postoperative delay 
CNI, daysb 3 (2–5) 3 (1–4) 2 (0–3) 2 (0–5) 0.35
Hospital stay
Days in ICU 3 (2–4) 3 (2–4) 4 (3–6) 8 (4–14) <0.001*
Days in hospital 20 (16–29) 24 (17–33) 24 (17–32) 37 (23–58) <0.001*
In-hospital mortality 4 (2) 15 (5) 9 (14) 8 (9) 0.003*
Due to uniformity, all continuous data are presented as median and inter-quartile range 
(IQR); all categorical data as number and percentage (%). CO, Cardiac Output; eGFR, 
estimated glomerular filtration rate; HTx, heart transplantation; AP, arterial pressure; PVR, 
continued
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pulmonary vascular resistance; SVR, systemic vascular resistance; RAP, right atrial pressure; 
PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; TPG, trans-pulmonary 
gradient; DPG, diastolic pulmonary gradient; PAPi, pulmonary artery pulsatility index; 
IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; ECMO, extracorporeal 
membrane oxygenator; ICU, Intensive Care Unit; ATG, anti-thymocyte globulins. 
a Other includes: perioperative bleeding, cardiac arrest, dosing of inotropes, pacemaker 
malfunction, acute rejection and instability of unknown cause. 
b Postoperative delay after heart transplantation before starting calcineurin inhibitor (CNI). 
* p-value for linear trend <0.05 is statistically significant.
Relationship of preoperative RHH parameters with 
postoperative AKI severity
Figure 2 summarizes the investigated hemodynamic parameters. Table 1 shows the 
values of RHH parameters according to the AKI stages. Patients with a higher AKI 
stage had also a higher baseline RAP (median: 7, 7, 8, 11 mmHg, p-trend=0.021) 
and RAP/PCWP ratio (0.37, 0.36, 0.40, 0.47, p-trend=0.009) and lower PAPi values 
(2.83, 3.17, 2.54, 2.31, p-trend=0.012). 
Table 2 and Figure S3 display the associations of the significant RHH parame-
ters with the risk of postoperative AKI severity. In the total cohort, higher RAP and 
lower PAPi values were associated with AKI severity independently of the patient’s 
BMI, baseline eGFR, diabetes, donor’s age and sex, ischemia time of the donor’s 
heart, time from right heart catheterization to HTx, postoperative RVF, and the 
postoperative use of induction therapy (adjusted OR[95%CI] per doubling: RAP 
1.16[1.02–1.32], p=0.029; PAPi 0.85[0.75–0.96], p=0.008). Moreover, we found a 
significant multiplicative interaction between RAP≥6 mmHg and PAPi values (p-
interaction=0.034), indicating even more pronounced association between lower 
PAPi values and higher probability of AKI severity in patients with elevated RAP 
(adjusted OR per doubling of PAPi: 0.70[0.56–0.87], p=0.002) (Table 2, Figure S4). 
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FIGU R E 2 Preoperative hemodynamic parameters and their relation to 
postoperative right ventricular failure and acute kidney injury early (≤30 days) 
after heart transplantation. An illustration of the assessed hemodynamic parameters 
of the heart including right atrial pressure (RAP); pulmonary artery (PA) systolic, diastolic, 
and mean pressures (PAmean pressure = [PAsystolic + 2*PAdiastolic] / 3); pulmonary artery pulsatility 
index (PAPi) (PAPi = [PAsystolic pressure – PAdiastolic pressure] / RAP; pulmonary capillary wedge pressure 
(PCWP); RAP/PCWP ratio; transpulmonary gradient (TPG) (TPG = PAmean pressure – PCWP); diastolic 
pulmonary gradient (DPG) (DPG = PAdiastolic pressure – PCWP); cardiac output (CO); pulmonary 
vascular resistance (PVR) (PVR = 80 * [PAmean pressure – PCWP] / CO); systolic, diastolic, and mean 
arterial pressure (MAP) (MAP = [APsystolic + 2 * APdiastolic] / 3); systemic vascular resistance (SVR) 
(SVR = 80 * [MAP – RAP] / CO). * indicates significant predictor of acute kidney injury (AKI); # 
indicates significant predictor of right ventricular failure (RVF); RA indicates right atrium; RV 
indicates right ventricle; PA indicates pulmonary artery; LA indicates left atrium; LV indicates 
left ventricle; Ao indicates aorta.
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TAB LE 2 Associations between preoperative hemodynamic parameters and 
postoperative AKI severity early after heart transplantation. 
Univariable model Multivariable model f
OR (95% CI) p-value OR (95% CI) p-value
Total cohort a
PAPi c 0.88 (0.79–0.99) 0.043* 0.85 (0.75–0.96) 0.008*
RAP c 1.12 (0.99–1.28) 0.07 1.16 (1.02–1.32) 0.029*
RAP/PCWP c 1.19 (1.01–1.39) 0.033* 1.15 (0.98–1.35) 0.10
Heart rate d 0.90 (0.81–1.00) 0.06 0.98 (0.87–1.11) 0.75
SVR e 0.96 (0.91–1.00) 0.06 0.96 (0.92–1.01) 0.13
Subgroup RAP ≥6 mmHg b
PAPi c 0.74 (0.60–0.92) 0.006* 0.70 (0.56–0.87) 0.002*
RAP c 1.62 (1.17–2.25) 0.004* 1.78 (1.27–2.50) 0.001*
RAP/PCWP c 1.44 (1.06–1.96) 0.019* 1.31 (0.95–1.08) 0.10
Heart rate d 0.88 (0.77–1.01) 0.08 0.95 (0.82–1.11) 0.52
 SVR e 0.98 (0.92–1.03) 0.42 0.99 (0.93–1.05) 0.78
OR (95% CI) indicates proportional odds ratio with 95% confidence interval; for other 
abbreviations please see table 1. *p-value <0.05 is statistically significant.
a total n=595, no AKI = 165, AKI stage 1 = 278, AKI stage 2 = 66, AKI stage 3 = 86. 
b total n=340, no AKI = 94, AKI stage 1 = 147, AKI stage 2 = 42, AKI stage 3 = 57. 
c OR are given per doubling of a preoperative hemodynamic parameter. OR are interpreted 
as the odds of having a more severe renal injury for any level of AKI (stage 3, stage 2, stage 
1, and no AKI). For example, if RAP increases from 7 to 14 mmHg (i.e., doubled) the odds of 
having AKI stage 3 versus combined AKI stages ≤2 and no AKI are 1.12 times greater. Odds of 
having AKI stages ≥2 versus combined AKI stage 1 and no AKI are 1.12 times greater. Finally, 
the odds of having AKI of any stage versus no AKI are 1.12 times greater. 
d OR per 10 units increase in preoperative heart rate (interpretation is the same as under c). 
e OR per 100 dynes sec/cm5 increase in preoperative SVR (interpretation is the same as under c). 
f preoperative hemodynamic parameters were adjusted for all variables with p<0.10 in 
univariable analysis and included patient’s BMI, baseline eGFR, diabetes, donor’s age and 
sex, ischemia time of donor’s heart, time from catheterization to HTx, postoperative RVF, 
and the postoperative use of induction therapy. Associations between these variables and 
postoperative AKI stages are presented in Table S1. 
For predicting AKI stage 3, adding each of the hemodynamic parameters, PAPi 
and RAP, significantly improved the models’ predictive accuracy compared to the 
best clinical model (PAPi: IDI=0.03, p=0.013 and total continuous NRI=0.320, 
p=0.007 with 25% reclassification for events and 7% reclassification for non-
events; RAP: IDI=0.02, p=0.040 and NRI=0.278, p=0.018 with 25% reclassification 
for events and 3% reclassification for non-events). In Figure 3, ROC-AUC analysis 
also showed significant discriminatory improvement (clinical model: AUC 76.1% 
[95%CI:70.4–81.3], clinical model + PAPi: 79.0% [73.8–83.8], p-delta=0.044; clini-
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cal model + RAP: 78.8% [73.6–83.5], p-delta=0.049; PAPi alone: 60.7% [53.8–67.1]; 
RAP alone: 62.2% [54.6–69.0]). Based on Youden’s index, the best cut-off point for 
predicting AKI stage 3 was PAPi <1.05 and RAP >11 mmHg. Finally, the associa-
tions of clinical data with postoperative AKI severity are shown in Table S1. 
FIGU R E 3 The ROC-AUC analysis for the prediction of AKI stage 3. AUC indicates 
area under the ROC curve with p-value for the difference between different models. 
Only predictors that remained significant (p<0.05) in the final model were used to assess 
discriminative power, and those were patient body mass index, baseline eGFR, postoperative 
right ventricular failure, and the postoperative use of induction therapy. A. The ROC curves 
of clinical model (green) and clinical model + PAPi (blue) for the prediction of AKI stage 3 
with AUCs and corresponding 95% confidence intervals; B. The ROC curves of clinical model 
(green) and clinical model + RAP (red) for the prediction of AKI stage 3. 
Predictors of RVF and its relation to AKI 
Of 595 patients, 57 (10%) experienced RVF early after HTx. Table S2 shows the pre-
dictors of early RVF among which the most significant clinical predictors were the 
patients’ impaired baseline eGFR and older donors; higher pulmonary artery systolic 
pressure was the only preoperative RHH parameter that predicted RVF. Further-
more, the occurrence of RVF was strongly associated with AKI severity (Table S1). 
Relationship of AKI with 1-year mortality
In total, 51 deaths occurred during the first year after HTx with a cumulative mor-
tality of 5%, 7%, 15%, and 14% for those without AKI and with AKI stages 1, 2, and 
3, respectively (log-rank test, p-trend=0.021; Figure S5A). The cumulative mortal-
ity was also higher in patients who received RRT during the first month than in 
those who had not (22 vs. 8%; log-rank test, p=0.001, Figure S5B). 
BA
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DISCUSSION
To the best of our knowledge, this study is the first to assess the predictive properties 
of different preoperative hemodynamic parameters in relation to the occurrence of 
postoperative AKI severity within 30 days after HTx. We found that lower PAPi and 
higher RAP values predict AKI severity independently of the recipient BMI, base-
line eGFR, diabetes, donor age and sex, ischemia time of the donor’s heart, time 
from right heart catheterization to HTx, postoperative RVF, and the use of induction 
therapy. These hemodynamic parameters routinely collected at the time of transplan-
tation listing could be used to predict AKI severity early after HTx.
Although renal injury after HTx has traditionally been attributed to the impaired 
arterial perfusion and CNI nephrotoxicity4, our results illustrate strong evidence of 
the independent relationship between preoperative right-sided hemodynamics and 
AKI severity after HTx. One of the potential explanations for this relationship may 
be the longstanding venous congestion that chronically compromises the kidneys. 
Subsequently, the kidneys may become more vulnerable to the development of AKI, 
especially in cases of postoperative hemodynamic instability with hypotensive epi-
sodes, or in the settings of de-novo RVF during the adaptation period of the new 
heart. However, we found that a de-novo RVF significantly contributed to the de-
velopment of AKI but could not entirely explain the relationships of preoperative 
RAP and PAPi with the postoperative renal injury. Several pathophysiological mech-
anisms may be responsible for this peculiar renal vulnerability, including attenuated 
vascular reflexes, elevated renal interstitial and intra-tubular pressure, activation of 
the renin-angiotensin-aldosterone system, and chronic venous pressure-induced tu-
bule-glomerular feedback dysfunction.26,27 Moreover, we found a significant interac-
tion between RAP and PAPi, indicating that probabilities of AKI (especially stages 2 
and 3) are markedly increasing with lower PAPi values, but mostly in patients with 
elevated RAP (≥6 mmHg). These findings are supported by Damman et al., who 
found that eGFR starts to significantly decline when RAP increases above 6 mmHg.28 
Altogether, it appears that preoperatively compromised right-sided venous pressures 
deserve clinical attention in the context of postoperative AKI and may be even more 
important for kidney functioning after HTx than low systemic pressures. 
Acute or chronic cardiac dysfunction has negative effects on kidney function and 
vice versa. This complex cross-talk was recently described as cardio-renal syndrome 
(CRS).29 Chronic HF leading to chronic renal congestion in the pre-HTx period is 
classified as CRS Type-2. On the other hand, early AKI post-HTx could be consid-
ered as CRS Type-1. Recognition of post-HTx CRS may provide possibilities of pre-
vention and treatment strategies in the settings of HTx. Importantly, early prediction 
of postoperative AKI based on preoperative RAP and PAPi could help to timely and 
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more proactively intervene in the patients who are at high risk, in terms of giving 
more attention to the perioperative volume overload, postponing the introduction of 
nephrotoxic CNI, prolonging the support of the right ventricle with inotropes, NO 
ventilation, and early introduction of pulmonary vasodilators (e.g., sildenafil).11,27,30-33 
Furthermore, these patients could possibly benefit from functional kidney stress tests 
to assess the renal functional reserve and identify patients who will progress to AKI 
post-HTx.34,35 In addition to decreasing values, PAPi can also go in the opposite di-
rection. Hence, the recovery of PAPi values may indicate improvement of right-sided 
pressure, which may be used to optimize perioperative hemodynamic support to 
preserve the kidneys from injury. However, prospective studies, preferably interven-
tional in nature, are needed to elucidate this promising concept. 
The overall AKI incidence was 72%, which fits at the high-end of the reported 
incidence range of 22 to 76% in HTx recipients.4-7 This widespread distribution prob-
ably results from the large heterogeneity between studies and deserves closer atten-
tion. Previously, most studies reported the older Risk Injury Failure Loss End-stage 
Renal Disease (RIFLE) criteria or the Acute Kidney Injury Network (AKIN) crite-
ria.6,36 However, we used the newer KDIGO criteria to define AKI stages.37 Second, 
time-intervals for the occurrence of AKI were different from the present study.4-7,38,39 
We targeted one month as the clinically relevant time-interval, whereas previous 
studies mainly focused on the first week.4,6,7,38 Our results show that, although all AKI 
stages peaked on day 7, the risk of AKI remains through the first month. This late 
postoperative peak of AKI could be attributed to the delay in starting of CNI. For this 
purpose, we use induction therapy especially in patients with impaired kidneys and/
or hemodynamic instability early after HTx to postpone CNI nephrotoxicity. In our 
data, the use of induction therapy was protective for the occurrence of AKI. Another 
important and more worrisome observation is that AKI incidence increased in re-
cent years. This is probably explained by an increasing proportion of HTx recipients 
being listed with more comorbidities such as chronic renal failure and diabetes, older 
heart donors, and probable changes in clinical management with more pro-active 
treatments protocols.2,40
Study limitations
First, this was a single-center study, and therefore, the clinical management and treat-
ment modalities may differ from other transplant centers. However, patient selection 
for transplantation listing and cardiac procedures were performed according to gen-
erally accepted international criteria.11 Second, its retrospective nature precluded the 
inclusion and evaluation of additional parameters such as echocardiography. Fur-
thermore, we were not able to analyze the postoperative RHH parameters due to un-
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availability and incompleteness of the historical data. Therefore, postoperative RVF 
could only been retrieved as reported or the need for postoperative RVAD. Further 
studies are needed to analyze the incremental value of post-HTx RHH parameters. 
Third, we did not include urine output in the definition of AKI because these pa-
tients were on intensive diuretic therapy, which would lead to misinterpretation of 
the urine output values. Altogether, this study is currently the largest HTx cohort in 
which the associations between preoperative hemodynamics and postoperative AKI 
were investigated. 
CONCLUSIONS
Preoperative PAPi and RAP strongly predict the postoperative AKI early after heart 
transplantation and can be used as early AKI predictors.
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SUPPLEMETARY INFORMATION
TAB LE S1 Associations of clinical data with postoperative AKI severity early 
after heart transplantation.
Univariable model a Multivariable model b
Clinical data OR (95% CI) p-value OR (95% CI) p-value
Preoperative
BMI per 1 kg/m2 increase 1.10 (1.05–1.15) <0.001* 1.06 (1.01–1.12) 0.019*
Diabetes 2.00 (1.12–3.57) 0.019* 1.38 (0.73–2.60) 0.32
eGFR per 10ml/min/1.73m2 decrease 1.18 (1.10–1.26) <0.001* 1.11 (1.02–1.19) 0.011*
Donor’s age per 5 years increase 1.11 (1.05–1.17) <0.001* 1.06 (1.00–1.13) 0.07
Donor’s female gender 1.40 (1.03–1.88) 0.029* 1.19 (0.86-1.66) 0.29
Ischemia time per 30 minutes longer 1.10 (0.99–1.21) 0.07 1.07 (0.96–1.19) 0.25
Time from RHC to HTx per 100 days longer 1.05 (1.01–1.10) 0.022* 1.06 (1.01–1.11) 0.027*
Postoperative
RVF 3.95 (2.37–6.57) <0.001* 3.82 (2.22–6.57) <0.001*
Induction therapy 0.42 (0.29–0.61) <0.001* 0.29 (0.19–0.44) <0.001*
BMI indicates body mass index; eGFR indicates estimated glomerular filtration rate; 
RVF indicates right ventricular failure; RHC indicates right heart catheterization; 
HTx indicates heart transplantation. OR (95% CI) indicates proportional odds ratio 
with 95% confidence interval, and are interpreted as the odds of having a more 
severe renal injury for any level of AKI. a Covariates that were found to be univariably 
associated with AKI severity (p<0.10) were entered into a multivariable ordinal 
regression model applying the full likelihood ratio method. b adjusted for each other. 
* p-value <0.05 is statistically significant.
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TAB LE S2 Associations of preoperative clinical and hemodynamic data with 
postoperative RVF early after heart transplantation.
Univariable model a Multivariable model b,c
OR (95% CI) p-value OR (95% CI) p-value
Preoperative clinical data
BMI per 1 kg/m2 increase 1.07 (0.99–1.16) 0.10
Diabetes 2.42 (1.06–5.52) 0.036*
eGFR per 10ml/min/1.73m2 decrease 1.22 (1.06–1.41) 0.005* 1.19 (1.02–1.36) 0.031*
Donor’s age per 5 years increase 1.21 (1.10–1.34) <0.001* 1.21 (1.08–1.35) 0.001*
Donor’s female gender 2.40 (1.34–4.31) 0.003*
Preoperative hemodynamic data
PA systolic per 5 mmHg increase 1.09 (0.99–1.17) 0.07 1.14 (1.03–1.25) 0.008*
TPG per 5 mmHg increase 1.28 (1.00–1.63) 0.05
IABP or ECMO use 2.21 (1.02–4.82) 0.045*
OR indicates odds ratio for having a postoperative RVF; 95% CI indicates 95% confidence 
interval for the corresponding OR; RVF indicates right ventricular failure; BMI indicates 
body mass index; eGFR indicates estimated glomerular filtration rate; PA systolic indicates 
pulmonary artery systolic pressure; TPG indicates transpulmonary gradient. aAll preoperative 
data from Table 1 were related to the early RVF; only variables with p<0.10 in univariate 
analysis were reported in this table. bVariables that were found to be univariably associated 
with early RVF (p<0.10) were entered into a multivariable binary logistic regression model 
applying the stepwise backward likelihood ratio method with a value of p=0.05 as a removal 
criterion for the final model. cAUC for the final multivariable model was 67.8% (95% CI: 59.8–
74.7), p<0.001. *p-value <0.05 is statistically significant.
FIGU R E S1 Time distribution of AKI occurance according to the severity 
stage during the first postopearative month. The X-axis depicts time in days; the 
Y-axis depicts proportion of patients per AKI stage. AKI, acute kidney injury; HTx, heart 
transplantation. 
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FIGU R E S2 Temporal trend in the incidence of postoperative AKI according to 
severity stage during the period from 1984 until 2016. The X-axis depicts 5-year 
intervals. The Y-axis depicts proportion of patients per 5-year category according to AKI 
stage. 
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FIGU R E S3 The relationships between preoperative RAP and PAPi values 
and the probabilities of different postoperative AKI stages early after heart 
transplantation. The X-axis on the left panel depicts the right atrial pressure (RAP) values 
on the 2log scale, whereas the X-axis on the right panel depicts pulmonary artery pulsatility 
index (PAPi) values on the 2log scale. Probabilities of each acute kidney injury (AKI) stage 
are presented in the Y-axis in descending order from AKI stage 3 to no AKI. The figure shows 
that probabilities of AKI stages 2 and 3 are increasing with higher RAP and lower PAPi values, 
while the corresponding probabilities for no AKI are decreasing.
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FIGU R E S4 Graphical display of the interaction effect between preoperative 
RAP and PAPi on the probabilities of different postoperative AKI stages early 
after heart transplantation. The X-axis on the left panel depicts the pulmonary artery 
pulsatility index (PAPi) values on the 2log scale in patients with normal right atrial pressure 
(RAP <6 mmHg), whereas the X-axis on the right panel depicts PAPi values in patients 
with elevated RAP (≥6 mmHg). Probabilities of each acute kidney injury (AKI) stage are 
presented in the Y-axis in descending order from AKI stage 3 to no AKI. The figure shows that 
probabilities of AKI stages 2 and 3 are markedly increasing with lower PAPi values in patients 
with elevated RAP, which is not the case in patients who had RAP within the reference range 
(p-interaction=0.034).
The following table displays the number of patients per category:
Number of patients Right atrial pressure
Kidneys status < 6 mmHg ≥ 6 mmHg Total
AKI stage 3 29 57 86
AKI stage 2 24 42 66
AKI stage 1 131 147 278
no AKI 71 94 165
   Total  255 340 595
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FIGU R E S5 Kaplan-Meier curves for time to death during the first year after 
heart transplantation. A. Survival distribution analysis stratified by AKI stage with 
crude hazard ratios (95% confidence intervals) relative to no AKI. B. Analysis stratified by 
requirements for RRT during the first month after heart transplantation.
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ABSTRACT
Background
We investigated the prognostic value of renal dysfunction and anemia separately 
and in combination, on mortality in AHF patients. Furthermore, we examined 
whether the improvement in prognosis was comparable between patients with and 
without renal dysfunction.
Methods
This prospective registry includes 1783 patients admitted to the (Intensive) Coro-
nary Care Unit for acute HF in the period of 1985-2008.
Results
In patients without renal dysfunction, anemia was associated with increased 30-
day mortality (HR 2.91 [95% CI: 1.69–5.00]), but not with 10-year outcome (HR 
1.13 [95% CI: 0.93-1.37]). On the contrary, anemia was found to influence progno-
sis in patients with renal dysfunction, both at 30 days (HR 1.93 [95% CI 1.33-2.80]) 
and at 10 years (HR 1.27 [95% CI 1.10-1.47]). Over time, the 10-year survival rate 
improved in patients with preserved renal function (HR 0.73 [95% CI 0.55-0.97]), 
but not in patients with renal dysfunction.
Conclusions
The long-term prognosis of acute HF patients with a preserved renal function was 
found to have improved significantly. However, the prognosis of patients with renal 
dysfunction did not change. Anemia was a strong predictor of short-term mortality 
in all patients. In patients with renal dysfunction, anemia was also associated with 
impaired long-term prognosis.
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INTRODUCTION
Acute heart failure (HF) is commonly accompanied by various non-cardiovascular 
comorbidities. Renal dysfunction is among one of the most common although its 
exact prevalence has varied between studies.1,2 Renal dysfunction in acute HF is 
associated with various adverse outcomes: longer hospital stay, higher re-hospital-
ization rate, and higher mortality.1,2 Of note, the follow-up period in most of these 
studies is restricted to only 1 year after the initial hospitalization.
In the last decades, an improvement in long-term outcome has been observed 
among patients with acute HF in several cohorts.3-5 New therapeutic options and an 
increased understanding of the pathophysiology of HF are most likely responsible for 
this trend. Importantly, renal dysfunction is a (relative) contraindication for some of 
the new therapeutic modalities.6 As of yet, it has not been established whether the 
improvement in prognosis over time of patients with acute HF is modified by the 
presence of renal dysfunction.
Anemia is another important and common comorbidity in patients with acute 
HF, with a prevalence up to almost 60%.7-12 There is conflicting data regarding the 
prognostic impact of anemia in patients with acute HF.10-13 Moreover, the combina-
tion of HF, renal dysfunction and anemia carries an incremental negative prognostic 
impact in patients with chronic HF.14 However, the additive prognostic value of ane-
mia in patients with acute HF with and without renal dysfunction remains scarce.
 Therefore, the aims of the present study were (1) to examine the impact of renal 
function on short- and long-term mortality of patients with acute HF, (2) to deter-
mine whether the improvement in prognosis of patients with acute HF and renal 
impairment was comparable to that of patients with normal renal function, and (3) 
to study the impact of anemia, alone or in combination with renal dysfunction, on 
mortality of patients with acute HF.
MATERIALS AND METHODS
Study population
This prospective registry was carried out among patients who were admitted with 
acute HF at the Intensive Coronary Care Unit (ICCU) in Erasmus MC, Rotterdam, 
the Netherlands during the period from 1985 until 2008. The study design and inclu-
sion have been described previously.5 Briefly, consecutive patients aged 18 years and 
older were included when they were diagnosed with acute HF or cardiogenic shock at 
admission. Both patients with de novo HF and patients with worsening symptoms of 
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chronic HF were included. Patients could only contribute once to the database, and 
if patients were admitted more than once with acute HF during the inclusion period, 
only the first admission was included for analyses.This was a prospective cohort reg-
istry. During the enrolment of the patients, approval from the local research ethics 
committee to conduct this study was not required. The study was conducted accord-
ing to the Declaration of Helsinki.15
Study Endpoints
The 30-day mortality, 1-year mortality and 10-year mortality were the main outcome 
measures. Heart transplantation and left ventricular assist device implantation were 
considered as equivalent to mortality. Survival status was assessed using the Municipal 
Civil Registries in January 2017 and was available for 98% of the included patients.
Variables and definitions
Baseline variables were derived from patient records and discharge letters. We collected 
the following variables: age, gender, Body Mass Index (BMI), cardiac history, etiology 
of HF, left ventricular ejection fraction (LVEF) and treatment at the ICCU. Further-
more, the results of the following laboratory tests were collected: sodium (mmol/L), 
potassium (mmol/L), creatinine (µmol/L), urea (mmol/L) and hemoglobin (mmol/L).
Diabetes mellitus was considered to be present when patients received antidiabetic 
therapy. The LVEF was classified into the following qualitative categories: good, moder-
ate and poor. If quantitative outcome for the LVEF was used, we applied the following 
cut-offs: >45%, 30-44% and <30% for good, moderate and poor LVEF, respectively.5 
The etiology of HF was categorized into ischemic cause versus non-ischemic cause of 
HF. For all laboratory tests, the first measured value during hospitalization was taken 
into account. The estimated glomerular filtration rate (eGFR) was estimated by us-
ing the Modification of Diet in Renal Disease (MDRD) equation for serum creatinine 
(µmol/L):  eGFR = 30849 × serum creatinine −1.154 × age −0.203 × 0.742 (if female) 
[eGFR in mL/min/1.73 m2].16 In line with the most recent HF guideline of the European 
Society of Cardiology,6 a renal function was categorized as follows: preserved renal 
function: eGFR ≥60 mL/min/1.73m2; moderately impaired renal function eGFR 30-59 
mL/min/1.73m2; severely impaired renal function eGFR <30 mL/min/1.73m2. We used 
the definition of the World Health Organization to define anemia: hemoglobin <7.5 
mmol/L in women and <8.2 mmol/L in men. Hyponatremia was defined as a serum 
sodium level ≤135 mmol/L. For the definition of hypo- and hyperkalemia the following 
cut-off values were applied: serum potassium <3.5 mmol/L and >5.0 mmol/L, respec-
tively.
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Statistical analysis
Categorical variables are presented as frequencies and percentages. The χ2 test and 
the Fisher-Freeman-Halton exact test were used to compare categorical variables. 
Normally distributed, continuous data are presented as mean values with standard 
deviation and were compared using the one-way ANOVA. Continuous data that were 
not normally distributed are presented as median and interquartile range (IQR). The 
Mann-Whitney U test or the Kruskal-Wallis H test was used to compare these data.
Since data for LVEF and etiology were incomplete for, respectively, 28% and 
12% of the patients, multiple imputations were performed by using baseline char-
acteristics as predictors. Pooled means are given for LVEF and etiology.
The Kaplan-Meier method was used for presenting the cumulative mortality 
curves and they were compared using the log-rank test. Secondary analyses were 
carried out among the 30-day survivors. Logistic regression for 30-day mortality 
and the Cox proportional hazard method for long-term mortality were applied in 
order to examine the independent association between renal function and mor-
tality, as well as between anemia and mortality. Adjustments were made for age, 
gender, history of HF, diabetes, hypertension, etiology of HF, atrial fibrillation at 
admission, LVEF, renal function and anemia.
All tests were two-tailed and p-values <0.05 were considered statistically sig-
nificant. Results of logistic regression and the Cox proportional hazard model were 
reported as odds ratios (ORs) and hazard ratios (HRs), respectively, with their cor-
responding 95% confidence interval (95% CI). All statistical analyses were carried 
out using SPSS software (SPSS 21.0, IBM Corp., Armonk, NY, USA).
RESULTS
Baseline characteristics
In total, 1810 patients were admitted with acute HF in the period 1985-2008. Of 
these, 1783 (99%) patients had at least one creatinine measurement and they con-
stitute the present study population. Over half of the patients were found to have 
renal dysfunction, which was severely impaired in 18% of patients. The proportion of 
patients with severe renal impairment remained stable over time, while the number 
of patients with preserved renal function increased and moderately impaired renal 
function became less prevalent (p<0.001; Figure 1).
Compared to patients with renal dysfunction, patients with preserved renal func-
tion were on average 6 years younger (Table 1). In addition, they less often had prior 
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myocardial infarction and coronary revascularization. With decreasing renal func-
tion, the prevalence of prior HF, diabetes and hypertension increased. Hyponatremia 
was also more common in patients with renal dysfunction, as was anemia.
Regarding therapy, patients with renal impairment were more frequently treated 
with intubation and mechanical ventilation, mechanical circulatory support and ino-
tropic agents (Table 1). Moreover, the degree of renal impairment was associated 
with lower in-hospital usage of beta-blockers, ACE-inhibitors and diuretics.
FIGU R E 1 Distribution of the study population according to the renal function 
and the admission period. eGFR, estimated glomerular filtration rate in mL/min/1.73m2
TAB LE 1 Baseline characteristics and therapy according to renal function.
eGFR ≥60 eGFR 30-59 eGFR <30 p-value*
No. of patients 688 (39%) 778 (44%) 317 (18%)
Age, years (mean±SD) 59.7 ± 16.3 66.1 ± 13.2 65.9 ± 12.9 <0.001
Male gender 458 (67%) 475 (61%) 201 (63%) 0.09
BMI, kg/m2  (mean±SD) 25.4 ± 5.2 24.9 ± 4.8 25.0 ± 4.7 0.57
Medical history
Myocardial infarction 237 (34%) 347 (45%) 120 (38%) <0.001
Coronary revascularization† 124 (18%) 187 (24%) 75 (24%) 0.01
Heart surgery (not CABG) 111 (16%) 87 (11%) 36 (11%) 0.01
Heart transplantation 2 (0.3%) 1 (0.1%) 6 (2%) 0.002
Waiting for heart transplantation 16 (2.3%) 11 (1.4%) 8 (2.5%) 0.33
Heart failure 300 (44%) 390 (50%) 188 (59%) <0.001
Rhythm- or conduction disorder 157 (23%) 210 (27%) 73 (23%) 0.14
Diabetes 132 (19%) 168 (22%) 81 (26%) 0.07
Hypertension 194 (28%) 257 (33%) 133 (42%) <0.001
Heart failure
Etiology of heart failure <0.05
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eGFR ≥60 eGFR 30-59 eGFR <30 p-value*
Ischemic origin 302 (44%) 392 (50%) 140 (44%)
Non-ischemic origin 386 (56%) 386 (50%) 177 (56%)
Atrial fibrillation at admission 159 (23%) 178 (23%) 49 (16%) 0.01
Left ventricular ejection fraction <0.05
Good 199 (29%) 225 (29%) 91 (29%)
Moderate 187 (27%) 156 (20%) 76 (24%)
Poor 302 (44%) 396 (51%) 149 (47%)
Laboratory values
Sodium (mean±SD) 137 ± 5 137 ± 6 135 ± 6 <0.001
Potassium (mean±SD) 4.0 ± 0.6 4.2 ± 0.7 4.6 ± 0.9 <0.001
Urea (median, IQR) 7.2 (5.7-9.3) 10.6 (8.2-14.4) 23.5 (17.5-30.8) <0.001
eGFR (median, IQR) 75 (66-89) 47 (39-53) 20 (14-25) <0.001
Creatinine (median, IQR) 80 (71-96) 123 (109-142) 258 (215-346) <0.001
Hemoglobin 8.3 ± 1.3 8.1 ± 1.4 6.9 ± 1.5 <0.001
Hyponatremia 221 (32%) 224 (29%) 151 (48%) <0.001
Hypokalemia 106 (15%) 98 (13%) 23 (7%) <0.001
Hyperkalemia 38 (6%) 81 (10%) 85 (27%) <0.001
Anemia 262 (38%) 334 (43%) 244 (77%) <0.001
Therapy during ICCU hospitalization
Intubation 69 (10%) 117 (15%) 57 (18%) 0.001
Resuscitation 19 (3%) 36 (5%) 15 (5%) 0.13
Mechanical circulatory support‡ 34 (5%) 41 (5%) 29 (9%) 0.02
Inotropics 196 (29%) 253 (33%) 123 (39%) 0.01
Beta-blocker 146 (21%) 111 (14%) 47 (15%) 0.001
Antiarrhythmics 115 (17%) 154 (20%) 45 (14%) 0.06
Calcium antagonist 77 (11%) 102 (13%) 72 (23%) <0.001
Digitalis 300 (44%) 347 (45%) 87 (27%) <0.001
ACE-inhibitor or ARB 422 (61%) 430 (55%) 113 (36%) <0.001
Diuretics 640 (93%) 718 (92%) 257 (81%) <0.001
Nitrates 234 (34%) 289 (37%) 121 (38%) 0.24
Nitroprusside 46 (7%) 74 (10%) 39 (12%) 0.01
Antiplatelet agents 200 (29%) 189 (24%) 71 (22%) 0.04
Oral anticoagulant 351 (51%) 406 (52%) 136 (43%) 0.02
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass 
Index; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; ICCU, 
intensive cardiac care unit; IQR, interquartile range; *p for any difference; †Percutaneous 
coronary intervention and/or CABG; ‡Intra-aortic balloon pump and/or left ventricular assist 
device and/or extracorporeal membrane oxygenation.
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Renal dysfunction and mortality
The median survival of patients with a severely impaired, moderately impaired 
and preserved renal function was 1.0, 2.1 and 4.4 years, respectively. The impact of 
renal function on outcome is shown in Figure 2 and Table 2. 
FIGU R E 2 Survival curve of patients with acute heart failure according to the 
renal function. eGFR, estimated glomerular filtration rate in mL/min/1.73 m2
TABLE 2 Mortality at different follow-up moments according to renal function.
  Mortality rate Univariable analysis* Multivariable analysis*
30 days    
eGFR ≥60 10% Reference Reference
eGFR 30-59 14% 1.51 (1.10-2.08) 1.50 (1.06-2.11)
eGFR <30 24% 2.85 (1.99-4.08) 2.32 (1.55-3.47)
1 year    
eGFR ≥60 28% Reference Reference
eGFR 30-59 36% 1.41 (1.17-1.69) 1.34 (1.11-1.62)
eGFR <30 50% 2.21 (1.79-2.73) 1.81 (1.44-2.28)
10 years    
eGFR ≥60 69% Reference Reference
eGFR 30-59 81% 1.42 (1.33-1.51) 1.24 (1.09-1.40)
eGFR <30 92% 2.14 (1.99-2.31) 1.68 (1.43-1.96)
*Odds ratio with 95% confidence interval (CI) for 30-day mortality, hazard ratio with 95% CI 
for 1-year and 10-year mortality; eGFR, estimated glomerular filtration rate in mL/min/1.73 
m2. Adjustments were made for age, gender, history of HF, diabetes, hypertension, etiology 
of HF, atrial fibrillation at admission, LVEF, renal function and anemia.
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Patients with a severely impaired renal function had the worst prognosis both 
at short- and long-term. These findings remained unchanged after multivariable 
adjustment for other prognostic factors. Although the influence of renal function 
on prognosis became less prominent with longer duration of follow-up, renal func-
tion still remained a strong predictor of mortality. 
Over time, the 10-year survival rate of patients with a preserved renal func-
tion improved significantly, both unadjusted (HR 0.70 [95% CI 0.61-0.81] for most 
recent period versus first period) and after adjustment for confounding variables 
(adjusted HR 0.73 [95% CI 0.55-0.97]; Figure 3A). This improvement was more 
pronounced among the 30-day survivors (adjusted HR 0.65 [95% CI 0.48-0.88]; 
Figure 3B). In contrast, this pattern was not present in patients with renal dysfunc-
tion. Consequently, the prognosis of these patients did not improve over time.
B
A
FIGU R E 3 Mortality over time among (A) the total population and (B) the 30-
day survivors of patients with acute heart failure. Results were divided into three 
groups according to the renal function. CI, confidence interval; eGFR, estimated glomerular 
filtration rate in mL/min/1.73 m2; HR, hazard ratio.
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Anemia and mortality
Almost 50% of the patients were found to have anemia. The characteristics of these 
patients differed in some aspects from those without anemia (Table 3). Anemic 
patients more frequently had previous HF and atrial fibrillation at admission. Im-
portantly, they more often had impaired renal function.
The prognosis of patients with anemia was worse than of patients without anemia 
(Figure 4). After adjustment for confounders, anemia remained significantly associ-
ated with increased 30-day, 1-year and 10-year mortality (HR 2.23 [95% CI 1.64-
3.03], HR 1.58 [95% CI 1.33-1.87] and HR 1.24 [1.11-1.39], respectively; Table 4). 
TAB LE 3 Baseline data and therapy of patients with and without anemia.
  Anemia + Anemia - p-value
No. of patients 850 (48%) 919 (52%)
Age, years (mean±SD) 63.1 ± 14.5 64.1 ± 15.0 0.15
Male gender 565 (67%) 560 (61%) 0.02
BMI, kg/m2 (mean±SD) 24.8 ± 4.8 25.4 ± 5.2 0.20
Medical history
Myocardial infarction 336 (40%) 362 (39%) 0.95
Coronary revascularization* 199 (23%) 183 (20%) 0.07
Heart surgery (not CABG) 131 (15%) 102 (11%) 0.01
Heart transplantation 8 (0.9%) 1 (0.1%) 0.02
Waiting for heart transplantation 22 (2.6%) 12 (1.3%) 0.05
Heart failure 440 (52%) 425 (46%) 0.02
Rhythm- or conduction disorder 215 (25%) 218 (24%) 0.44
Diabetes 199 (23%) 181 (20%) 0.06
Hypertension 271 (32%) 308 (34%) 0.47
Heart failure
Etiology of heart failure >0.05
Ischemic origin 387 (45%) 438 (48%)
Non-ischemic origin 463 (55%) 481 (52%)
Atrial fibrillation at admission 141 (17%) 243 (26%) <0.001
Left ventricular ejection fraction >0.05
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  Anemia + Anemia - p-value
Good 260 (31%) 250 (27%)
Moderate 192 (23%) 227 (25%)
Poor 399 (47%) 442 (48%)
Laboratory values
Sodium (mean±SD) 136 ± 6 138 ± 5 <0.001
Potassium (mean±SD) 4.3 ± 0.8 4.1 ± 0.7 0.001
Urea (median, IQR) 12.6 (8.3-20.4) 8.4 (6.6-11.6) <0.001
eGFR (median, IQR) 47 (26-64) 57 (43-73) <0.001
Creatinine (median, IQR) 123 (94-200) 102 (82-130) <0.001
Hemoglobin (mean±SD) 6.7 ± 0.9 9.0 ± 0.8 <0.001
Hyponatremia 359 (42%) 233 (25%) <0.001
Hypokalemia 100 (12%) 125 (14%) 0.28
Hyperkalemia 122 (14%) 85 (9%) 0.001
Therapy during ICCU hospitalization
Intubation 151 (18%) 92 (10%) <0.001
Resuscitation 36 (4%) 34 (4%) 0.56
Mechanical circulatory support† 80 (9%) 23 (3%) <0.001
Inotropics 329 (39%) 238 (26%) <0.001
Beta-blocker 128 (15%) 174 (19%) 0.03
Antiarrhythmics 143 (17%) 165 (18%) 0.53
Calcium antagonist 130 (15%) 123 (13%) 0.25
Digitalis 305 (36%) 419 (46%) <0.001
ACE-inhibitor or ARB 417 (49%) 540 (59%) <0.001
Diuretics 747 (88%) 854 (93%) <0.001
Nitrates 295 (35%) 342 (37%) 0.27
Nitroprusside 73 (9%) 86 (9%) 0.57
Antiplatelet agents 238 (28%) 224 (24%) 0.08
Oral anticoagulant 383 (45%) 497 (54%) <0.001
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass 
Index; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; ICCU, 
intensive cardiac care unit; IQR, interquartile range; *Percutaneous coronary intervention 
and/or CABG; †Intra-aortic balloon pump and/or left ventricular assist device and/or 
extracorporeal membrane oxygenation.
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TAB LE 4 Mortality at different follow-up moments according to the presence 
of anemia.
  Mortality rate Univariable analysis* Multivariable analysis*
30 days    
No anemia 9% Reference Reference
Anemia 20% 2.55 (1.92-3.38) 2.23 (1.64-3.03)
1 year    
No anemia 28% Reference Reference
Anemia 43% 1.75 (1.49-2.05) 1.58 (1.33-1.87)
10 years    
No anemia 75% Reference Reference
Anemia 83% 1.35 (1.28-1.43) 1.24 (1.11-1.39)
* Odds ratio with 95% confidence interval (CI) for 30-day mortality, hazard ratio with 95% 
CI for 1-year and 10-year mortality. Adjustments were made for age, gender, history of HF, 
diabetes, hypertension, etiology of HF, atrial fibrillation at admission, LVEF, renal function 
and anemia.
FIGU R E 4 Survival curve of acute heart failure patients with and without 
anemia.
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FIGU R E 5 Prognostic impact of anemia at different follow-up moments in 
the total population and 30-day survivors.  Analyses were separately done for renal 
impairment whether or not. CI, confidence interval; eGFR, estimated glomerular filtration 
rate in mL/min/1.73 m2; HR, hazard ratio; *outcome at 30 days was reported as odds ratio 
with 95% CI.
Since anemia was a predictor of poor outcome in the total population of acute 
HF patients, we separately analyzed whether anemia had incremental prognostic 
value independent from renal dysfunction (Figure 5). Among patients with a pre-
served renal function, anemia proved to be a strong predictor for 30-day mortality, 
but its prognostic value decreased with longer duration of follow-up. In contrast, 
anemia was associated with worse outcome both during short- and long-term fol-
low-up among patients with renal dysfunction. This relationship persisted after the 
exclusion of patients who died within 30 days after admission.
DISCUSSION
In this prospective registry of patients with acute HF, we found that renal dysfunc-
tion was a strong predictor for poor outcome up to 10 years following initial hos-
pitalization. Importantly, this study is the first to show that patients with acute HF 
and an impaired renal function had no improvement in prognosis that occurred 
in the last three decades. This contrasts findings in patients with a preserved renal 
0.5 1.0 2.0
Hazard ratio
4.0 8.0
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function. Furthermore, we found that the prognostic impact of anemia was depen-
dent on the presence of renal function. Anemia had no impact on the long-term 
prognosis of patients with a preserved renal function. On the other hand, anemia 
was associated with impaired prognosis among patients with renal dysfunction.
Renal dysfunction and mortality
Renal dysfunction proved to be a strong predictor of a poor outcome: the poorer 
the renal function, the poorer the prognosis. Among studies that demonstrated the 
adverse association between renal dysfunction and poor survival,1,2 most only used 
a short follow-up period, usually up to 1 year after hospitalization. Our results sup-
port and extend these findings by demonstrating that renal dysfunction continued 
to be a strong predictor for long-term mortality (i.e., 10 years). 
It is generally assumed that the new therapeutic options for the treatment of HF 
developed during the last decades are responsible for the prognostic improvement 
in the total population of patients acute HF. Our finding that only patients with a 
normal renal function experienced an improved long-term prognosis in the most 
recently study period is novel. This contrasts with the findings currently obtained 
among patients with renal dysfunction. Their prognosis remained stable over time. 
So far, the temporal trends in prognosis have not been studied separately for pa-
tients with and without renal dysfunction. Two potential mechanisms may explain 
this finding. First, some of the new therapeutics, like ACE inhibitors, ARBs and 
MRAs, that are considered to be responsible for the prognostic improvement of 
patients with HF over the last decades, interact with the renal function.6 Therefore, 
it is plausible that patients with renal dysfunction were less frequently treated with 
these drugs and that, in case they were treated, the optimal dose was not achieved. 
Indeed, we found that ACE inhibitors were less frequently prescribed during ad-
mission in patients with renal dysfunction. Although data on medical therapy dur-
ing follow-up were not included in this registry, it can be assumed that this pattern 
of prescription continued after discharge. Another possible explanation for the 
disparity in temporal trends between patients with and without renal dysfunction 
may be the grade of their illness. Patients with renal dysfunction had more comor-
bidities and were more frequently treated with intubation, mechanical circulatory 
support and inotropics than patients with preserved renal function. This suggests 
that patients with renal dysfunction were more critically ill as compared to those 
with a preserved renal function, and they might thus experience a more progressive 
course of their disease and, therefore, a poorer prognosis.
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Anemia and mortality
The second result of our study was the finding that anemia was associated with 
both an impaired short- and long-term prognosis among patients with acute HF. 
The relation between anemia and adverse outcome in patients with acute HF has 
been published previously, although the data are not consistent.10-13 Two studies 
that did not report anemia to be a prognosticator of poor outcome had study popu-
lations with quite different characteristics than ours.10,13 
When we studied the prognostic value of anemia in more detail, we found that 
anemia was an independent predictor of short-term mortality in all patients, ir-
respective of renal function. However, while anemia also was independently as-
sociated with an impaired outcome during long-term follow-up in patients with 
renal dysfunction, its presence had no incremental long-term prognostic impact 
in patients with a preserved renal function. The reasons for this difference are not 
totally clear. A possible explanation may be the actual cause of the anemia. How-
ever, as we were not able to assess the exact etiology of the anemia, the following 
hypothesis should be studied further in the future. 
Anemia in patients with HF is well known, and has been attributed to multiple 
factors including iron deficiency, renal dysfunction, HF as a chronic disease and 
hemodilution.14 The iron status was not assessed in our patients so we cannot make 
any conclusions as whether there was a difference in iron status between patients 
with and without renal dysfunction. The fact that anemia was associated with im-
paired long-term outcome in patients with renal dysfunction but not in patients 
with a preserved renal function might be due to the fact that patients with renal 
dysfunction more frequently had ‘true anemia’. 
Hemodilution is one of the potential causes of anemia in patients with HF.17 The 
causal factor in that case is a low hemoglobin level caused by an increased extra-
cellular volume. When the extracellular volume decreases, for example by diuretic 
therapy, the hemoglobin level will increase and the patient will no longer be classi-
fied as having anemia. Therefore, in case of hemodilution anemia should be seen as 
a marker of fluid retention, just as sodium level. We hypothesize that hemodilution 
as the only cause of anemia was more frequent in patients without renal dysfunc-
tion than in those with renal dysfunction. Probably, patients with an impaired renal 
function had also anemia based on hemodilution but in addition, could also have 
suffered from ‘true anemia’. There are several reasons for such a phenomenon. First, 
it is well known that renal failure is associated with anemia.14 Second, in our study, 
chronic HF was more common among patients with renal dysfunction than among 
those without renal dysfunction. Since chronic HF has been associated with elevated 
plasma levels of cytokines,18 chronic HF can cause anemia of chronic diseases. These 
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cytokines suppress the erythropoietic stem cells in the bone marrow and reduce the 
release of iron form the reticulo-endothelial system, resulting in anemia.19
The so-called cardiorenal anemia syndrome has not been investigated exten-
sively in patients with acute HF. Investigators form the ATTEND registry also 
found anemia to be a strong predictor of in-hospital mortality both among patients 
with and without renal dysfunction.20 Furthermore, their results with respect to 
the 1-year outcome were consistent with our data. In addition, these authors also 
showed that anemia had additive prognostic value for increased 1-year mortality 
only in the patients with renal dysfunction but not in those with a preserved renal 
function.21 Because these investigators used anemia at discharge as predictor, and 
thus made hemodilution less likely as cause from anemia, this supports our hy-
pothesis of ‘true anemia’ among patients with renal dysfunction. Our data provide 
new evidence on the very long-term prognosis of patients with acute HF since we 
found that anemia, even after 10 years of follow-up, continued to have additive 
prognostic value among patients with renal dysfunction.
The unique strength of our study is the duration of the follow-up of 10 years af-
ter the initial hospitalization. This enabled us to investigate the prognostic impact 
of renal dysfunction, anemia, as well as their interrelationship on short- en (very) 
long-term. Research covering three decades with such a long follow-up time is 
quite unique in this research field.
Study limitations
Despite these strengths, some limitations should be considered in the interpreta-
tion of the results of this study. Since our study was done in a tertiary referral hos-
pital, external validity could have been affected. However, despite the fact that our 
hospital was a tertiary referral center, a significant part of our patients still were 
primary and secondary referrals. Therefore, our population consisted of patients 
within the whole, broad range of patients admitted with acute HF. Second, we were 
not able to identify the cause of anemia in all patients, nor were we always able 
to assess whether patients had chronic or acute renal dysfunction. Furthermore, 
while it has been suggested that changing hemoglobin and creatinine levels during 
admission may influence prognosis,2,22 the design of our study did not allow us to 
assess trends in hemoglobin and creatinine levels. Finally, since we had no data on 
the ethnicity of our patients, we could not multiply for black race in the MDRD 
formula. Therefore, the eGFR that we employed might be an underestimation of 
the real renal function. However, such misclassification could have only led to un-
derestimation of the effects observed.
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CONCLUSION
We found renal dysfunction to be a strong predictor of both short- and long-term 
mortality among patients with acute HF. In addition, we established that the long-
term prognosis of patients with a preserved renal function significantly improved 
over the last decades. However, in patients with renal dysfunction, the prognosis 
did not improve over the last decades. These findings emphasize the importance 
of renal dysfunction as comorbidity in patients with HF and underscore the need 
for new therapeutic modalities, especially for patients with renal dysfunction. Fur-
thermore, we established anemia as a prognosticator of short-term mortality both 
among acute HF patients with and without renal dysfunction. Among patients with 
renal dysfunction, the presence of anemia was also associated with impaired long-
term prognosis. Anemia did not influence the long-term prognosis of patients with 
preserved renal function. Further research should be undertaken to investigate the 
pathogenesis of the prognostic impact of anemia and renal dysfunction among pa-
tients with acute HF.
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CHAPTER 14
DISCUSSION
 
The understanding of the interactions between the heart and the kidneys is funda-
mental to achieve proper assessment and management of patients in whom both 
organ systems are affected. In this thesis, new findings on heart-kidney interac-
tions are presented with particular focus on the temporal aspects of their relation-
ship. For this purpose, we have studied several aspects of kidney functioning in 
a wide spectrum of at-risk populations such as patients with heart failure (HF) 
including those with acute HF, chronic HF, and end-stage HF, and patients with 
ischemic heart disease (IHD) at different stages of their disease. 
The main objective of this work was to identify and quantify new signals along 
the heart-kidney axis that precede and relate to adverse clinical outcomes, but also 
to place these new findings in the context of improvement of a patient’s risk assess-
ment and management. The following summary addresses the main findings of 
this thesis and discusses their clinical perspectives and future directions. 
SUMMARY
Part I Methodological concepts
The first part of this thesis focuses on two important methodological concepts 
within the current trends in clinical research. The first concept is dynamic predic-
tion modeling using repeated-measures study designs to assess the dynamic nature 
of medical conditions and to derive personalized estimates of prognosis (chap-
ter 2). Such study designs include repeated measurements of biological markers 
over the time-course of a disease, which enables us to perform valid inferences 
on disease dynamics and to assess patient prognosis. Yet, when analyzing repeat-
edly measured biological markers the question arises how to properly relate this 
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information to prognosis. To this end, we explain the joint modeling of repeatedly 
measured and time-to-event data within an individual patient to derive personal-
ized prognosis using time-varying markers. 
The second concept includes analysis of statistical interaction to assess whether 
the effect of a certain factor (i.e., exposure or intervention) on a certain outcome 
differs across different types of patients or whether a combined effect of the fac-
tors exceeds their effects considered separately (chapter 3). To this end, review 
studies on statistical interaction have demonstrated that it is studied in the ma-
jority of clinical studies. However, most studies still have difficulties to properly 
assess, interpret, and report this kind of analysis. Therefore, chapter 3 outlines the 
challenges associated with assessment, interpretation, and reporting of statistical 
interactions in clinical studies, as well as recommendations that, if adhered to, will 
increase the clarity and the completeness of future studies.  
Part II The role of the kidneys in heart failure and beyond
The second part of this thesis focuses on the role of the kidneys in chronic heart 
failure (HF) using the unique study design of the Serial Biomarker Measurements 
and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in 
Tailored Prediction of Prognosis (Bio-SHiFT) study. The Bio-SHiFT study is a pro-
spective cohort of 263 clinically stable patients with chronic HF recruited dur-
ing their regular outpatient visits at Erasmus MC, in Rotterdam, and at Noord-
west Ziekenhuisgroep, in Alkmaar, the Netherlands. Study follow-up visits were 
predefined by the study protocol, and scheduled every 3 months to a maximum 
follow-up duration of 30 months. At baseline and at each study follow-up visit, a 
medical evaluation was performed and both blood and urine samples were collect-
ed. This unique repeated-measures design allowed us to explore in detail temporal 
trajectories of many biomarkers during progression of chronic HF. These dynamic 
biomarker patterns were subsequently used to estimate a patient’s risk of future 
adverse clinical outcomes. By doing so, a window of opportunity may be gained to 
timely modify the treatment before a future outcomes occurs. 
Chapter 4 demonstrates that renal dysfunction is an indivisible component of 
the syndrome of HF, but its single assessment does not sufficiently reflect clinically 
silent progression of HF prior to adverse outcome. To our best knowledge, this 
study is the first to simultaneously assess glomerular and tubular function over 
time during several years of follow-up and to show that both renal compartments 
chronically deteriorate, but not in parallel, during progression of HF. The results 
demonstrate that patient-specific trajectories of glomerular indices (creatinine, es-
Summary and Conclusion
Chapter 14
307
timated glomerular filtration rate [eGFRCr], and cystatin C) and tubular damage 
markers (urinary N-acetyl-beta-D-glucosaminidase [NAG] and kidney-injury-
molecule [KIM]-1) predict adverse clinical outcomes independently of patients’ 
clinical characteristics, pharmacological treatment, cardiac natriuretic peptides 
and troponins, and for tubular markers also independently of eGFR. In this con-
text, both the levels of these renal markers and their slopes (i.e., rates of change) 
may be useful for dynamic risk profiling. Such dynamic risk profiling can enable 
physicians to better detect disease progression and to make individualized treat-
ment decisions.
In chapter 5, we further explored decline of glomerular filtration (GD) and 
progressive tubular damage (PTD) during clinically silent progression of chronic 
HF. We found that if GD and PTD coexist during follow-up the clinical prognosis 
worsens. Yet, PTD carried poor prognosis even in the absence of GD. This is par-
ticularly important to note since in current clinical practice tubular markers are 
not routinely assessed, leaving the degree of PTD undetermined. However, our 
findings suggest that “renoprotective” treatment targeted at the tubules may be 
even more effective than treatment aiming at improving renal function in terms 
of eGFR. This issue will be further explored in chapter 12 where we investigated 
the temporal effects of HF medication adjustments on these biomarkers during pa-
tients’ follow-up. Finally, patients’ clinical profiles differed between PTD and GD, 
which also supports that these renal indices should be jointly assessed.  
Chapter 6 describes the temporal profiles of new, emerging cardiorenal and 
pulmonary candidate biomarkers during clinically silent stages of chronic HF. In 
this regard, osteopontin (OPN), osteoprotegerin (OPG), trefoil factor-3 (TFF-3), 
and heparin-binding protein (HBP) strongly predicted adverse clinical outcomes 
in patients with chronic HF. The use of these markers may be clinically relevant 
as they may further refine estimation of a patient’s prognosis, provide additional 
pathophysiological insights into HF, and may ultimately be useful for designing 
more effective strategies for biomarker (trajectory)-guided therapy. 
Although it is known that multiple hormonal and metabolic alterations occur in 
chronic HF, the cardiometabolic biomarkers that reflect these alterations have been 
insufficiently explored. Chapter 7 exclusively demonstrates that temporal trends 
of cardiometabolic biomarkers such as insulin-like binding protein (IGFBP)-1, -2, 
and -7, as well as adipokine fatty-acid binding protein-4 are strongly related to 
adverse clinical outcomes in patients with clinically stable HF. Their clinical role 
may be to assist in the care for HF patients by means of better phenotyping of the 
disease, but also their dynamical changes may be practically important to detect 
more aggressive forms of chronic HF.   
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Furthermore, chapter 8 describes the prognostic value of dynamic profiles of 
fourteen cardiac remodeling candidate biomarkers during follow-up of patients 
with chronic HF including ST2, Gal-3, Gal-4, GDF-15, MMP-2, 3 and 9, TIMP-4, 
PLC, AP-N, CASP3, CTSD, CTSZ and CSTB. Their dynamic nature is important 
considering the dynamic nature of myocardial remodeling, which has a pivotal role 
in the progression of HF. 
Altogether, our results suggest a promising role for repeatedly assessed, estab-
lished and novel biomarkers in prognostication of patients with chronic HF. As 
a next step, well-organized clinical trials are needed to provide definite evidence 
if such established markers, as well as the novel biomarkers that are expected to 
emerge in near future, can be used for biomarker (trajectory)-guided therapy. 
Part III Implications of renal function for ischemic heart 
disease
Not only does renal dysfunction play one of the key roles in the syndrome of HF, 
altered renal function is also a major determinant of cardiovascular outcome in 
patients with IHD. Therefore, part III focuses on the implications of renal function 
for patients with acute coronary syndrome (ACS) and for those with stable angina 
pectoris (SAP). 
In chapter  9, we studied patients hospitalized with ACS enrolled in the BIO-
Marker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS), which 
is a multi-centre prospective study conducted in 18 Dutch hospitals. Here, our aim 
was to describe the evolution of renal function from its initial change during ACS 
until stabilization; and to investigate the predictive value of serial renal assessments 
during the first year on the occurrence of clinical events, including recurrent ACS 
or death. Considering that existing studies have mostly investigated renal function 
only at a single time moment (e.g., at admission, a moment during in-hospital stay, 
or at discharge), its temporal patterns following and preceding ACS remain un-
clear. Knowing these temporal patterns may help us identify high-risk subgroups of 
patients with ACS. In this regard, we demonstrate that plasma cystatin C levels in-
dicate disturbances in renal function earlier than creatinine or eGFR do during the 
initial ACS. We also show that disturbances in renal indices usually do not stabilize 
during hospitalization, which usually lasts up to 7 days, but on average stabilize 
two weeks after ACS. Finally, we show that during the first year of follow-up after 
ACS, cystatin C levels predict clinical events independently of GRACE risk score in 
patients with normal to moderately impaired renal function.
In chapter 10, we focus on the relations of a glomerular marker, plasma cys-
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tatin C, and a tubular marker, plasma neutrophil gelatinase-associated lipocalin 
(NGAL), with coronary atherosclerosis and occurrence of 1-year major adverse 
cardiac events (MACE) within the European Collaborative Project on Inflamma-
tion and Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound 
(ATHEROREMO-IVUS) study. The ATHEROREMO-IVUS study included patients 
who underwent coronary angiography for ACS or SAP and in whom intravascular 
ultrasound (IVUS) imaging of a non-culprit coronary artery was performed. Using 
virtual histology (VH)-IVUS, the extent and composition of coronary atheroscle-
rosis were assessed and high-risk lesions were identified including thin-cap fibro-
atheroma (TCFA), lesions with plaque burden (PB)≥70%, and lesions with minimal 
luminal area ≤4.0 mm2. In patients with normal renal function higher CysC levels 
were associated with fewer high-risk lesions such as TCFA and PB≥70%. However, 
in patients with mildly-to-moderately impaired kidneys these ‘protective’ effects 
of cystatin C were absent, and higher cystatin C levels predicted MACE. Conver-
sly, NGAL did not show clear assciations with coronary atherosclerosis or MACE. 
These findings indicate that renal dysfunction modifes the relationship between 
plasma cystatin C and coronary atherosclerosis. 
Part IV Lessons learned from clinical practice
The fourth part of this thesis investigates several aspects of current clinical practice 
in order to provide additional insights into heart-kidney interactions. 
Chapter 11 describes the temporal effects of neurohormonal antagonists and 
loop diuretics on serially assessed cardiac, renal, and anti-inflammatory biomark-
ers, patient functional status, and occurrence of adverse clinical outcomes during 
outpatient follow-up of patients with chronic HF and reduced ejection fraction 
within the Bio-SHiFT study. Here, we found that decrease in dosage or withholding 
of angiotensin-converting enzyme (ACE)-inhibitors/angiotensin II receptor block-
ers (ARBs) solely based on glomerular function is not justified because of their 
beneficial cardiac, tubular and anti-inflammatory effects. To our best knowledge, 
our findings are the first to show the beneficial effects of ACE-inhibitors/ARBs on 
renal tubules in chronic HF. Finally, higher dosage and increase in dosage of loop 
diuretics during follow-up marked progression towards end-stage HF.
In patients undergoing heart transplantation (HTx), postoperative acute kidney 
injury (AKI) continues to be a frequent complication with poor prognosis (chapter 
12). Although renal injury after heart transplantation has traditionally been attrib-
uted to impaired arterial perfusion and calcineurin inhibitors’ nephrotoxicity, our 
results provide strong evidence for an independent relationship between preopera-
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tive right-sided hemodynamics (lower pulmonary artery pulsatility index [PAPi] 
and higher right atrial pressure [RAP] values) and postoperative AKI severity. Al-
together, these data suggest that preoperatively compromised right-sided venous 
pressures deserve clinical attention in the context of postoperative AKI and that 
preoperative PAPi and RAP values may be used as early AKI predictors.
In chapter 13, we explore our 23-year long registry data (from 1985 to 2008) on 
the short- and long-term clinical prognosis of patients hospitalized with acute HF. 
Our results demonstrate that long-term prognosis of patients in whom renal func-
tion is preserved has significantly improved in recent years. However, the long-
term prognosis in those with renal dysfunction has remained impaired. We also 
found that the presence of anemia was associated with poor short-term prognosis 
in all patients. Finally, in patients with renal dysfunction, anemia was associated 
with impaired long-term prognosis. 
MAIN CONCLUSIONS
This thesis suggests a promising role for dynamic prediction modeling using re-
peatedly assessed, established and novel biomarkers in prognostication of patients 
with chronic HF. Similarly, the statistical interaction analysis may help us to learn 
how to use an intervention most effectively, who would and who would not benefit, 
how patients’ comorbidities influence the effect, and whether it would be harmful 
in specific subpopulations.  
Although the failing heart affects both the glomerular and tubular compart-
ments of the kidneys, the degree of damage in these renal compartments is usu-
ally not temporally coupled. Importantly, the deterioration of either glomerular or 
tubular compartment, and especially their simultaneous damage entail poor prog-
nosis in chronic HF. During clinically silent progression of HF, the patient-specific 
evolutions of glomerular markers (plasma creatinine, eGFR and cystatin C) and tu-
bular markers (urinary NAG and KIM-1) dynamically predict adverse clinical out-
comes such as HF rehospitalizations and death. In a multi-organ syndrome such 
as HF, circulating biomarkers that reflect its multi-organ pathophysiology may be 
a valuable clinical tool, as these cellular signals precede cardiac decompensation 
and may provide early tissue- and organ-specific information. In this respect, we 
identified several new biomarkers that carry potential to further characterize the 
multi-organ pathophysiology of chronic HF, but may also help in monitoring dis-
ease progression during outpatient follow-up. 
In patients with ACS, plasma CysC levels indicate deterioration of renal func-
tion earlier than creatinine-based indices do, and higher CysC levels contain prog-
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nostic information for the recurrence of ACS and death during the first year after 
ACS in patients with mild-to-moderate renal dysfunction.  Such renal dysfunction 
also modifies the relationship between CysC and the presence of VH-IVUS high-
risk coronary lesions. These findings should not be neglected because such mild 
renal dysfunction usually does not require medical attention, yet the subtle differ-
ences captured by cystatin C appear to carry potential for improving patient risk 
stratification.
Decrease or withholding of ACE-inhibitors/ARBs solely based on glomerular 
function markers is not justified in stable patients with HF because of their benefi-
cial cardiac, tubular and anti-inflammatory effects. In contrast, higher dosage and 
increase in dosage of loop diuretics during follow-up mark progression towards 
end-stage HF. In patients with end-stage HF, preoperative right-sided hemody-
namic indices such as PAPi and RAP strongly predict severity of postoperative 
AKI, suggesting a key role for chronic renal venous congestion in renal injury early 
after heart transplantation. 
CLINICAL PERSPECITVES AND FUTURE DIRECTIONS 
This thesis describes additional insights into heart-kidney interactions that may en-
hance their early identification and their monitoring in order to improve risk predic-
tion in patients in whom both organ systems are affected. Specifically, it demonstrates 
that temporal biomarker patterns assessed in individuals carry additional prognos-
tic information on top of the traditional single (baseline) assessment approach. For 
physicians, it is also medically relevant to use all available information (baseline and 
follow-up) to accurately detect disease dynamics and to profile individual prognosis. 
Such dynamic prognostication could be integrated into clinical decision-making and 
could be particularly useful for tissue-specific targeting of therapies. 
To accomplish this, we report the results of a large array of established and 
emerging biomarkers and cover various phases of biomarker research. These phas-
es include initial proof of concept testing (i.e., assessing whether specific biomark-
ers significantly differ between patients with and without outcome), prospective 
validation (i.e., prediction of future outcomes in prospective cohort studies), and 
assessment of their incremental value to traditional risk predictors. As such, this 
thesis provides a solid basis for future studies to examine the clinical utility of the 
biomarkers investigated here, within a biomarker (trajectory)-guided treatment 
strategy. Altogether, we hope that the results of our work as reported in this thesis 
will contribute to reducing patients’ mortality- and hospitalization rates, improving 
their quality of life, but also reducing healthcare costs.
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NEDERLANDSE SAMENVATTING
Inzicht in  de wisselwerking tussen hart en nieren is essentieel voor het adequaat 
beoordelen en behandelen van patiënten bij wie deze beide organen zijn aangedaan. 
In dit proefschrift worden nieuwe bevindingen besproken met betrekking tot de in-
teractie tussen hart en nieren, met bijzondere aandacht voor het tijdsbeloop van de 
onderlinge relatie tussen deze orgaansystemen. We hebben hiervoor verschillende 
aspecten van de nierfunctie bestudeerd in een breed spectrum van risicopopulat-
ies. Zo worden er in dit proefschrift patiënten met hartfalen (HF) besproken, waar-
onder patiënten met acuut HF, chronisch HF en eindstadium HF. Tevens wordt er 
aandacht besteed aan patiënten met ischemische hart ziekte (IHZ) in verschillende 
stadia van de ziekte.
Het hoofddoel van dit onderzoek was het identificeren en kwantificeren van 
nieuwe signalen op de hart-nier-as, die voorafgaan aan en betrekking hebben op 
ongunstige klinische uitkomsten. Eveneens was het voor ons van belang om deze 
nieuwe bevindingen te plaatsen in de context van verbetering van risicoschatting 
en behandelstrategie van de patiënt. De volgende samenvatting geeft een weergave 
van de belangrijkste bevindingen uit dit proefschrift en bespreekt de klinische per-
spectieven en toekomstige mogelijkheden.
Deel I Methodologische concepten
Het eerste deel van dit proefschrift focust op twee belangrijke methodologische 
concepten die passen binnen de huidige trend van klinisch onderzoek. Het eerste 
concept is dynamische voorspellingsmodellering, dat gebruik maakt van een 
onderzoeksopzet met herhaalde metingen. Het doel van dit model is om de dyna-
mische aard van medische aandoeningen inzichtelijk te maken en om een geper-
sonaliseerde voorspelling van de prognose te verkrijgen (hoofdstuk 2). Dergelijke 
studieopzetten bevatten herhaalde metingen van biologische markers gedurende 
het beloop van een ziekte, hetgeen ons in staat stelt om conclusies te trekken over 
de dynamiek van de ziekte en om de prognose van de patiënt in te schatten. Bij het 
analyseren van herhaaldelijk gemeten biologische markers, dient de vraag zich aan 
hoe de veelvuldig gemeten markers op de juiste manier kunnen worden gerelateerd 
aan de prognose. Daarom gebruikten we “joint modeling”, waarbij rekening wordt 
gehouden met herhaalde (biomarker) metingen in een individuele patiënt, maar 
ook met verschillen tussen de patiënten in de database. Deze methode stelt ons 
in staat om de herhaalde (bio)marker metingen over de tijd te gebruiken om een 
gepersonaliseerde prognose in te schatten.
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Het tweede methodologische concept omvat statistische interactie analyses. 
Deze analyses beoordelen of het effect van een bepaalde factor (bijvoorbeeld een 
blootstelling of een interventie) op een bepaald resultaat verschilt tussen verschil-
lende typen patiënten of dat een gecombineerd effect van deze factoren groter is 
dan iedere factor afzonderlijk (hoofdstuk 3). Reviewonderzoek naar statistische 
interactie heeft aangetoond dat statistische interactie in veel klinische onderzoeken 
wordt bestudeerd. De meeste studies hebben echter moeite om dit soort analyses 
te beoordelen, te interpreteren en te rapporteren. Hoofdstuk 3 schetst daarom de 
uitdagingen die gepaard gaan met de beoordeling, interpretatie en rapportage van 
statistische interacties in klinische onderzoeken, waarbij ook aanbevelingen wor-
den gegeven die de duidelijkheid en de volledigheid van toekomstige studies zullen 
vergroten.
Deel II De rol van de nieren in hartfalen en verder 
Het tweede deel van dit proefschrift focust op de rol van de nieren in chronisch 
hartfalen doormiddel van de unieke studieopzet in de zogenoemde “Serial Bio-
marker Measurements and New Echocardiographic Techniques in Chronic Heart 
Failure Patients Result in Tailored Prediction of Prognosis (Bio-SHiFT)” studie. De 
Bio-SHiFT studie is een prospectief cohort van 263 klinisch stabiele patiënten met 
chronisch HF. Deze patiënten zijn geïncludeerd tijdens hun reguliere polikliniek 
bezoek in het Erasmus MC, Rotterdam, of in de Noordwest Ziekenhuisgroep, Al-
kmaar, Nederland. Vervolgbezoeken voor de studie werden vooraf gedefinieerd in 
het onderzoeksprotocol, namelijk iedere 3 maanden, tot een maximale follow-up 
duur van 30 maanden. Zowel bij het eerste bezoek als bij alle vervolgbezoeken, 
werd een medische evaluatie uitgevoerd en werden er zowel bloed- als urinemon-
sters verzameld. Door deze unieke studieopzet van herhaalde metingen waren we 
in staat om tijdens het proces van chronisch HF het beloop van vele biomarkers 
te bestuderen. Deze dynamische patronen van de biomarkers werden vervolgens 
gebruikt om het risico van een patiënt te schatten op ongunstige klinische uitkom-
sten. Hierdoor ontstaat er een kans om de behandeling tijdig aan te passen, voordat 
deze negatieve ziekte-uitkomst optreedt.
Hoofdstuk 4 toont aan dat renale disfunctie onlosmakelijk verbonden is met 
het syndroom van HF. Echter, één afzonderlijke meting van de nier(dis)functie 
weerspiegelt niet voldoende de progressie van HF tijdens de klinisch ogenschijn-
lijk stabiele fase voorafgaand aan een ongunstige ziekte uitkomst. Voor zover wij 
weten is dit de eerste studie die zowel de glomerulaire als de tubulaire functie over 
een tijdsbestek van enkele jaren beoordeelt en daarmee aantoont dat tijdens het 
ziektebeloop van HF beide nier compartimenten chronisch verslechteren, maar dat 
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ze dit niet tegelijkertijd doen. De resultaten tonen aan dat het patiënt-specifieke 
beloop van glomerulaire indicatoren (creatinine, geschatte glomerulaire filtraties-
nelheid [eGFRCr] en cystatin C) en markers van tubulaire schade (urinary N-ace-
tyl-beta-d-glucosaminidase (NAG) en kidney-injury-molecule (KIM) -1) ongun-
stige klinische uitkomsten voorspellen. Deze bevindingen zijn onafhankelijk van 
de klinische kenmerken van een patiënt, farmacologische behandeling, cardiale 
natriuretische peptiden en troponinen en wat betreft tubulaire markers is de voor-
spellende waarde ook onafhankelijk van de eGFR. In deze context kunnen zowel 
de levels van de nier-markers, als ook hun helling (d.w.z. de snelheid van de veran-
dering over de tijd) nuttig zijn voor dynamische risicoprofilering. Een dergelijke 
dynamische risicoprofilering kan de arts in staat stellen om progressie van de ziekte 
beter te detecteren en om geïndividualiseerde behandelbeslissingen te nemen.
In hoofdstuk 5 hebben we de achteruitgang van glomerulaire filtratie (GD) 
en progressieve tubulaire schade (PTD) verder onderzocht tijdens progressie van 
chronisch HF, terwijl deze progressie klinisch nog niet waarneembaar was. We 
vonden dat als zowel GD als PTD gelijktijdig bestaan gedurende de follow-up, de 
klinische prognose slechter wordt. Alleen het hebben van PTD leidde ook tot een 
slechte prognose, zelfs bij afwezigheid van GD. Dit is met name belangrijk om op 
te merken, aangezien in de huidige klinische praktijk tubulaire markers niet rou-
tinematig worden bepaald, waardoor de mate van PTD onbekend blijft. Onze bev-
indingen suggereren echter dat “nier protectieve” behandelingen, gericht op de tu-
buli, zelfs effectiever kunnen zijn dan behandeling alleen gericht op het verbeteren 
van de nierfunctie in termen van de eGFR. Dit punt zal verder worden onderzocht 
in hoofdstuk 12, waar we de effecten van HF-medicijnaanpassingen over de tijd 
hebben onderzocht op deze biomarkers gemeten tijdens de follow-up. Ten slotte 
verschilden de klinische profielen van patiënten met PTD en GD, wat ook onder-
steunt dat deze renale indicatoren gezamenlijk moeten worden beoordeeld.
Hoofdstuk 6 beschrijft de profielen van nieuwe, opkomende cardiorenale en 
pulmonale biomarker kandidaten over de tijd in de klinisch stabiele fase van chro-
nisch HF. In dit opzicht voorspelden osteopontin (OPN), osteoprotegerin (OPG), 
trefoil factor-3 (TFF-3) en heparin-binding protein (HBP) sterk de ongunstige 
klinische uitkomsten bij patiënten met chronisch HF. Het gebruik van deze mark-
ers kan klinisch relevant zijn omdat ze de inschatting van de prognose van een 
patiënt kunnen verfijnen, extra pathofysiologische inzichten in HF kunnen geven 
en uiteindelijk nuttig kunnen zijn voor het opstellen van effectievere strategieën 
voor biomarker-geleide therapie.
Hoewel bekend is dat bij chronisch HF meerdere hormonale en metabole ve-
randeringen optreden, zijn de cardiometabolische biomarkers die deze veranderin-
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gen weerspiegelen onvoldoende onderzocht. Hoofdstuk 7 laat uitsluitend zien dat 
trends van cardiometabolische biomarkers over de tijd zoals insulin-like binding 
protein (IGFBP)-1, -2 en -7, evenals adipokine fatty-acid binding protein-4 sterk 
gerelateerd zijn aan ongunstige klinische uitkomsten bij patiënten met klinisch 
stabiel HF. Deze biomarkers kunnen een klinische rol vervullen bij de zorg voor 
HF-patiënten door middel van betere fenotypering van de ziekte, maar ook de 
dynamische veranderingen kunnen van belang zijn om agressievere vormen van 
chronisch HF te detecteren.
Verder beschrijft hoofdstuk 8 de prognostische waarde van 14 kandidaat bio-
markers, die te maken met de remodelering van het hart, tijdens de follow-up 
van patiënten met chronisch HF. De prognostische waarden van de dynamische 
profielen van ST2, Gal-3, Gal-4, GDF-15, MMP-2, 3 en 9, TIMP -4, PLC, AP-N, 
CASP3, CTSD, CTSZ en CSTB worden hier beschreven. De dynamische aard van 
deze markers is belangrijk gezien de dynamische aard van myocardiale remodeler-
ing, wat een cruciale rol speelt in de progressie van HF.
Al met al suggereren onze resultaten een veelbelovende rol voor herhaaldelijk 
gemeten, klassieke maar ook nieuwe biomarkers bij de prognose van patiënten met 
chronisch HF. Als volgende stap zijn goed georganiseerde klinische onderzoeken 
nodig om definitief bewijs te leveren of de klassieke markers, evenals de nieuwe 
biomarkers die naar verwachting in de nabije toekomst zullen verschijnen, kunnen 
worden gebruikt voor biomarker (traject)-geleide therapie.
Deel III Implicaties van de nierfunctie voor ischemische 
hartaandoeningen
Niet alleen speelt renale disfunctie een sleutelrol in het syndroom van HF, een 
veranderding van de nierfunctie is ook een belangrijke bepalende factor voor car-
diovasculaire uitkomsten bij patiënten met IHZ. Daarom richt deel III zich op de 
implicaties van de nierfunctie bij patiënten met acuut coronair syndroom (ACS) en 
patiënten met stabiele angina pectoris (SAP).
In hoofdstuk 9 bestudeerden we patiënten die waren opgenomen in een ziek-
enhuis in verband met ACS en die deelnamen aan de “BIOMarker study to iden-
tify the Acute risk of a Coronary Syndrome” ofwel BIOMArCS studie. Dit is een 
prospectieve multicenter studie uitgevoerd in 18 Nederlandse ziekenhuizen. In dit 
hoofdstuk was ons doel om de evolutie van de nierfunctie te beschrijven vanaf de 
initiële verandering tijdens ACS tot stabilisatie. Tevens hebben we de voorspellen-
de waarde van herhaalde nierfunctie metingen onderzocht tijdens het eerste jaar 
na een ACS op het optreden van klinische gebeurtenissen (waaronder opnieuw een 
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ACS of overlijden). In overweging nemende dat bestaande studies de nierfunctie 
meestal alleen op één enkel moment hebben onderzocht (bijvoorbeeld bij opname, 
een moment tijdens ziekenhuisverblijf of bij ontslag), blijven de temporele pa-
tronen na en voorafgaand aan ACS onduidelijk. Als we deze patronen over de tijd 
leren kennen kan dit ons helpen om risicovolle subgroepen van patiënten met ACS 
te identificeren. Vanuit dit oogpunt demonstreren we dat het niveau van plasma 
cystatin C eerder stoornissen in de nierfunctie aangeven dan creatinine of eGFR 
tijdens het initiële ACS. We laten ook zien dat stoornissen in de nier-indicatoren 
gewoonlijk niet stabiliseren tijdens de ziekenhuisopname, die meestal tot 7 dagen 
duurt, maar gemiddeld twee weken na het ACS stabiliseert. Tot slot laten we zien 
dat het niveau van plasma cystatin C, tijdens het eerste jaar van follow-up na een 
ACS, klinische verschijnselen kan voorspellen onafhankelijk van de GRACE-risi-
coscore bij patiënten met een normale tot matig verminderde nierfunctie.
In hoofdstuk 10 concentreren we ons op de relatie van een glomerulaire 
marker, plasma cystatin C en een tubulaire marker, plasma neutrophil gelatinase-
associated lipocalin (NGAL), met coronaire atherosclerose en het optreden ern-
stige cardiale aandoeningen (MACE) binnen 1 jaar in de “European Collaborative 
Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis – Intra-
vascular Ultrasound”(ATHEROREMO-IVUS) studie. De ATHEROREMO-IVUS 
studie bestaat uit patiënten die coronaire angiografie ondergingen i.v.m. ACS of 
SAP en bij wie beeldvorming  middels intravasculaire echografie (IVUS) van een 
“non-culprit” bloedvat van het hart werd uitgevoerd. Met behulp van virtuele his-
tologie (VH)-IVUS werd de mate en samenstelling van coronaire atherosclerose 
vastgesteld en werden hoog-risico laesies geïdentificeerd, waaronder “thin-cap fi-
broatheroma” (TCFA), laesies met een “plaque burden” (PB) ≥70% en laesies met 
een minimale luminale oppervlakte ≤4.0 mm2. Bij patiënten met een normale ni-
erfunctie waren hogere cystatin C waarden geassocieerd met minder hoog-risico 
laesies, zoals TCFA en PB≥70%. Bij patiënten met een licht tot matig gestoorde 
nierfunctie waren deze ‘beschermende’ effecten van cystatin C afwezig en ho-
gere niveaus van cystatin C voorspelden MACE. Omgekeerd toonde NGAL geen 
duidelijke associaties met coronaire atherosclerose of MACE. Deze bevindingen 
wijzen erop dat renale disfunctie de relatie tussen plasma cystatin C en coronaire 
atherosclerose modificeert.
Deel IV Lessen uit de klinische praktijk
Het vierde deel van dit proefschrift onderzoekt verschillende aspecten van de hui-
dige klinische praktijk om aanvullende inzichten te bieden in de interacties tussen 
hart en nieren.
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Hoofdstuk 11 beschrijft de effecten over de tijd van neurohormonale antago-
nisten en lisdiuretica op herhaaldelijk gemeten cardiale, renale en anti-inflamma-
toire biomarkers, functionele status van patiënten en het optreden van ongunstige 
klinische uitkomsten tijdens poliklinische follow-up van patiënten met chronisch 
HF en verminderde ejectiefractie in de Bio-SHiFT-studie. Hierin vonden we het 
verlagen van de dosering of het niet-geven van ACE-remmers/ARB’s, uitsluitend 
gebaseerd op glomerulaire functie, niet gerechtvaardigd is vanwege de gunstige 
cardiale, tubulaire en ontstekingsremmende effecten die ze hebben. Voor zover wij 
weten zijn onze bevindingen de eerste die de gunstige effecten aantonen van ACE-
remmers/ARB’s op de niertubuli bij chronisch HF. Tenslotte, hogere dosering en 
verhoging van de dosering van lisdiuretica tijdens de follow-up duidde op pro-
gressie naar eindstadium HF.
Bij patiënten die een harttransplantatie (HTx) ondergaan, blijft postoperatieve 
acute nierbeschadiging (AKI) een veelvoorkomende complicatie met een slechte 
prognose (hoofdstuk 12). Hoewel nierbeschadiging na harttransplantatie van 
oudsher wordt toegeschreven aan verminderde arteriële perfusie en nefrotoxiciteit 
door calcineurineremmers, leveren onze resultaten sterk bewijs voor een onafhan-
kelijke relatie tussen preoperatieve rechtszijdige hemodynamica (lagere pulmonale 
arteriële pulsatiliteitsindex [PAPi] en hogere rechteratriumdruk [RAP]-waarden) 
en de ernst van postoperatieve AKI. Deze gegevens suggereren dat preoperatief 
gecompromitteerde rechtszijdige veneuze druk klinische aandacht verdient in de 
context van postoperatieve AKI en dat preoperatieve PAPi en RAP-waarden kun-
nen worden gebruikt als vroege voorspellers van AKI.
In hoofdstuk 13 gebruiken we onze 23-jaar omvattende registratiegegevens 
(van 1985 tot 2008) om de korte en lange termijn klinische prognose te onder-
zoeken van patiënten die zijn opgenomen met acuut HF. Onze resultaten tonen aan 
dat de langetermijnprognose van patiënten bij wie de nierfunctie behouden blijft, 
de afgelopen jaren aanzienlijk is verbeterd. De langetermijnprognose bij diegenen 
met nierfunctiestoornissen is echter verslechterd. We ontdekten ook dat de aan-
wezigheid van anemie geassocieerd is met een slechte prognose op korte termijn 
bij alle patiënten. Ten slotte was anemie bij patiënten met renale disfunctie geas-
socieerd met een verminderde langetermijnprognose.
CONCLUSIES
Dit proefschrift suggereert een veelbelovende rol voor dynamische voorspell-
ingsmodellering met behulp van herhaaldelijk gemeten, klassieke en nieuwe 
biomarkers bij het inschatten van de prognose van patiënten met chronisch HF. 
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Eveneens kan statistische interactie-analyse ons helpen om te leren hoe we een 
interventie het meest effectief kunnen gebruiken, wie wel en wie er niet van zou 
profiteren, hoe de comorbiditeiten van patiënten het effect beïnvloeden en of het 
schadelijk zou zijn in specifieke subpopulaties.
Hoewel het falende hart zowel de glomerulaire als ook de tubulaire comparti-
menten van de nieren aantast, is de mate van beschadiging in deze compartimenten 
meestal niet simultaan over de tijd. Belangrijk is dat de verslechtering van ofwel het 
glomerulaire ofwel het tubulaire compartiment, en met name gelijktijdige besch-
adiging van beide compartimenten, een slechte prognose bij chronisch HF met zich 
meebrengt. Het patiënt-specifieke beloop van glomerulaire markers (plasma cre-
atinine, eGFR en cystatin C) en tubulaire markers (urinary NAG en KIM-1) voor-
spelt op dynamische wijze de ongunstige klinische uitkomsten zoals ziekenhuishe-
ropname door HF en overlijden, tijdens de ogenschijnlijk klinisch stabiele fase van 
HF. In een multi-orgaan syndroom zoals HF kunnen circulerende biomarkers die 
de multi-orgaan pathofysiologie weerspiegelen een waardevol klinisch hulpmid-
del zijn, aangezien deze cellulaire signalen voorafgaan aan decompensatie van het 
hart en vroege weefsel- en orgaan specifieke informatie kunnen verschaffen. In dit 
opzicht hebben we verschillende nieuwe biomarkers geïdentificeerd die de potentie 
hebben om de multi-orgaanpathofysiologie van chronisch HF verder te karakter-
iseren, maar die ook kunnen helpen bij het monitoren van ziekteprogressie tijdens 
poliklinische follow-up.
Bij patiënten met ACS wijzen de waarden van plasma cystatin C eerder op ver-
slechtering van de nierfunctie dan creatinine-gebaseerde indicatoren dat doen. 
Bovendien wijzen hogere cystatin C waarden als prognostische indicator op het 
opnieuw krijgen van ACS en overlijden, tijdens het eerste jaar na ACS bij patiënten 
met milde tot matige renale disfunctie. Een dergelijke renale disfunctie modificeert 
ook de relatie tussen cystatin C en de aanwezigheid van VH-IVUS coronaire laesies 
met hoog risico. Deze bevindingen mogen niet worden verwaarloosd. Een dergeli-
jke milde nieraandoening vereist meestal geen medische aandacht, maar de sub-
tiele verschillen die door cystatin C worden weergegeven lijken potentie te hebben 
om de risicostratificatie van patiënten te verbeteren.
Verlagen van de dosis of het niet-geven van ACE-remmers / ARB’s uitsluitend 
op basis van glomerulaire nierfunctiemarkers is niet gerechtvaardigd bij stabiele 
patiënten met HF vanwege de gunstige cardiale, tubulaire en ontstekingsremmende 
effecten. Daarentegen, een hogere dosering en verhoging van de dosering van lis-
diuretica tijdens follow-up indiceert progressie naar eindstadium HF. Bij patiënten 
met terminaal HF voorspellen preoperatieve rechtszijdige hemodynamische indi-
catoren, zoals PAPi en RAP, de ernst van postoperatieve AKI, wat een sleutelrol 
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suggereert voor chronische renale veneuze congestie bij nierbeschadiging kort na 
een harttransplantatie.
KLINISCHE PERSPECTIEVEN EN TOEKOMSTIGE  
AANBEVELINGEN
Dit proefschrift beschrijft aanvullende inzichten in de interacties tussen hart en 
nieren die mogelijk vroege identificatie en monitoring kunnen verbeteren, om op 
die manier de risicovoorspelling te verbeteren bij patiënten bij wie deze beide or-
gaansystemen zijn aangedaan. Dit proefschrift toont met name aan dat biomark-
erpatronen in individuen over de tijd extra prognostische informatie bevatten, 
bovenop de traditionele benadering met een eenmalige (baseline) meting. Voor 
artsen is het medisch relevant om alle beschikbare informatie (op baseline en ti-
jdens follow-up) te gebruiken om het dynamische ziekteverloop nauwkeurig te de-
tecteren en om individuele prognoses te kunnen stellen. Een dergelijke dynamische 
prognose zou kunnen worden geïntegreerd in de klinische besluitvorming en zou 
bijzonder nuttig kunnen zijn voor therapieën die aangrijpen op specifieke weefsels.
Om dit te bereiken rapporteren we de resultaten van een groot aantal klassieke 
en opkomende biomarkers en behandelen we verschillende fasen van biomark-
eronderzoek. Deze fasen omvatten initiële hypothese genererende testen (d.w.z. het 
beoordelen of specifieke biomarkers significant verschillen tussen patiënten met en 
zonder ziekte uitkomst), prospectieve validatie (d.w.z. het voorspellen van toekom-
stige uitkomsten in prospectieve cohortonderzoeken) en beoordeling van de ad-
ditieve waarde bovenop traditionele risicovoorspellers. Hierdoor biedt dit proef-
schrift een solide basis voor toekomstige studies om de klinische bruikbaarheid 
van de hier beschreven biomarkers te onderzoeken, voor een biomarker-geleide 
behandelingsstrategie. We hopen dat de resultaten van ons werk, zoals beschreven 
in dit proefschrift, zullen bijdragen aan het verlagen van de mortaliteit- en zieken-
huisopnamecijfers van patiënten, het verbeteren van de kwaliteit van leven bij deze 
patiënten en ook het verlagen van de kosten voor de gezondheidszorg.
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Milos Brankovic, MD, has completed 
his PhD thesis on the heart-kidney inter-
actions in acquired heart disease. 
Born in Belgrade, Serbia, he studied 
medicine at the School of Medicine, 
University of Belgrade, where he was 
elected Editor-in-Chief of the student 
scientific journal “Medical Youth” and 
Vice-President of Organizing Commit-
tee of the first Global Students Con-
ference of Biomedical Sciences in Bel-
grade. Having achieved a ranking in the 
top 1% of his class, he received a two-
month scholarship in 2013 to train un-
der the mentorship of Dr. Bud Frazier at 
the Texas Heart Institute, in Houston. In 
2014, he received a four-month research 
scholarship at the Netherlands Institute for Health Sciences (NIHES), Erasmus 
MC, Rotterdam. For his work, he was awarded several times including the “Nikola 
Spasic” award for the best-graduated medical student at the University of Bel-
grade. In 2014, he obtained his MD degree with an average grade of 10,00/10,00. 
Subsequently, he completed his internship at the Clinic for Vascular and Endo-
vascular Surgery, Clinical Center of Serbia, in Belgrade, where he has authored 
four peer-reviewed publications on different vascular pathologies. In June 2015, 
he started working on his PhD thesis at the Department of Cardiology, Erasmus 
MC, under the mentorship of Prof. Eric Boersma. In February 2016, he studied at 
the Institute of Public Health, University of Cambridge, in Cambridge, as a part 
of the NIHES MSc program. In September 2016, he obtained his MSc degree in 
Clinical Epidemiology at the NIHES, where he was awarded for the best master’s 
research paper. 
His research interests include coronary artery disease, heart failure, heart trans-
plantation, mechanical circulatory support, chronic kidney disease, aortic dis-
eases, and vascular malformations with a focus on clinical-decision making, bio-
statistics, and epidemiology.
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